



PROJECT PERIODIC REPORT
Project Management and Use of
Resources
Revised version 21 May 2013

Grant Agreement number: 270089

Project acronym: p-medicine

Project title: From data sharing and integration via VPH models to personalised medicine

Funding Scheme: Collaborative Project
FP7-ICT-2009-6

Date of latest version of Annex I against which the assessment will be made:
27 October 2011

Interim report: 1st 2nd 3rd 4th

Period covered: from 1 February 2012 to 31 January 2013

Name, title and organisation of the scientific representative of the project's coordinator:

Prof. Norbert Graf
Universität des Saarlandes

Tel: +49 6841 1628397

Fax: +49 6841 1628302

E-mail: graf@uks.eu

Project website address: www.p-medicine.eu

Table of Contents

1	Publishable Summary	i
2	Project objectives for the period	1
3	Work progress and achievements during the period	9
3.1	Work Package 1: Project Management	9
3.2	Work Package 2: User Needs and Requirements	9
3.3	Work Package 3: IT Architecture	11
3.4	Work Package 4: Standardisation, Semantic Interoperability and Data Integration	13
3.5	Work Package 5: Legal and Ethical Framework	16
3.6	Work Package 6: Integration in Clinical Research Infrastructures.....	19
3.7	Work Package 7: Data Warehouse	20
3.8	Work Package 8: p-medicine Workbench.....	23
3.9	Work Package 9: Clinical Trials.....	26
3.10	Work Package 10: Access to Biobanks.....	33
3.11	Work Package 11: Patterns for Data Mining and Predictive Analysis	35
3.12	Work Package 12: VPH Modelling and the Integrated Oncosimulator.....	37
3.13	Work Package 13: Clinical Decision Support	41
3.14	Work Package 14: Collaborative Environment for Patient Empowerment Tools..	45
3.15	Work Package 15: Quality Assurance, Evaluation and Validation	47
3.16	Work Package 16: Education and Training	50
3.17	Work Package 17: Exploitation and Dissemination	52
4	Deliverables and milestones tables	59
4.1	Deliverables	59
4.2	Milestones	66
5	Project management	68
6	Explanation of the use of the resources	90
6.1	Budget Overview	90
6.2	Budget Explanations	93
6.3	Planned versus actual efforts	93
7	Financial Statements	95
7.1	Forms C and Summary Financial Statement	95
7.2	Certificates	96
8	Annexes	97
8.1	p-medicine PM Effort Calculation	97

4 Project management

Consortium management tasks and achievements

The consortium management is covered by WP1 and includes

- Task 1.1: Decision making management
- Task 1.2: Administrative coordination
- Task 1.3: Reporting procedures
- Task 1.4: Financial management.

The following achievements were made during the second year of the project's duration:

The **3rd Progress Meeting (MS3)** was held on 19-21 March 2012. It was hosted by the p-medicine partners at Poznan Supercomputing and Networking Center (PSNC) in Poznan, Poland. The purpose of the meeting was, among other things, to discuss important technical and clinical issues, the general progress of the project and to find satisfying and prompt solutions to problems that have occurred. Members of the p-medicine EAB were also present. The project management team was happy to report that the foundations for NDAs with the EAB/IEC were laid and that the NDAs regarding the cooperation with VPH-Share were signed by all partners.

What is more, a detailed agenda of the 1st Review Meeting of the p-medicine project was developed collaboratively within the consortium during the meeting. Much attention was paid to the balance of the clinical and technical aspects of the p-medicine project as well as to the fact that end users of the p-medicine tools have to be integrated into the project as early as possible.

The **1st Review Meeting** took place on 3rd May 2012 in Brussels. The coordinator Prof. Norbert Graf gave an overview of the progress achieved in the first year of the project, before members of the p-medicine consortium presented concisely various aspects of p-medicine such as clinical trial data, quality management, the legal and security framework, architecture and workbench, etc. Moreover, the p-medicine data warehouse, the Oncosimulator including complete workflows, the p-medicine portal, ObTiMA and other tools and applications were demonstrated to the reviewers. The reviewers see the project on track and consider the goals of the 1st year achieved. They complimented the p-medicine partners on their high level of cooperation within the consortium but recommend that cooperation with external projects such as ENCCA or VPH-Share be intensified. As stated in the WP17 report above, interfacing with these and other related projects has been well under way during this reporting period and a joint meeting of VPH-Share and p-medicine partners was held during the 4th Progress Meeting in St. Augustin. p-medicine is further advised to define potential markets for exploitation of the project outcome and to investigate follow-up activities in Europe and overseas.

A **4th Progress Meeting (MS4)** was held on 29-30 August 2012 at FhG-IAIS in St. Augustin, Germany, where the work done so far was presented and the work anticipated for the upcoming months was discussed. To intensify the on-going collaboration and define new areas of common work and research, a large number of partners from VPH-Share joined us for a whole day on August 31 for a fruitful joint meeting of both projects.

The **first meeting of the p-medicine International Ethical Committee** took place on 13 December 2012 at the Saarland University Hospital in Homburg, Germany. The committee was represented by Prof Dr Wolfram Henn (Saarland University) and Prof Dr Roberto W. Andorno (University of Zurich). The p-medicine project was described in detail and areas of potential IEC work were discussed. The IEC agreed to provide a white paper at the end of the project, dealing with ethics in personalized medicine in the VPH setting.

A **5th Progress Meeting (MS5)** was held on 6-8 March 2013 at SIB in Lausanne, Switzerland. Apart from an overview of the work done so far in all the work packages, an approach was formulated on how to integrate the p-medicine tools in the p-medicine architecture most effectively. The discussion resulted in a working document accompanying deliverable D2.6. This working document defines workflows and use cases, data requirements and responsibilities. It will be continuously updated by the p-medicine partners to ensure maximum quality control. Moreover, with regard to the upcoming 2nd Review Meeting, an agenda was developed collaboratively during the meeting in Lausanne.

Task 1.3, Reporting procedures: A second internal progress report was prepared by Eurice in close cooperation with all the team leaders and WP leaders. The internal report is used to monitor the overall progress of the project, discover potential and actual problems and find adequate solutions. For the (internal) reporting period in question (M13-M18), no significant problems had occurred. The report was distributed among the consortium members in October 2012 and a copy was e-mailed to the project officer at the European Commission.

The **2nd Review Meeting** will be held on 25 April 2013 at the European Commission DG CNECT headquarters in Brussels.

Task 1.4, Financial Management: The **first periodic payment** was received by the coordinator and timely and duly distributed to the partners according to the table below:

n°	Abbrev.	Total costs after amendment	Total funding after amendment	1st pre-financing acc. to original budget	claimable pre-financing acc. to new budget	difference pre-financing paid/claimable	Accepted funding year 1	1st periodic payment	Total received so far
1	USAAR	1,921,360,00	1,554,160,00	506,156,06	543,956,06	37,800,00	218,793,00	256,593,00	762,749,06
2	Eurice	701,948,00	701,948,00	228,598,33	245,681,83	17,083,50	125,441,00	142,524,50	371,122,83
3	FORTH	1,292,532,00	1,005,247,00	338,685,94	351,836,49	13,150,55	189,177,00	202,327,55	541,013,49
4	UCL	1,473,864,00	1,121,741,00	367,963,09	392,609,40	24,646,31	253,806,00	278,452,31	646,415,40
5	FhG	2,016,153,00	1,530,712,00	535,749,26	535,749,26	0,00	328,018,00	328,018,00	863,767,26
6	LUH	759,114,00	582,851,00	203,997,87	203,997,87	0,00	125,163,00	125,163,00	329,160,87
7	Custodix	813,400,00	624,625,00	212,476,28	218,618,78	6,142,50	88,249,00	94,391,50	306,867,78
8	Philips	1,697,214,00	887,920,00	310,772,04	310,772,04	0,00	130,749,00	130,749,00	441,521,04
9	UDUS	632,468,00	526,311,00	184,208,87	184,208,87	0,00	91,456,00	91,456,00	275,664,87
10	ICCS	859,400,00	674,200,00	235,970,03	235,970,03	0,00	85,934,00	85,934,00	321,904,03
11	UPM	647,320,00	506,790,00	177,376,52	177,376,52	0,00	120,582,00	120,582,00	297,958,52
12	CAU	438,400,00	340,000,00	119,000,01	119,000,01	0,00	22,116,00	22,116,00	141,116,01
	Third Party						1,887,00	1,887,00	1,887,00
13	IEO	727,022,00	430,118,00	150,541,32	150,541,32	0,00	54,409,00	54,409,00	204,950,32
14	ecancer	1,007,600,00	858,480,00	300,468,04	300,468,04	0,00	206,582,00	206,582,00	507,050,04
15	UOXF	771,180,00	583,980,00	201,033,02	204,393,02	3,360,00	61,341,00	64,701,00	265,734,02
16	Biovista	662,324,00	393,001,00	137,550,37	137,550,37	0,00	115,729,00	115,729,00	253,279,37
17	SIB	661,080,00	501,920,00	175,672,02	175,672,02	0,00	99,760,00	99,760,00	275,432,02
18	Uhok	320,808,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00
19	IBM	0,00	0,00	228,725,73	0,00	-228,725,73	0,00	0,00	0,00
20	PSNC	663,508,00	505,903,00	50,523,21	177,066,07	126,542,86	105,910,00	232,452,86	338,362,86
		18,066,695,00	13,329,907,00	4,665,468,01	4,665,468,00	-0,01	2,425,102,00	2,653,827,72	7,145,956,79

The € 228.725,73 of the total pre-financing payable to IBM based on their share in the original total funding were not paid to IBM due to its non-accession to the Grant Agreement. The money has been divided among those partners taking over IBM's work. Together with the first periodic payment, IBM's share of the total pre-financing was distributed to those partners who have taken over work from IBM according to the revised work plan.

Changes in the consortium

There have been no changes within the Consortium during the reporting period.

List of project meetings, dates and venues

Title	Date	Venue	Local organizer
Internal Meeting with Fraunhofer Institute for Algorithms and Scientific Computing SCAI	10 February 2012	FhG-SCAI, Bonn, Germany	FhG
Portal authentication (SSO), authorization, user management, pseudonymisation and ObTiMA meeting	14-15 February 2012	Dept. of Pediatric Oncology, Homburg, Germany	USAAR
Patient Empowerment Meeting	27 February 2012	UCL, London, UK	UCL
Education and Dissemination meeting	29 February 2012	Tenovus, Cardiff, UK	ecancer
Clinical Decision Support and Data Mining on Leukemia Data	29 Feb. – 01 March 2012	Medical University, Hannover, Germany	FhG-IAIS
Local meeting USAAR and FhG-IBMT	02 March 2012	Dept. of Pediatric Oncology, Homburg, Germany	USAAR, FhG-IBMT
Anonymization of Oxford data meeting & Data warehouse security meeting	12-13 March 2012	Oxford, UK	UOXF
GPOH Meeting	15 March 2012	Court Yard, Hannover, Germany	LUH
3 rd Progress Meeting	19-21 March 2012	Poznan Supercomputing and Networking Center (PSNC), Poznan, Poland	PSNC
ObTiMA Validation Simulation	04 April 2012	University of Duesseldorf, Germany	UDUS
IEmS/Education platform meeting	10 April 2012	IEO, Milan, Italy	IEO
OECI Education and Patient Empowerment meeting	25 April 2012	Bari, Italy	ecancer/OECI
General rehearsal for the First Annual Review	26 April 2012	Saarland University Hospital, Homburg, Germany	USAAR-HOM
1 st Review Meeting	03 May 2012	Avenue de Beaulieu, Brussels, Belgium	European Commission
ObTiMA meeting	04 May 2012	Custodix, Sint-Martens-Latem, Belgium	CUSTODIX
3 rd VPH study group on VPH Toolkit	07 May 2012	University Pompeu Fabra – UPF, Barcelona, Spain	UPF
SIOP-RTSG meeting	11 June 2012	Grand Hotel Gianicolo, Rome, Italy	
European Association of Personalised Medicine meeting	12 June 2012	European Parliament, Brussels, Belgium	ecancer/ European Association of Personalized Medicine
USAAR/FhG-IBMT ObTiMA developer meeting	24 June 2012	Saarland University Hospital, Homburg, Germany	USAAR, FhG-IBMT
Meeting with INTEGRATE	26 June 2012	Institute Jules Bordet, Brussels, Belgium	
2 nd meeting on decision support and data mining on leukemia data	05-06 July 2012	Pediatric Hospital, Kiel, Germany	CAU
Ontology status and planning update	06 July 2012	Saarland University Hospital, Homburg, Germany	USAAR
Discussions with oncology	21 July 2012	Graz, Austria	USAAR-IFOMIS

experts			
USAAR/FhG-IBMT ObTiMA developer meeting	08 August 2012	Fraunhofer IBMT, St. Ingbert, Germany	FhG-IBMT
Dissemination meeting with Medical School/University of Namibia and Ministry of Health	19-26 August 2012	UNAM, Windhoek, Namibia	USAAR, Eurice
4 th Progress Meeting	29-31 August 2012	Fraunhofer Institute, Schloss Birlinghoven, St. Augustin, Germany	FhG-IAIS
Hackathon PESF Integration ObTiMA	11-12 September 2012	Custodix, Sint-Martens-Latem, Belgium	CUSTODIX
ENCCA – WP11, Task 11.3	19 September 2012	University College London, UK	UCL
p-medicine/ TUMOR/ RICORDO – semantic interoperability	20 September 2012	Institute of Engineering and Technology, London, UK	
European Medical Association – Education platform	21 September 2012	European Medical Association	ecancer
WP14 Skype meeting	27 September 2012	Skype	
Hackathon data warehouse security integration	08-10 October 2012	Custodix, Sint-Martens-Latem, Belgium	Custodix
Panel Discussion and Lunch (topic: role of DR in rare and orphan diseases and its potential for personalized medicine)	18 October 2012	Washington DC	Biovista
Review of the nephroblastoma trial and the involvement of p-medicine	18-19 October 2012	CRUK, London, UK	
ObTiMA Meeting	31 October 2012	Fraunhofer IBMT, St. Ingbert, Germany	FhG-IBMT
TOB Meeting	30 November 2012	Wing International, Yokohama Kannai, Japan	
ObTiMA Meeting	12 December 2012	Fraunhofer IBMT, St. Ingbert, Germany	FhG-IBMT
International Ethical Committee Meeting	13 December 2012	Saarland University Hospital, Homburg, Germany	USAAR
ALGA trial set-up meeting	16 December 2012	Jules Bordet Institute, Paris, France	ecancer
LUH / CUSTODIX meeting	09-10 January 2013	Brussels, Belgium	CUSTODIX
ENCCA Consortium Meeting	16-18 January 2013	Brussels, Belgium	LUH
ObTiMA workshop	23 January 2013	Fraunhofer IBMT, St. Ingbert, Germany	FhG-IBMT
EMA Advisory Board Meeting	30 January 2013		LUH

Related documentation is available in the project management tool.

Cooperation with other projects/programmes

For cooperation with other projects/programmes reference is made to task 17.6 “Interfacing with other projects” described in the WP17 report.

Project planning and status

In general, the project’s work plan was implemented as foreseen.

Minor deviations from the original work plan occurred in the following work packages.

Work has started early in the following task:

WP11: Task 11.4 (M24-M48)

Because data for clinical decision support tasks was available earlier than expected, task 11.4 could be started ahead of plan in this reporting period. Moreover, for technical reasons the decision support scenario based on the ALL data was selected as the primary scenario for the overall integrated p-medicine demonstrator, such that an earlier involvement of this task was necessary.

Additional work has been done in the following tasks:

WP2: Task 2.1 (M1-M8), Task 2.2 (M1-M9) and Task 2.4 (M1-M12)

The deliverables for these tasks were updated (D2.1, D2.2 and D2.4) in order to clarify the current status as well as the needs and requirements for further work.

WP4: Task 4.1 (M3-M12)

The initial integration of HDOT in ObTiMA was finalized by FhG-IBMT. HDOT was further extended with a patient empowerment module, a biobank module, a pathological formation module, and a more general disease module.

Content has been added in the following tasks to improve the work to be performed:

WP9: Clinical trials

As a result of the SIOP meetings in London and Lyon, it was decided that a further period of registration of new patients (approx. 24 months) is needed with associated high quality prospective data and sample collection, to include DICOM files and tissue samples.

Shift of person months:

Reference is made to the respective section in the reports on the work packages.

All these deviations do not have any negative impact on other tasks and do not influence the resources originally planned. They will, in general, add value to the work carried out in p-medicine.

Impact of possible deviations from the planned milestones and deliverables

In the second year of the project, deliverables and milestones have mostly been submitted or achieved as foreseen in Annex I.

Problems have occurred with regard to Deliverable D13.3, which was due on 01 June 2012. Since a number of relevant datasets and protocols were not made available to the partners involved in the deliverable on time, work was delayed and only a pre-final version of the deliverable could be handed in. Due to delayed partner contributions, deliverable D13.4 (due 31 January 2013) will also be delayed. However, the deliverable will be ready in time for the 2nd Review.

Deliverable 14.3 has also been delayed. When defining the task 14.3 upon application for p-medicine, it was anticipated that, within the consortium, retrospective data on layered consent would be available. At the consortium meeting in St. Augustin, the Coordinator confirmed that this will not be the case for the time being. For the ALL use case, we have the more detailed information that different categories of consent indeed have been and are being collected, but only documented in writing and not in an electronic format. Hence retrospective data underpinning D 14.3 will definitely not be available throughout the p-medicine project. Since a new approach could be clarified no earlier than August/September last year, WP14 have not yet been able to discuss their work with WP5 in detail and agree upon the text of D14.3. In addition, categories of consent anticipated for the SIOP biobanking scenario should also be included in this discussion with WP5, in order to provide a consistent

solution for p-medicine. Hence, the deliverable has been delayed, but will be finished and submitted to the European Commission before the second Review Meeting.

Further explanations about the new approach for D14.3 as well as on other delayed deliverables can be found in the deliverables list in section 4.

Any changes to the legal status of any of the beneficiaries

There were no changes to the legal status of any of the beneficiaries.

Development of the Project website

More information on the features of the website is available in Deliverable D17.1 (Internal and external p-medicine website).

Statement on the use of the resources

Planned versus actual efforts in WP1			
Partner	Planned PM Total	Planned PM Period 2	Actual PM Period 2
1 – USAAR	12.00	3.00	1.72
2 – Eurice	38.00	9.52	9.90
3 – FORTH	5.00	1.00	0.00
Total	55.00	13.52	11.62

Dissemination activities and publications

As an overview of the dissemination of foreground, a list of dissemination activities (divided into workshops/conferences and press) as well as a list of publications produced in the current reporting period are provided below.

Workshops and conferences

Title	Type	Main leader/Participants	Event	Venue	Date
GPOH Meeting	Workshop	USAAR-HOM	GPOH Meeting	Hannover, Germany	15-16 March 2012
eHealth Week 2012	Conference	LUH	eHealth Week 2012	Copenhagen, Denmark	09 May 2012
3 rd VPH Study Group on VPH Toolkit	Workshop	USAAR-HOM, ICCS	3 rd VPH Study Group on VPH Toolkit	Barcelona, Spain	07-11 May 2012
Personalised medicine symposium	Symposium	ecancer	Personalised medicine symposium	Copenhagen, Denmark	4 June 2012
Personalized medicine: from data sharing and integration via VPH models to personalized medicine	Conference, posters, flyers	USAAR-HOM	eHealth conference 2012	Saarbruecken, Germany	05 June 2012
A mathematical approach to data evaluation with focus on prediction of minimal residual disease in pediatric ALL	Conference, presentation	CAU	25. Jahrestagung der Kind-Philipp-Stiftung für Leukämieforschung	Wilsede, Germany	07 June 2012
Survivors and Chronic Cancer Patients conference	Conference, poster	ecancer	Survivor and Chronic Cancer Patients Conference	Sicily, Italy	8 June 2012
SIOP-RTSG Meeting	Workshop, Conference	USAAR-HOM	Annual Meeting of the SIOP Renal Tumor Study Group	Rome, Italy	11-12 June 2012
Von Datenaustausch und Integration über VPH Modelle zur Personalisierten Medizin	Conference	USAAR-HOM and FhG-IBMT	PerMediCon 2012	Cologne, Germany	19 June 2012
JANET conference	Conference	UOXF	JANET Conference 2012	London, UK	21 June 2012
p-medicine: from data sharing and integration via VPH models to personalized medicine	Conference	FhG-IBMT and USAAR-HOM	PerMediCon 2012	Cologne, Germany	25 June 2012

Title	Type	Main leader/Participants	Event	Venue	Date
Beyond omics Revolutions: integrative knowledge management for empowered healthcare and research	Conference		Beyond omics Revolutions 2012	Barcelona, Spain	03-05 July 2012
3 rd US-Turkey Advanced Institute on Global Healthcare Grand Challenges	Conference		3 rd US-Turkey Advanced Institute on Global Healthcare Grand Challenges	Antalya, Turkey	09-15 July 2012
Visualizing Clinical Trial Data Using Pluggable Components.	Conference	UHok	16 th International Conference on Information Visualization	Montpellier, France	10-13 July 2012
Computerized Clinical Guidelines: Current Status & Principles for Future Research.	Conference	FORTH	Medical Informatics Europe (MIE) 2012	Pisa, Italy	26-29 August 2012
A software prototype for the assessment of tumor treatment response using diffusion and perfusion MR imaging	Conference	FORTH	Engineering in Medicine and Biology Society (EMBC 2012)	San Diego, California, USA	28 August 2012
An architecture for integrating cancer model repositories.	Conference	FORTH, ICCS, UOXF, USAAR	Engineering in Medicine and Biology Society (EMBC 2012)	San Diego, California, USA	28 August 2012
Very large scale systematic drug repositioning as a business and technology driver	Conference	BIOVISTA	World Drug Repositioning Congress	London, UK	10-13 September 2012
In Silico Oncology: a Novel and Explicit Numerical Treatment of the Neumann Boundary Conditions Imposed by the Skull on a Multiscale Diffusion-Reaction Model of Glioblastoma Growth. Clinical Validation Aspects.	Conference	ICCS	VPH 2012	London, UK	18-20 September 2012
VPH2012	Conference	UOXF	VPH2012	London, UK	18-20 September 2012
Decoding Clinical Trials to Improve Treatment of ME/CFS	Conference	BIOVISTA	CFIDS conference	Banbury Center, Cold Spring Harbor, NY, USA	30 Sept. – 5 Oct. 2012

Title	Type	Main leader/Participants	Event	Venue	Date
European Health Forum	Conference	LUH	European Health Forum	Bad Gastein, Austria	04 October 2012
World Congress for Paediatric Oncology	Conference	USAAR, UCL	44 th Congress of the International Society of Paediatric Oncology	Barbican Centre, London, UK	05-08 October 2012
Ontology Evolution, Assisting Query Migration.	Conference	FORTH	31st International Conference on Conceptual Modeling	Florence, Italy	15-18 October 2012
Collaboration between Research Initiatives and Infrastructures for Personalized Medical Research: an Underestimated Challenge	Conference	UDUS	eChallenges 2012	Lisbon, Portugal	17-19 October 2012
A Scenario-Driven Approach to Enable Collaboration Among Research Infrastructures and Initiatives	Conference	UDUS	eChallenges 2012	Lisbon, Portugal	17-19 October 2012
Modeling the interplay between pathological angiogenesis and solid tumor growth: The anti-angiogenic treatment effect	Conference, Workshop	ICCS	5 th International Advanced Research Workshop on In Silico Oncology and Cancer Investigation	Royal Olympic Hotel, Athens, Greece	22-23 October 2012
Hybrid model for tumor spheroids with intratumoral oxygen supply heterogeneity	Conference, Workshop	FORTH	5 th International Advanced Research Workshop on In Silico Oncology and Cancer Investigation	Royal Olympic Hotel, Athens, Greece	22-23 October 2012
The Continuous Mathematics Based Glioblastoma Oncosimulator: Application of an explicit three dimensional numerical treatment of the skull-glioblastoma Neumann boundary condition on real anatomical data	Conference, Workshop	ICCS	5 th International Advanced Research Workshop on In Silico Oncology and Cancer Investigation	Royal Olympic Hotel, Athens, Greece	22-23 October 2012
Modeling nephroblastoma treatment response cases with In-Silico scenarios	Conference, Workshop	ICCS, USAAR	5 th International Advanced Research Workshop on In Silico Oncology and Cancer Investigation	Royal Olympic Hotel, Athens, Greece	22-23 October 2012

Title	Type	Main leader/Participants	Event	Venue	Date
The Health Data Ontology Trunk (HDOT). Towards an ontological representation of cancer-related knowledge	Conference, Workshop	USAAR	5 th International Advanced Research Workshop on In Silico Oncology and Cancer Investigation	Royal Olympic Hotel, Athens, Greece	22-23 October 2012
Scientific workflows to support in silico modeling in cancer research	Conference, Workshop	FORTH	5 th International Advanced Research Workshop on In Silico Oncology and Cancer Investigation	Royal Olympic Hotel, Athens, Greece	22-23 October 2012
Towards patient personalization of an Acute Lymphoblastic Leukemia Model during the oral administration of prednisone in children: Initiating the ALL Oncosimulator	Conference, Workshop	ICCS	5 th International Advanced Research Workshop on In Silico Oncology and Cancer Investigation	Royal Olympic Hotel, Athens, Greece	22-23 October 2012
Clinical Evaluation of DoctorEye Platform in Nephroblastoma	Conference, Workshop	USAAR, ICCS, FORTH	5 th International Advanced Research Workshop on In Silico Oncology and Cancer Investigation	Royal Olympic Hotel, Athens, Greece	22-23 October 2012
CRI sequencing conference	Conference	UOXF	CRI sequencing Conference	Cambridge, UK	02-04 November 2012
p-BioSPRE – An ICT and Contractual Framework for Transnational Biomaterial Sharing and Access	Conference, Poster	FhG	Granada Biobanking Conference	Granada Conference and Exhibition Centre	07-09 November 2012
IEmS: A collaborative Environment for Patient Empowerment.	Conference	FORTH, IEO, ecancer	12 th International Conference on Bioinformatics and BioEngineering (BIBE)	Golden Bay Beach Hotel, Larnaca, Cyprus	11-13 November 2012
A technical infrastructure to support personalized medicine.	Conference	FORTH, USAAR	12 th International Conference on Bioinformatics and BioEngineering (BIBE)	Golden Bay Beach Hotel, Larnaca, Cyprus	11-13 November 2012
An innovative mathematical analysis of routine MRI scans in patients with glioblastoma using DoctorEye	Conference	USAAR, FORTH, ICCS	12 th International Conference on Bioinformatics and BioEngineering (BIBE)	Golden Bay Beach Hotel, Larnaca, Cyprus	11-13 November 2012

Title	Type	Main leader/Participants	Event	Venue	Date
EMA Workshop on clinical trial data and transparency	Workshop	LUH	EMA Workshop on clinical trial data and transparency	London, UK	22 November 2012
Panel Discussion	Conference	LUH	Nordic Conference on Legal Informatics	Stockholm, Sweden	22 November 2012
Online Education Conference	Conference	Ecancer	Online Education Conference	Berlin, Germany	29 November 2012
Partnering for Cures – Innovator Presentations Session	Conference	Biovista	Partnering for Cures Conference 2012	New York, USA	28-30 November 2012
54th Annual Meeting of the Japanese Society of Pediatric Hematology and Oncology (JSPHO2012)	Conference		54th Annual Meeting of the Japanese Society of Pediatric Hematology and Oncology (JSPHO2012)	PACIFICO, Yokohama, Japan	30 Nov. – 02 Dec. 2012
World Drug Repositioning Congress	Conference	Biovista	World Drug Repositioning Congress	Washington DC, USA	04 December 2012
Cooperation between p-medicine and BioMedBridges Use Case 8	Workshop	UDUS	BioMedBridges Workshop	FIMM, Helsinki, Finland	17 January 2013

Publications

Title	Contact person	Involved Institutions	Reference	Category	Publication date	Co-Authors	Status
Personal Health Record Systems Evaluation through the Lenses of EU Research Projects - A systematic review of the currently available PHR systems and their comparative evaluation based on PHR system requirements and visions from currently running EU-funded research projects.	Lefteris Koumakis	FORTH	Elsevier - Computers in Biology and Medicine, special issue "The state of the personal health record".	Peer-reviewed journal article	2013		Planned
Towards an environment for data mining based analysis processes in bioinformatics & personalized medicine	Dennis Wegener	SIB, UOXF, FhG	Journal for Network Modeling Analysis in Health Informatics and Bioinformatics	Peer-reviewed journal article	2013		Accepted for publication in Jan. 2013
miRNA Profiles as a Predictor of Chemosensitiveness in Blastemal Wilms' Tumour	Jenny A. Watson	USAAR	DOI: 10.1371/journal.pone.0053417 PLoS ONE 8:1	Peer-reviewed journal article	2013	Kenneth Bryan, Richard Williams, Sergey Popov, Gordan Vujanic, Aurore Coulomb, Liliane Boccon-Gibod, Norbert Graf, Kathy Pritchard-Jones, Maureen O'Sullivan	Published
Navigating legal constraints in clinical data warehousing: a case study in personalized medicine.	Benjamin Jefferys	UCL, USAAR, LUH, Custodix	DOI: 10.1098/rsfs.2012.0088 Interface Focus 3	Peer-reviewed journal article	6 April 2013	Nwankwo Iheanyi, Neri Elias, Chang David CW, Sharmardin Lev, Hänold Stefanie, Graf Norbert, Forgó Nikolaus, Coveney Peter	Published
Integrative approaches to computational biomedicine	Peter Coveney	UCL, USAAR	DOI: 10.1098/rsfs.2013.0003 Interface Focus 3	Peer-reviewed journal article	6 April 2013	Vanessa Diaz-Zuccarini, Graf N, Peter Hunter, Peter Kohl, Jesper Tegner, Marco Viceconti	Published

Distributed Delays in a Hybrid Model of Tumor-Immune System Interplay	Alberto d'Onofrio	IEO	DOI: 10.3934/mbe.2013.10.37 Mathematical Biosciences and Engineering, vol. 10, no. 1, pp. 37-57	Peer-reviewed journal article	1 February 2013	G. Caravagna, A. Graudenzi	Published
Tumor Development under Combination Treatments with Anti-angiogenic Therapies	Urszula Ledzewicz	IEO	DOI: 10.1007/978-1-4614-4178-6 Mathematical Methods and Models in Biomedicine, volume of the series Lecture Notes on Mathematical Modelling in the Life Sciences, pp. 311-337	Peer-reviewed book article	1 January 2013	A. d'Onofrio, H. Schättler	Published
Multifaceted Kinetics of Immuno-Evasion from Tumor Dormancy	Alberto d'Onofrio	IEO	DOI: 10.1007/978-1-4614-1445-2_7 Advances in Experimental Medicine and Biology, vol. 734, pp. 111-143	Peer-reviewed journal article	1 January 2013		Published
Collaboration between Research Initiatives and Infrastructures for Personalized Medical Research: an Underestimated Challenge	Wolfgang Kuchinke	UDUS	eChallenges e-2012 Conference Proceedings	Conference Proceedings	2012	Wolfgang Kuchinke, Toeresin Karakoyun, Christian Ohmann	Published
A Scenario-Driven Approach to Enable Collaboration Among Research Infrastructures and Initiatives	Toeresin Karakoyun	UDUS	eChallenges e-2012 Conference Proceedings	Conference Proceedings	2012	Wolfgang Kuchinke, Christian Ohmann, Hans Jakob Auer	Published
Modeling the interplay between pathological angiogenesis and solid tumor growth: The anti-angiogenic treatment effect	Katerina D. Argyri	ICCS	Proceedings of the 2012 5th International Advanced Research Workshop on In Silico Oncology and Cancer Investigation - The TUMOR Project Workshop (IARWISOCI)	Conference Proceedings	2012	Georgios Stamatakos, Dimitra Dionysiou	Published

Hybrid model for tumor spheroids with intratumoral oxygen supply heterogeneity	Georgios Tzedakis	FORTH	Proceedings of the 2012 5th International Advanced Research Workshop on In Silico Oncology and Cancer Investigation - The TUMOR Project Workshop (IARWISOCI)	Conference Proceedings	2012	Eleftheria Tzamali, Vangelis Sakkalis, Alexandros Roniotis, Kostas Marias	Published
The Continuous Mathematics Based Glioblastoma Oncosimulator: Application of an explicit three dimensional numerical treatment of the skull-glioblastoma Neumann boundary condition on real anatomical data	Stavroula Giliati	ICCS	Proceedings of the 2012 5th International Advanced Research Workshop on In Silico Oncology and Cancer Investigation - The TUMOR Project Workshop (IARWISOCI)	Conference Proceedings	2012	Georgios Stamatakos	Published
Modeling nephroblastoma treatment response cases with In-Silico scenarios	Eleni Georgiadi	ICCS, USAAR	Proceedings of the 2012 5th International Advanced Research Workshop on In Silico Oncology and Cancer Investigation - The TUMOR Project Workshop (IARWISOCI)	Conference Proceedings	2012	Dimitra Dionysiou, Norbert Graf, Georgios Stamatakos	Published
The Health Data Ontology Trunk (HDOT). Towards an ontological representation of cancer-related knowledge	Emilio Sanfilippo	USAAR	Proceedings of the 2012 5th International Advanced Research Workshop on In Silico Oncology and Cancer Investigation - The TUMOR Project Workshop (IARWISOCI)	Conference Proceedings	2012	Ulf Schwarz, Luc Schneider	Published
Scientific workflows to support in silico modeling in cancer research	Stelios Sfakianakis	FORTH	Proceedings of the 2012 5th International Advanced Research Workshop on In Silico Oncology and Cancer Investigation - The TUMOR Project Workshop (IARWISOCI)	Conference Proceedings	2012	Vangelis Sakkalis, Kostas Marias	Published

Towards patient personalization of an Acute Lymphoblastic Leukemia Model during the oral administration of prednisone in children: Initiating the ALL Oncosimulator	Eleftherios N. Ouzounoglou	ICCS	Proceedings of the 2012 5th International Advanced Research Workshop on In Silico Oncology and Cancer Investigation - The TUMOR Project Workshop (IARWISOCI)	Conference Proceedings	2012	Dimitra D. Dionysiou, Martin Stanulla, Georgios S. Stamatakos	Published
Clinical Evaluation of DoctorEye Platform in Nephroblastoma	Ruslan David	USAAR, ICCS, FORTH	Proceedings of the 2012 5th International Advanced Research Workshop on In Silico Oncology and Cancer Investigation - The TUMOR Project Workshop (IARWISOCI)	Conference Proceedings	2012	N.Graf, I.Karatzanis, H.Stenzhorn, G.Manikis, V.Sakkalis,G.Stamatakos, K.Marias	Published
Smart recommendation services in support of patient empowerment and personalized medicine	Haridimos Kondylakis	FORTH, ecaner	Multimedia Services in Intelligent Environments - Recommendation Services	Edited Volume	2012	L. Koumakis, M. Tsiknakis, K. Marias, E. Genitsaridi, G. Pravettoni, A. Gorini, K. Mazzocco	Published
A framework for multi-modal imaging biomarker extraction with application to brain MRI	Kostas Marias	FORTH, USAAR	DOI: 10.1007/978-1-4614-2107-8_6 Data Mining for Biomarker Discovery Source: Springer Optimization and Its Applications, Springer New York/Vienna, Ed. by P.M. Pardalos, et al., Vol. 65, pp. 91-116, 2012, ISBN 978-1-4614-2106-1	Chapter in an Anthology	2012	Vangelis Sakkalis, Norbert Graf	Published

In Silico Oncology: a Novel and Explicit Numerical Treatment of the Neumann Boundary Conditions Imposed by the Skull on a Multiscale Diffusion-Reaction Model of Glioblastoma Growth. Clinical Validation Aspects	Georgios Stamatakos	ICCS	Proceedings of the VPH2012 Integrative Approaches to Computational Biomedicine	Conference Proceedings	2012	Stavroula Giliati	Published
An architecture for integrating cancer model repositories	Stelios Sfakianakis	FORTH, ICCS, UOXF, USAAR	DOI: 10.1109/EMBC.2012.6347514 Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society	Conference Proceedings	2012	Vangelis Sakkalis, Kostas Marias, Georgios Stamatakos, Steve McKeever, Thomas S Deisboeck, Norbert Graf	Published
Multiscale Modeling for Image Analysis of Brain Tumor Studies	Stefan Bauer	ICCS	DOI: 10.1109/TBME.2011.2163406 IEEE Transactions on Biomedical Engineering 59: 1	Peer-reviewed article	2012	Christian May, Dimitra D. Dionysiou, Georgios S. Stamatakos, Philippe Büchler, Mauricio Reyes	Published
From depression to neurodegeneration and heart failure: re-examining the potential of MAO inhibitors	SN Deftereos	Biovista	Expert Reviews in Clinical Pharmacology 5: 4	Peer-reviewed article	2012	E. Dodou, C. Andronis, A. Persidis	Published
Unchain the code: how to ease quality control in research, tips or requirements?	Antonio F. DiNarzo	SIB	Biohelikon Computational Biology 1: 1	Peer-reviewed article	2012	Simona Rossi	Published
Mechanism of Drug Efficacy within the Epidermal Growth Factor Receptor Revealed by Microsecond Molecular Dynamics Simulation	S. Wan	UCL	DOI: 10.1158/1535-7163.MCT-12-0644-T Molecular Cancer Therapeutics, 11: 11	Peer-reviewed article	2012	Peter Coveney	Published

Regulation of JAK2 Activation by Janus Homology 2: Evidence from Molecular Dynamics Simulations	S. Wan	UCL	DOI: 10.1021/ci300308g Journal of Chemical Information and Modeling 52: 11	Peer-reviewed article	2012	Peter Coveney	Published
From base pair to bedside: molecular simulation and the translation of genomics to personalized medicine	D.W. Wright	UCL	DOI 10.1002/wsbm.1186 Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 4:6	Peer-reviewed article	2012	S. Wan, N. Shublaq, S. J. Zasada, P. V. Coveney	Published
Top-Down Multiscale Simulation of Tumor Response to Treatment in the Context of In Silico Oncology. The Notion of Oncosimulator	Georgios Stamatakos	ICCS	DOI: 10.1007/978-88-470-2571-4_19 New Challenges for Cancer Systems Biomedicine, Edition: 2012, Publisher: Springer, Editors: A. d'Onofrio, P. Cerrai, A. Gandolfi	Book Chapter	2012		Published
Mining scientific and clinical databases to identify novel uses for existing Drugs	C. Andronis	Biovista	Drug Repositioning: Bringing New Life to Shelved Assets and Existing Drugs (eds M. J. Barratt and D. E. Frail), John Wiley & Sons, Inc.	Book Chapter	2012	A. Sharma, S. Deftereos, V. Virvilis, O. Konstanti, Andreas Persidis, Aris Persidis	Published
Business development Strategies in the Repositioning Industry	A. Persidis	Biovista	Drug Repositioning: Bringing New Life to Shelved Assets and Existing Drugs (eds M. J. Barratt and D. E. Frail), John Wiley & Sons, Inc.	Book Chapter	2012	Elizabeth T. Starck	Published

Proceedings of the 2012 5th International Advanced Research Workshop on In Silico Oncology and Cancer Investigation – The TUMOR Project Workshop (IARWISOCI) [OPEN ACCESS VERSION and IEEE Xplore version]	Georgios Stamatakos	ICCS		Edited conference proceedings	2012	Dimitra Dionysiou	Published
An innovative mathematical analysis of routine MRI scans in patients with glioblastoma using DoctorEye	Jonathan Zepp	USAAR, FORTH, ICCS	DOI: 10.1109/BIBE.2012.6399773 Proceeding of the 2012 IEEE 12th International Conference on Bioinformatics & Bioengineering (BIBE)	Conference Proceedings	2012	Norbert Graf, Holger Stenzhorn, Wolfgang Reith, Ioannis Karatzanis, Georgios C.Manikis, Vangelis Sakkalis, Konstantinos Marias, Georgios Stamatakos	Published
Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells.	E Favaro	UOXF	DOI: 10.1016/j.cmet.2012 Cell Metabolism 16: 6	Peer-reviewed journal article	05 December 2012	Favaro E, Bensaad K, Chong MG, Tennant DA, Ferguson DJ, Snell C, Steers G, Turley H, Li JL, Günther UL, Buffa FM, McIntyre A, Harris AL.	Published
IEmS: A collaborative Environment for Patient Empowerment.	Haridimos Kondylakis	FORTH, IEO, ecancer	IEEE 12th International Conference on Bioinformatics and BioEngineering (BIBE)	Conference Proceedings	11-13 November 2012	Manolis Tsiknakis, Kostas Marias, L. Koumakis, Gabriella Pravettoni, Alessandra Gorini, Ketti Mazzocco	Published
A technical infrastructure to support personalized medicine.	Stelios Sfakianakis	FORTH, USAAR	IEEE 12th International Conference on Bioinformatics and BioEngineering (BIBE)	Conference Proceedings	11-13 November 2012	Manolis Tsiknakis, Kostas Marias, Norbert Graf	Published
Towards In Silico Oncology: Adapting a Four Dimensional Nephroblastoma Treatment Model to a Clinical Trial Case Based on Multi-Method Sensitivity Analysis	E. Georgiadi	ICCS, USAAR	DOI: 10.1016/j.combiomed.2012.08.008 Computers in Biology and Medicine 42:11	Peer-reviewed journal article	01 November 2012	Dimitra Dionysiou, Norbert Graf, Georgios Stamatakos	Published

On the Dynamics of Tumor-Immune System Interactions and Combined Chemo- and Immunotherapy	Urszula Ledzewicz	IEO	DOI: 10.1007/978-88-470-2571-4_13 Mathematical Oncology: new challenges for systems biomedicine, vol. 1 of SIMAI Springer Series	Peer-reviewed book article	30 October 2012	A. d'Onofrio, H. Schättler	Published
Ontology Evolution, Assisting Query Migration.	Haridimos Kondylakis	FORTH	31st International Conference on Conceptual Modeling	Conference Proceedings	15-18 October 2012	D. Plexousakis	Published
Evasion of tumours from the control of the immune system: consequences of brief encounters	Alberto d'Onofrio	IEO	DOI: 10.1186/1745-6150-7-31 Biology Direct, vol. 7, art. 31	Peer-reviewed journal article	25 September 2013	Mohannad Al-Tameemi, Mark Chaplain	Published
IMENSE: An e-infrastructure environment for patient specific multiscale data integration, modelling and clinical treatment	Stefan Zasada	USAAR, UCL	DOI: 10.1016/j.jocs.2011.07.001 Journal of Computational Science 3:5	Peer-reviewed journal article	01 September 2012	T. Wang, A Haidar, E. Liu, N. Graf, G. Clapworthy, M. Steven, P. Coveney	Published
A software prototype for the assessment of tumor treatment response using diffusion and perfusion MR imaging	Vangelis Sakkalis	FORTH	DOI: 10.1109/EMBC.2012.6345950 Proceedings of the Engineering in Medicine and Biology Society (EMBC 2012)	Conference Proceedings	28 August 2012	Manikis, G.C., Papanikolaou, N., Karatzanis, I., Marias, K	Published
Computerized Clinical Guidelines: Current Status & Principles for Future Research	Haridimos Kondylakis	FORTH	Quality of Life Through Quality of Information: Proceedings of MIE2012	Conference Proceedings	26-29 August 2012	Manolis Tsiknakis	Published
Spatiotemporal bounded noises and transitions induced by them in solutions of the real Ginzburg-Landau model	Alberto d'Onofrio	IEO	DOI: 10.1103/PhysRevE.86.021118 Physical Review E, vol. 86, art. 021118	Peer-reviewed journal article	16 August 2012	S. de Franciscis	Published

Treatment independent miRNA signature in blood of Wilms tumor patients	J. Schmitt	USAAR	DOI: 10.1186/1471-2164-13-379 BMC Genomics 13:1	Peer-reviewed journal article	07 August 2012	Backes, C., Nourkami-Tutdibi, N., Leidinger, P., Deutscher, S., Beier, M., Gessler, M., Graf, N., Lenhof, H.-P., Keller, A. & Meese, E.	Published
Multicenter study identified molecular blood-born protein signatures for Wilms tumor	J. Schmitt	USAAR	DOI: 10.1002/ijc.26419 International Journal of Cancer 131:3	Peer-reviewed journal article	01 August 2012	S. Heisel, A. Keller, P. Leidinger, N. Ludwig, N. Habel, R. Furtwängler, N. Nourkami-Tutdibi, J. Wegert, P. Grundy, M. Gessler, N. Graf, H.P. Lenhof, E. Meese	Published
Visualizing Clinical Trial Data Using Pluggable Components	Jonas Sjöbergh	UHok	DOI: 10.1109/IV.2012.56 Proceedings of the 16 th International Conference on Information Visualization	Conference Proceedings	July 2012	Micke Kuwahara, Yuzuru Tanaka	Published
The Norton-Simon hypothesis and the onset of non-genetic resistance to chemotherapy induced by stochastic fluctuations	Alberto d'Onofrio	IEO	DOI: 10.1016/j.physa.2012.07.025 Physics A, vol. 391, pp. 6484-6496	Peer-reviewed journal article	20 July 2012	A. Gandolfi, S. Gattoni	Published

Nanoinformatics: developing new computing applications for nanomedicine	Victor Maojo	UPM, USAAR	DOI: 10.1007/s00607-012-0191-2 Computing in Science and Engineering 94:6	Peer-reviewed journal article	June 2012	M Fritts, F Martin-Sanchez, D De la Iglesia, RE Cachau, M Garcia-Remesal, J Crespo, JA Mitchell, A Anguita, N Baker, JM Barreiro, SE Benitez, G De la Calle, JC Facelli, P Ghazal, A Geissbuhler, F Gonzalez-Nilo, N Graf, P Grangeat, I Hermosilla, R Hussein, J Kern, S Koch, Y Legre, V Lopez-Alonso, G Lopez-Campos, L Milanese, V Moustakis, C Munteanu, P Otero, A Pazos, D Perez-Rey, G Potamias, F Sanz, C Kulikowski	Published
A Detailed Numerical Treatment of the Boundary Conditions Imposed by the Skull on a Diffusion-Reaction Model of Glioma Tumor Growth. Clinical Validation Aspects	Stavroula Giliati	ICCS	DOI: 10.1016/j.amc.2012.02.036, Applied Mathematics and Computation 218:17	Peer-reviewed journal article	01 May 2012	Georgios Stamatakos	Published
Characterization of the chromosomal translocation t(10;17) (q23; p13) in clear cell sarcoma of kidney	E. O'Meara	USAAR	DOI: 10.1002/path.3985 The Journal of Pathology	Peer-reviewed journal article	May 2012	D. Stack, C.-H. Lee, A.J. Garvin, T. Morris, P. Argani, J. Han, J. Karlsson, D. Gisselson, I. Leuschner, M. Gessler, N. Graf, J. Fletcher, M. O'Sullivan	Published
Knowledge engineering for health: A new discipline required to bridge the "ICT gap" between research and healthcare	Tim Beck	USAAR	DOI: 10.1002/humu.22066 Human Mutation 33:5	Peer-reviewed journal article	May 2012	S. Gollapudi, S. Brunak, Norbert Graf, U.H. Lemke, D. Dash, I. Buchan, C. Diaz, F. Sanz, A.J. Brookes	Published

Fine-tuning anti-tumor immunotherapies via stochastic simulations	Alberto d'Onofrio	IEO	DOI: 10.1186/1471-2105-13-S4-S8 BMC Bioinformatics, vol. 13, issue 4, art. S8	Peer-reviewed journal article	1 March 2012	G. Caravagna, R. Barbuti	Published
Characterization of primary Wilms tumor cultures as an in vitro model	Jenny Wegert	USAAR	DOI: 10.1002/gcc.20936 Genes, Chromosomes, Cancer 51:1	Peer-reviewed journal article	January 2012	S. Bausewein, S. Roth, Norbert Graf, E. Geissinger, M. Gessler	Published

5 Explanation of the use of the resources

5.1 Budget Overview

Cost Budget Follow-up Table										
Contract n°	270089	Project acronym								
PARTICIP.	TYPE of EXPENDITURE (as defined by participants)	BUDGET	ACTUAL COSTS (EUR)					Percentage spent	Remaining Budget (EUR)	
			Period 1	Period 2	Period 3	Period 4	Total	Total/ Budget		
			M1-M12	M13-M24	M25-M36	M25-M48				
USAAR	Total Person-month	193,00	28,45	40,54	0,00	0,00	68,99	36%	124,01	
	Personnel	965.000,00	149.096,00	248.392,00			397.488,00	41%	567.512,00	
	Other direct costs	232.100,00	21.349,00	28.435,00			49.784,00	21%	182.316,00	
	Subcontracting	6.000,00	0,00	0,00			0,00	0%	6.000,00	
	Adjustments						0,00	0%	0,00	
	Indirect costs	718.260,00	102.265,00	166.094,00			268.359,00	37%	449.901,00	
	Total Costs	1.921.360,00	272.710,00	442.921,00	0,00	0,00	715.631,00	37%	1.205.729,00	
EURICE	Total Person-month	56,00	14,34	15,50	0,00	0,00	29,84	53%	26,16	
	Personnel	363.440,00	65.697,00	79.144,00			144.841,00	40%	218.599,00	
	Other direct costs	29.584,00	3.902,00	8.204,00			12.106,00	41%	17.478,00	
	Subcontracting	0,00	0,00	0,00			0,00	0%	0,00	
	Adjustments			-14.075,00			-14.075,00	0%	14.075,00	
	Indirect costs	308.924,00	55.842,00	67.154,00			122.996,00	40%	185.928,00	
	Total Costs	701.948,00	125.441,00	140.427,00	0,00	0,00	265.868,00	38%	436.080,00	
FORTH	Total Person-month	146,00	43,77	38,46	0,00	0,00	82,23	56%	63,77	
	Personnel	606.484,00	114.630,00	90.446,00			205.076,00	34%	401.408,00	
	Other direct costs	67.500,00	21.999,00	21.401,00			43.400,00	64%	24.100,00	
	Subcontracting	6.000,00	0,00				0,00	0%	6.000,00	
	Adjustments			-6.298,00			-6.298,00	0%	6.298,00	
	Indirect costs	612.548,00	108.899,00	78.688,00			187.587,00	31%	424.961,00	
	Total Costs	1.292.532,00	245.528,00	184.237,00	0,00	0,00	429.765,00	33%	862.767,00	
UCL	Total Person-month	188,00	30,42	48,56	0,00	0,00	78,98	42%	109,02	
	Personnel	788.011,00	152.818,00	220.867,00			373.685,00	47%	414.326,00	
	Other direct costs	125.654,00	58.688,00	18.380,00			77.068,00	61%	48.586,00	
	Subcontracting	12.000,00	0,00	0,00			0,00	0%	12.000,00	
	Adjustments			-17.724,00			-17.724,00	0%	17.724,00	
	Indirect costs	548.199,00	126.903,00	143.547,00			270.450,00	49%	277.749,00	
	Total Costs	1.473.864,00	338.409,00	365.070,00	0,00	0,00	703.479,00	48%	770.385,00	
FhG	Total Person-month	158,00	42,72	49,46	0,00	0,00	92,18	58%	65,82	
	Personnel	1.017.361,00	232.174,00	309.185,00			541.359,00	53%	476.002,00	
	Other direct costs	74.500,00	19.382,00	15.527,00			34.909,00	47%	39.591,00	
	Subcontracting	14.000,00	0,00	0,00			0,00	0%	14.000,00	
	Adjustments			1.430,00			1.430,00	0%	-1.430,00	
	Indirect costs	910.292,00	185.579,00	255.740,00			441.319,00	48%	468.973,00	
	Total Costs	2.016.153,00	437.135,00	581.882,00	0,00	0,00	1.019.017,00	51%	997.136,00	
LUH	Total Person-month	68,00	17,77	18,95	0,00	0,00	36,72	54%	31,28	
	Personnel	440.572,00	98.855,00	71.627,00			170.482,00	39%	270.090,00	
	Other direct costs	32.000,00	5.448,00	6.005,00			11.453,00	36%	20.547,00	
	Subcontracting	3.000,00	0,00	0,00			0,00	0%	3.000,00	
	Adjustments						0,00	0%	0,00	
	Indirect costs	283.544,00	62.581,00	46.579,00			109.160,00	38%	174.384,00	
	Total Costs	759.114,00	166.884,00	124.211,00	0,00	0,00	291.095,00	38%	468.019,00	
Custodix	Total Person-month	67,00	14,26	16,76	0,00	0,00	31,02	46%	35,98	
	Personnel	522.600,00	77.221,00	91.193,00			168.414,00	32%	354.186,00	
	Other direct costs	25.500,00	4.992,00	3.422,00			8.414,00	33%	17.086,00	
	Subcontracting	4.000,00	0,00	0,00			0,00	0%	4.000,00	
	Adjustments			-273,00			-273,00	0%	273,00	
	Indirect costs	261.300,00	35.413,00	50.056,00			85.469,00	33%	175.831,00	
	Total Costs	813.400,00	117.626,00	144.398,00	0,00	0,00	262.024,00	32%	551.376,00	

Philips	Total Person-month	94,00	18,00	22,30	0,00	0,00	40,30	43%	53,70
	Personnel	887.548,00	79.940,00	106.147,00			186.087,00	21%	701.461,00
	Other direct costs	29.500,00	0,00	0,00			0,00	0%	29.500,00
	Subcontracting	8.000,00	0,00	0,00			0,00	0%	8.000,00
	Adjustments			2.580,00			2.580,00	0%	-2.580,00
	Indirect costs	772.166,00	181.559,00	206.655,00			388.214,00	50%	383.952,00
	Total Costs	1.697.214,00	261.499,00	315.382,00	0,00	0,00	576.881,00	34%	1.120.333,00
UDUS	Total Person-month	52,00	13,93	18,51	0,00	0,00	32,44	62%	19,56
	Personnel	285.168,00	74.656,00	100.602,00			175.258,00	61%	109.910,00
	Other direct costs	107.000,00	1.504,00	5.911,00			7.415,00	7%	99.585,00
	Subcontracting	5.000,00	0,00				0,00	0%	5.000,00
	Adjustments			942,00			942,00	0%	-942,00
	Indirect costs	235.301,00	45.695,00	63.664,00			109.359,00	46%	125.942,00
	Total Costs	632.468,00	121.855,00	171.119,00	0,00	0,00	292.974,00	46%	339.494,00
ICCS	Total Person-month	92,00	9,17	28,89	0,00	0,00	38,06	41%	53,94
	Personnel	460.000,00	62.636,00	179.291,00			241.927,00	53%	218.073,00
	Other direct costs	74.000,00	8.644,00	6.130,00			14.774,00	20%	59.226,00
	Subcontracting	5.000,00	0,00	0,00			0,00	0%	5.000,00
	Adjustments						0,00	0%	0,00
	Indirect costs	320.400,00	42.767,00	111.251,00			154.018,00	48%	166.382,00
	Total Costs	859.400,00	114.047,00	296.672,00	0,00	0,00	410.719,00	48%	448.681,00
UPM	Total Person-month	74,00	17,80	22,38	0,00	0,00	40,18	54%	33,82
	Personnel	319.162,00	82.656,00	88.849,00			171.505,00	54%	147.657,00
	Other direct costs	38.000,00	9.021,00	3.795,00			12.816,00	34%	25.184,00
	Subcontracting	8.000,00	0,00	0,00			0,00	0%	8.000,00
	Adjustments						0,00	0%	0,00
	Indirect costs	282.159,00	69.100,00	61.945,00			131.045,00	46%	151.114,00
	Total Costs	647.320,00	160.777,00	154.589,00	0,00	0,00	315.366,00	49%	331.954,00
CAU	Total Person-month	50,00	4,19	12,93	0,00	0,00	17,12	34%	32,88
	Personnel	250.000,00	18.430,00	65.182,00			83.612,00	33%	166.388,00
	Other direct costs	24.000,00	0,00	0,00			0,00	0%	24.000,00
	Subcontracting	0,00	0,00	0,00			0,00	0%	0,00
	Adjustments						0,00	0%	0,00
	Indirect costs	164.400,00	11.058,00	39.109,20			50.167,20	31%	114.232,80
	Total Costs	438.400,00	29.488,00	104.291,20	0,00	0,00	133.779,20	31%	304.620,80
Third Party - Uniklinikum	Total Person-month	0,00	0,00	0,00	0,00	0,00	0,00	0%	0,00
	Personnel	0,00	0,00	0,00			0,00	0%	0,00
	Other direct costs	0,00	1.573,00	5.449,00			7.022,00	0%	-7.022,00
	Subcontracting	0,00	0,00	0,00			0,00	0%	0,00
	Adjustments						0,00	0%	0,00
	Indirect costs	0,00	943,00	3.269,00			4.212,00	0%	-4.212,00
	Total Costs	0,00	2.516,00	8.718,00	0,00	0,00	11.234,00	0%	-11.234,00
IEO	Total Person-month	95,00	27,51	46,96	0,00	0,00	74,47	78%	20,53
	Personnel	581.685,00	85.145,00	152.324,00			237.469,00	41%	344.216,00
	Other direct costs	20.000,00	2.006,00	1.734,00			3.740,00	19%	16.260,00
	Subcontracting	5.000,00	0,00	0,00			0,00	0%	5.000,00
	Adjustments						0,00	0%	0,00
	Indirect costs	120.337,00	17.429,00	30.811,00			48.240,00	40%	72.097,00
	Total Costs	727.022,00	104.580,00	184.869,00	0,00	0,00	289.449,00	40%	437.573,00
ecancer	Total Person-month	92,00	26,60	25,56	0,00	0,00	52,16	57%	39,84
	Personnel	460.000,00	119.152,00	103.279,00			222.431,00	48%	237.569,00
	Other direct costs	163.500,00	37.568,00	21.644,00			59.212,00	36%	104.288,00
	Subcontracting	10.000,00	0,00	0,00			0,00	0%	10.000,00
	Adjustments						0,00	0%	0,00
	Indirect costs	374.100,00	94.031,00	74.953,00			168.984,00	45%	205.116,00
	Total Costs	1.007.600,00	250.751,00	199.876,00	0,00	0,00	450.627,00	45%	556.973,00
UOXF	Total Person-month	67,00	10,87	17,61	0,00	0,00	28,48	43%	38,52
	Personnel	402.000,00	45.194,00	77.265,00			122.459,00	30%	279.541,00
	Other direct costs	77.800,00	5.924,00	5.935,00			11.859,00	15%	65.941,00
	Subcontracting	3.500,00	0,00				0,00	0%	3.500,00
	Adjustments						0,00	0%	0,00
	Indirect costs	287.880,00	30.670,00	49.920,00			80.590,00	28%	207.290,00
	Total Costs	771.180,00	81.788,00	133.120,00	0,00	0,00	214.908,00	28%	556.272,00

BIOVISTA	Total Person-month	97,00	35,00	47,63	0,00	0,00	82,63	85%	14,37
	Personnel	398.088,00	93.511,00	126.154,00			219.665,00	55%	178.423,00
	Other direct costs	101.000,00	35.676,00	21.852,00			57.528,00	57%	43.472,00
	Subcontracting	4.000,00	0,00	0,00			0,00	0%	4.000,00
	Adjustments			6.855,00			6.855,00	0%	-6.855,00
	Indirect costs	159.236,00	14.016,00	21.446,00			35.462,00	22%	123.774,00
	Total Costs	662.324,00	143.203,00	176.307,00	0,00	0,00	319.510,00	48%	342.814,00
SIB	Total Person-month	59,00	12,00	12,00	0,00	0,00	24,00	41%	35,00
	Personnel	395.300,00	75.627,00	78.273,00			153.900,00	39%	241.400,00
	Other direct costs	16.000,00	5.983,00	2.054,00			8.037,00	50%	7.963,00
	Subcontracting	3.000,00	0,00	0,00			0,00	0%	3.000,00
	Adjustments						0,00	0%	0,00
	Indirect costs	246.780,00	48.965,00	48.195,00			97.160,00	39%	149.620,00
	Total Costs	661.080,00	130.575,00	128.522,00	0,00	0,00	259.097,00	39%	401.983,00
UHok	Total Person-month	28,00	5,90	7,80	0,00	0,00	13,70	49%	14,30
	Personnel	123.340,00	22.333,00	29.325,00			51.658,00	42%	71.682,00
	Other direct costs	144.000,00	14.086,00	2.723,00			16.809,00	12%	127.191,00
	Subcontracting	0,00	0,00	0,00			0,00	0%	0,00
	Adjustments						0,00	0%	0,00
	Indirect costs	53.468,00	7.283,00	6.409,00			13.692,00	26%	39.776,00
	Total Costs	320.808,00	43.702,00	38.457,00	0,00	0,00	82.159,00	26%	238.649,00
PSNC	Total Person-month	86,00	19,18	29,13	0,00	0,00	48,31	56%	37,69
	Personnel	380.120,00	78.568,00	113.078,00			191.646,00	50%	188.474,00
	Other direct costs	34.573,00	9.691,00	6.804,00			16.495,00	48%	18.078,00
	Subcontracting	0,00	0,00	0,00			0,00	0%	0,00
	Adjustments						0,00	0%	0,00
	Indirect costs	248.816,00	52.955,00	71.929,00			124.884,00	50%	123.932,00
	Total Costs	663.508,00	141.214,00	191.811,00	0,00	0,00	333.025,00	50%	330.483,00
Total	Total Person-month	1.762,00	391,88	525,49	0,00	0,00	917,37	52%	844,63
	Personnel	9.645.879,00	1.728.339,00	2.330.623,00	0,00	0,00	4.058.962,00	42%	5.586.917,00
	Other direct costs	1.416.211,00	267.436,00	185.405,00	0,00	0,00	445.819,00	32%	970.392,00
	Subcontracting	96.500,00	0,00	0,00	0,00	0,00	0,00	0%	96.500,00
	Adjustments	0,00	0,00	-26.563,00	0,00	0,00	-26.563,00	0%	26.563,00
	Indirect costs	6.908.110,00	1.293.953,00	1.597.414,20	0,00	0,00	2.887.155,20	42%	4.020.954,80
	Total Costs	18.066.695,00	3.289.728,00	4.086.879,20	0,00	0,00	7.365.373,20	41%	10.701.321,80

5.2 Budget Explanations

The Explanation of the Use of the Resources as directly provided via NEF is attached in the following.

5.3 Planned versus actual efforts

Planned versus actual efforts are included in each work package report. An overview of the planned efforts compared to the actual efforts is provided in a separate Excel table submitted with the report.

The following changes have occurred:

FORTH

Work Package	PM according to DoW	New distribution of PM
WP1	5.00	6.00
WP2	5.00	8.00
WP3	26.00	40.00
WP4	15.00	28.00
WP7	10.00	15.00
WP8	52.00	76.00
WP10	2.00	3.00
WP12	10.00	16.00
WP13	12.00	6.00
WP14	0.00	36.00
WP16	5.00	7.00
WP17	4.00	6.00
Total	146.00	222.00

Originally, FORTH was not directly involved in WP14. However, FORTH is the developer of IEmS and has been involved in the organization of regular Skype and teleconference meetings as well as in a WP14 meeting in Milan to discuss its implementation. Therefore, 5 PMs had to be added to WP14.

The reason for the increase of PMs without subsequent change of the budget is that FORTH had planned the budget on higher salary, experienced post-docs at an average rate given by our central administration. Eventually, no appropriate senior post-docs could be hired and instead a larger number of less experienced Engineers (Graduates) was hired for the project at lower rates. The result was an increase in the number of actual PMs for FORTH.

FhG-IAIS

Work Package	PM according to DoW	New distribution of PM
WP2	2.00	2.50
WP3	9.00	9.00
WP5	3.00	3.00
WP7	6.00	6.00
WP11	41.00	38.50
WP13	6.00	6.00
WP15	6.00	8.00
WP17	3.00	3.00
Total	76.00	76.00

FhG-IAIS noticed during the first phase of the project that they need to spend more effort on the requirements engineering and management of requirements and thus want to increase the priority of this kind of work. Decreasing the number of person month for WP11 will not affect the work initially planned in the DoW.

CAU

Work Package	PM according to DoW	New distribution of PM
WP2	3.00	2.40
WP6	4.00	3.70
WP9	36.00	33.40
WP12	3.00	3.00
WP17	4.00	4.00
Total	50.00	46.50

The total person months in WP9 had been reduced from 36 to 33.4 in order to allow the financing of adequate biostatistical data management software.

When setting up the budget for p-medicine the calculations of personnel costs were made on different assumptions. In October 2011, CAU found a qualified employee to carry out the work as proposed in the DoW. To compensate this lack of personnel during the first half year, Martin Stanulla and Martin Zimmermann have contributed their own efforts. Accordingly, the work has been done as planned in the DoW but they have not been paid by the project. On the basis of the money not paid for personnel in the first half year, CAU proposes to optimize its cost distribution and use such money to compensate the need for technical equipment. To provide an adequate IT infrastructure for CAU's new employee, Ms. Antje Torge, two new computers with different operating systems plus mathematical software required will amount to approx. 6.000€. In addition, an update and adaptation of the data management software Scopeland for biobanking and diagnostics is foreseen to facilitate an international virtual biobank scenario, in cooperation with FhG-IBMT at Potsdam. In a first approach to generate a use case for such a scenario, it was decided at a Berlin meeting with FhG-IBMT, CAU and representatives of the Department of Pediatric Hematology and Oncology at Charité Berlin to aim at integration of existing biobank data systems of a frontline and corresponding secondline clinical trial group on treatment of childhood acute lymphoblastic leukemia in Germany as an initial step for developing an unified international virtual biobank for this disease. Therefore, already existing laboratory software at CAU will have to be adapted in order to allow optimal integration of biobanks at CAU (frontline trial group) and at the Department of Pediatric Hematology and Oncology at Charité Berlin (secondline trial group). Partial financing of this prerequisite through the project will amount to approx. 10.000€.

The shift of costs will give CAU the possibility to create optimal conditions for its work in p-medicine.

BIOVISTA

Due to their relatively large increase in PM in work packages 11 and 13, Biovista expects that the total number of person months will be increased by the end of the project. This increase should leave the budget unaffected. A table showing the redistribution of Biovista's person months in each work package will be provided in the next report.

6 Financial Statements

6.1 Forms C and Summary Financial Statement

Forms C are submitted via the NEF tool in parallel. In the following, a copy of the summary financial report as available in the NEF tool is attached, together with copies of the Forms C of all beneficiaries.

6.2 Certificates

Beneficiary	Organisation short name	Certificate on the Financial Statements provided? Yes/No	Comments
1	USAAR	Yes	
2	Eurice	No	
3	FORTH	No	
4	UCL	Yes	
5	FhG	No	According to the Certificate on the Methodology a CFS needs to be handed in only at the end of the project.
6	LUH	No	
7	Custodix	No	
8	Philips	No	
9	UDUS	No	
10	ICCS	No	
11	UPM	No	
12	CAU	No	
13	IEO	No	
14	Ecancer	No	
15	SIB	No	
16	Biovista	No	
17	SIB	No	
18	UHok	No	
19	PSNC	No	

7 Annexes

7.1 p-medicine PM Effort Calculation

Provided separately in Excel format.

FP7 - Grant Agreement - Annex VI - Collaborative project

Summary Financial report - Collaborative project

Project acronym	p-medicine	Project nr	270089	Reporting period from	01/02/2012	to	31/01/2013	Page	1/1
-----------------	------------	------------	--------	-----------------------	------------	----	------------	------	-----

Funding scheme		CP		Type of activity								Total		Req. EC Contrib.	Receipts	Interest
Benef. nr	If 3rd Party, linked to benef.	Adjustment (Yes/No)	Organisation Short Name	RTD (A)		Demonstration (B)		Management (C)		Other (D)		Total (A+B+C+D)				
				Total	Max EC Contrib.	Total	Max EC Contrib.	Total	Max EC Contrib.	Total	Max EC Contrib.	Total	Max EC Contrib.			
1		No	USAAR	356,196	267,147	0	0	29,388	29,388	57,337	57,337	442,921	353,872	353,872	0	4,368
2		No	EURICE	0	0	0	0	100,577	100,577	53,925	53,925	154,502	154,502	154,502	0	
2		Yes (1)	EURICE	0	0	0	0	-13,723	-13,723	-352	-352	-14,075	-14,075	-14,075	0	
3		No	FORTH	177,539	133,154	0	0	1,948	1,948	11,048	11,048	190,535	146,150	146,150	0	
3		Yes (1)	FORTH	-5,675	-4,256	0	0	-361	-361	-262	-262	-6,298	-4,879	-4,879	0	
4		No	UCL	354,785	266,088	0	0	0	0	28,009	28,009	382,794	294,097	294,097	0	
4		Yes (1)	UCL	-17,724	-13,293	0	0	0	0	0	0	-17,724	-13,293	-13,293	0	
5		No	FhG	572,645	429,483	0	0	0	0	7,807	7,807	580,452	437,290	437,290	0	
5		Yes (1)	FhG	1,393	1,044	0	0	0	0	37	37	1,430	1,081	1,081	0	
6		No	LUH	124,211	93,158	0	0	0	0	0	0	124,211	93,158	93,158	0	
7		No	CUSTODIX	142,016	106,512	0	0	0	0	2,655	2,655	144,671	109,167	109,167	0	
7		Yes (1)	CUSTODIX	-273	-204	0	0	0	0	0	0	-273	-204	-204	0	
8		No	Philips	309,612	154,806	0	0	0	0	3,190	3,190	312,802	157,996	157,996	0	
8		Yes (1)	Philips	2,580	1,290	0	0	0	0	0	0	2,580	1,290	1,290	0	
9		No	UDUS	163,173	122,379	0	0	0	0	7,004	7,004	170,177	129,383	129,383	0	
9		Yes (1)	UDUS	942	706	0	0	0	0	0	0	942	706	706	0	
10		No	ICCS	263,156	197,367	0	0	0	0	33,516	33,516	296,672	230,883	230,883	0	
11		No	UPM	145,138	108,853	0	0	0	0	9,451	9,451	154,589	118,304	118,304	0	
12		No	CAU	100,891	75,668	0	0	0	0	3,400	3,400	104,291	79,068	79,068	0	
-999	12	No	UKSH	8,483	6,362	0	0	0	0	235	235	8,718	6,597	6,597	0	
13		No	IEO	178,718	89,359	0	0	0	0	6,151	6,151	184,869	95,510	95,510	0	
14		No	ecancer	126,384	94,788	0	0	0	0	73,492	73,492	199,876	168,280	168,280	0	
15		No	UOXF.BP	132,920	99,690	0	0	0	0	200	200	133,120	99,890	99,890	0	
16		No	BIOVISTA	129,035	96,776	0	0	0	0	40,417	40,417	169,452	137,193	137,193	0	
16		Yes (1)	BIOVISTA	4,578	3,433	0	0	0	0	2,277	2,277	6,855	5,710	5,710	0	
17		No	SIB	122,780	92,085	0	0	0	0	5,742	5,742	128,522	97,827	97,827	0	
18		No	UHok	38,457	28,842	0	0	0	0	0	0	38,457	28,842		0	
20		No	PSNC	191,811	143,858	0	0	0	0	0	0	191,811	143,858	143,858	27,595	
Total				3,623,771	2,595,095	0	0	117,829	117,829	345,279	345,279	4,086,879	3,058,203	3,029,361	27,595	

FP7 - Grant Agreement - Annex VI - Collaborative project

Form C - Financial Statement (to be filled in by each beneficiary)

Project Number	270089	Funding scheme	Collaborative project
Project Acronym	p-medicine		
Period from	01/02/2012	Is this an adjustment to a previous statement ?	No
To	31/01/2013		
Legal Name	UNIVERSITAET DES SAARLANDES	Participant Identity Code	999929545
Organisation Short Name	USAAR	Beneficiary nr	1
Funding % for RTD activities (A)	75.0	If flat rate for indirect costs, specify %	60

1. Declaration of eligible costs/lump sum/flat-rate/scale of unit (in €)

	Type of Activity				Total (A+B+C+D)
	RTD (A)	Demonstration (B)	Management (C)	Other (D)	
Personnel costs	216,548	0	11,169	20,675	248,392
Subcontracting	0	0	0	0	0
Other direct costs	6,075	0	7,199	15,161	28,435
Indirect costs	133,573	0	11,020	21,501	166,094
Total costs	356,196	0	29,388	57,337	442,921
Maximum EU contribution	267,147	0	29,388	57,337	353,872
Requested EU contribution					353,872

2. Declaration of receipts

Did you receive any financial transfers or contributions in kind, free of charge from third parties or did the project generate any income which could be considered a receipt according to Art.II. 17 of the grant agreement ?
If yes, please mention the amount (in €)

No

3. Declaration of interest yielded by the pre-financing (to be completed only by the coordinator)

Did the pre-financing you received generate any interest according to Art.II.19 ?

Yes

If yes, please mention the amount (in €)

4,368

4. Certificate on the methodology

Do you declare average personnel costs according to Art.II.14.1 ?

No

Is there a certificate on the methodology provided by an independent auditor and accepted by the Commission according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €), if charged under this project	
---------------------	--	---	--

5. Certificate on the financial statements

Is there a certificate on the financial statements provided by an independent auditor attached to this financial statement according to Art.II.4.4 ?

Yes

Name of the auditor	Ellen Krippner	Cost of the certificate (in €)	1,131
---------------------	----------------	--------------------------------	-------

6. Beneficiary's declaration on its honour

We declare on our honour that:

- the costs declared above are directly related to the resources used to attain the objectives of the project and fall within the definition of eligible costs specified in Articles II.14 and II.15 of the grant agreement, and, if relevant, Annex III and Article 7 (special clauses) of the grant agreement;
- the receipts declared above are the only financial transfers or contributions in kind, free of charge, from third parties and the only income generated by the project which could be considered as receipts according to Art.II.17 of the grant agreement;
- the interest declared above is the only interest yielded by the pre-financing which falls within the definition of Art.II.19 of the grant agreement;
- there is full supporting documentation to justify the information hereby declared. It will be made available at the request of the Commission and in the event of an audit by the Commission and/or by the Court of Auditors and/or their authorised representatives.

Beneficiary's Stamp	Name of the Person(s) Authorised to sign this Financial Statement
	Claudia Theis
	Date & signature

FP7 - Grant Agreement - Annex VI - Collaborative project

Form C - Financial Statement (to be filled in by each beneficiary)

Project Number	270089	Funding scheme	Collaborative project
Project Acronym	p-medicine		
Period from	01/02/2012	Is this an adjustment to a previous statement ?	No
To	31/01/2013		
Legal Name	EUROPEAN RESEARCH AND PROJECT OFFICE GMBH	Participant Identity Code	999778419
Organisation Short Name	EURICE	Beneficiary nr	2
Funding % for RTD activities (A)	75.0	If flat rate for indirect costs, specify %	N/A

1. Declaration of eligible costs/lump sum/flat-rate/scale of unit (in €)

	Type of Activity				Total (A+B+C+D)
	RTD (A)	Demonstration (B)	Management (C)	Other (D)	
Personnel costs	0	0	52,341	26,803	79,144
Subcontracting	0	0	0	0	0
Other direct costs	0	0	3,824	4,380	8,204
Indirect costs	0	0	44,412	22,742	67,154
Total costs	0	0	100,577	53,925	154,502
Maximum EU contribution	0	0	100,577	53,925	154,502
Requested EU contribution					154,502

2. Declaration of receipts

Did you receive any financial transfers or contributions in kind, free of charge from third parties or did the project generate any income which could be considered a receipt according to Art.II. 17 of the grant agreement ?
If yes, please mention the amount (in €)

No

4. Certificate on the methodology

Do you declare average personnel costs according to Art.II.14.1 ?

No

Is there a certificate on the methodology provided by an independent auditor and accepted by the Commission according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €), if charged under this project	
---------------------	--	---	--

. Certificate on the financial statements

Is there a certificate on the financial statements provided by an independent auditor attached to this financial statement according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €)	
---------------------	--	--------------------------------	--

6. Beneficiary's declaration on its honour

We declare on our honour that:

- the costs declared above are directly related to the resources used to attain the objectives of the project and fall within the definition of eligible costs specified in Articles II.14 and II.15 of the grant agreement, and, if relevant, Annex III and Article 7 (special clauses) of the grant agreement;
- the receipts declared above are the only financial transfers or contributions in kind, free of charge, from third parties and the only income generated by the project which could be considered as receipts according to Art.II.17 of the grant agreement;
- the interest declared above is the only interest yielded by the pre-financing which falls within the definition of Art.II.19 of the grant agreement;
- there is full supporting documentation to justify the information hereby declared. It will be made available at the request of the Commission and in the event of an audit by the Commission and/or by the Court of Auditors and/or their authorised representatives.

Beneficiary's Stamp	Name of the Person(s) Authorised to sign this Financial Statement
	Pascal Fichot
	Date & signature

FP7 - Grant Agreement - Annex VI - Collaborative project

Form C - Financial Statement (to be filled in by each beneficiary)

Project Number	270089	Funding scheme	Collaborative project
Project Acronym	p-medicine		
Period from	01/02/2012	Is this an adjustment to a previous statement ?	Yes
To	31/01/2013	Adjustment relates to Period :	1
Legal Name	EUROPEAN RESEARCH AND PROJECT OFFICE GMBH	Participant Identity Code	999778419
Organisation Short Name	EURICE	Beneficiary nr	2
Funding % for RTD activities (A)	75.0	If flat rate for indirect costs, specify %	N/A

1. Declaration of eligible costs/lump sum/flat-rate/scale of unit (in €)

	Type of Activity				Total (A+B+C+D)
	RTD (A)	Demonstration (B)	Management (C)	Other (D)	
Personnel costs	0	0	-7,416	-188	-7,604
Subcontracting	0	0	0	0	0
Other direct costs	0	0	0	0	0
Indirect costs	0	0	-6,307	-164	-6,471
Total costs	0	0	-13,723	-352	-14,075
Maximum EU contribution	0	0	-13,723	-352	-14,075
Requested EU contribution					-14,075

2. Declaration of receipts

Did you receive any financial transfers or contributions in kind, free of charge from third parties or did the project generate any income which could be considered a receipt according to Art.II. 17 of the grant agreement ?

If yes, please mention the amount (in €)

No

4. Certificate on the methodology

Do you declare average personnel costs according to Art.II.14.1 ?

Is there a certificate on the methodology provided by an independent auditor and accepted by the Commission according to Art.II.4.4 ?

No

No

Name of the auditor		Cost of the certificate (in €), if charged under this project	
---------------------	--	---	--

. Certificate on the financial statements

Is there a certificate on the financial statements provided by an independent auditor attached to this financial statement according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €)	
---------------------	--	--------------------------------	--

6. Beneficiary's declaration on its honour

We declare on our honour that:

- the costs declared above are directly related to the resources used to attain the objectives of the project and fall within the definition of eligible costs specified in Articles II.14 and II.15 of the grant agreement, and, if relevant, Annex III and Article 7 (special clauses) of the grant agreement;
- the receipts declared above are the only financial transfers or contributions in kind, free of charge, from third parties and the only income generated by the project which could be considered as receipts according to Art.II.17 of the grant agreement;
- the interest declared above is the only interest yielded by the pre-financing which falls within the definition of Art.II.19 of the grant agreement;
- there is full supporting documentation to justify the information hereby declared. It will be made available at the request of the Commission and in the event of an audit by the Commission and/or by the Court of Auditors and/or their authorised representatives.

Beneficiary's Stamp	Name of the Person(s) Authorised to sign this Financial Statement
	Pascal Fichot
	Date & signature

FP7 - Grant Agreement - Annex VI - Collaborative project

Form C - Financial Statement (to be filled in by each beneficiary)

Project Number	270089	Funding scheme	Collaborative project
Project Acronym	p-medicine		
Period from	01/02/2012	Is this an adjustment to a previous statement ?	No
To	31/01/2013		
Legal Name	FOUNDATION FOR RESEARCH AND TECHNOLOGY HELLAS	Participant Identity Code	999995893
Organisation Short Name	FORTH	Beneficiary nr	3
Funding % for RTD activities (A)	75.0	If flat rate for indirect costs, specify %	N/A

1. Declaration of eligible costs/lump sum/flat-rate/scale of unit (in €)

	Type of Activity				Total (A+B+C+D)
	RTD (A)	Demonstration (B)	Management (C)	Other (D)	
Personnel costs	88,034	0	0	2,412	90,446
Subcontracting	0	0	0	0	0
Other direct costs	12,915	0	1,948	6,538	21,401
Indirect costs	76,590	0	0	2,098	78,688
Total costs	177,539	0	1,948	11,048	190,535
Maximum EU contribution	133,154	0	1,948	11,048	146,150
Requested EU contribution					146,150

2. Declaration of receipts

Did you receive any financial transfers or contributions in kind, free of charge from third parties or did the project generate any income which could be considered a receipt according to Art.II. 17 of the grant agreement ?

If yes, please mention the amount (in €)

No

4. Certificate on the methodology

Do you declare average personnel costs according to Art.II.14.1 ?

Is there a certificate on the methodology provided by an independent auditor and accepted by the Commission according to Art.II.4.4 ?

No

No

Name of the auditor		Cost of the certificate (in €), if charged under this project	
---------------------	--	---	--

. Certificate on the financial statements

Is there a certificate on the financial statements provided by an independent auditor attached to this financial statement according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €)	
---------------------	--	--------------------------------	--

6. Beneficiary's declaration on its honour

We declare on our honour that:

- the costs declared above are directly related to the resources used to attain the objectives of the project and fall within the definition of eligible costs specified in Articles II.14 and II.15 of the grant agreement, and, if relevant, Annex III and Article 7 (special clauses) of the grant agreement;
- the receipts declared above are the only financial transfers or contributions in kind, free of charge, from third parties and the only income generated by the project which could be considered as receipts according to Art.II.17 of the grant agreement;
- the interest declared above is the only interest yielded by the pre-financing which falls within the definition of Art.II.19 of the grant agreement;
- there is full supporting documentation to justify the information hereby declared. It will be made available at the request of the Commission and in the event of an audit by the Commission and/or by the Court of Auditors and/or their authorised representatives.

Beneficiary's Stamp	Name of the Person(s) Authorised to sign this Financial Statement
	Prof. Manolis Tsiknakis & Mrs. Evangelia Hatzidaki
	Date & signature

FP7 - Grant Agreement - Annex VI - Collaborative project

Form C - Financial Statement (to be filled in by each beneficiary)

Project Number	270089	Funding scheme	Collaborative project
Project Acronym	p-medicine		
Period from	01/02/2012	Is this an adjustment to a previous statement ?	Yes
To	31/01/2013	Adjustment relates to Period :	1
Legal Name	FOUNDATION FOR RESEARCH AND TECHNOLOGY HELLAS	Participant Identity Code	999995893
Organisation Short Name	FORTH	Beneficiary nr	3
Funding % for RTD activities (A)	75.0	If flat rate for indirect costs, specify %	N/A

1. Declaration of eligible costs/lump sum/flat-rate/scale of unit (in €)

	Type of Activity				Total (A+B+C+D)
	RTD (A)	Demonstration (B)	Management (C)	Other (D)	
Personnel costs	1,535	0	0	0	1,535
Subcontracting	0	0	0	0	0
Other direct costs	0	0	0	0	0
Indirect costs	-7,210	0	-361	-262	-7,833
Total costs	-5,675	0	-361	-262	-6,298
Maximum EU contribution	-4,256	0	-361	-262	-4,879
Requested EU contribution					-4,879

2. Declaration of receipts

Did you receive any financial transfers or contributions in kind, free of charge from third parties or did the project generate any income which could be considered a receipt according to Art.II. 17 of the grant agreement ?
If yes, please mention the amount (in €)

No

4. Certificate on the methodology

Do you declare average personnel costs according to Art.II.14.1 ?

No

Is there a certificate on the methodology provided by an independent auditor and accepted by the Commission according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €), if charged under this project	
---------------------	--	---	--

. Certificate on the financial statements

Is there a certificate on the financial statements provided by an independent auditor attached to this financial statement according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €)	
---------------------	--	--------------------------------	--

6. Beneficiary's declaration on its honour

We declare on our honour that:

- the costs declared above are directly related to the resources used to attain the objectives of the project and fall within the definition of eligible costs specified in Articles II.14 and II.15 of the grant agreement, and, if relevant, Annex III and Article 7 (special clauses) of the grant agreement;
- the receipts declared above are the only financial transfers or contributions in kind, free of charge, from third parties and the only income generated by the project which could be considered as receipts according to Art.II.17 of the grant agreement;
- the interest declared above is the only interest yielded by the pre-financing which falls within the definition of Art.II.19 of the grant agreement;
- there is full supporting documentation to justify the information hereby declared. It will be made available at the request of the Commission and in the event of an audit by the Commission and/or by the Court of Auditors and/or their authorised representatives.

Beneficiary's Stamp	Name of the Person(s) Authorised to sign this Financial Statement
	Prof. Manolis Tsiknakis & Mrs. Evangelia Hatzidaki
	Date & signature

FP7 - Grant Agreement - Annex VI - Collaborative project

Form C - Financial Statement (to be filled in by each beneficiary)

Project Number	270089	Funding scheme	Collaborative project
Project Acronym	p-medicine		
Period from	01/02/2012	Is this an adjustment to a previous statement ?	No
To	31/01/2013		
Legal Name	UNIVERSITY COLLEGE LONDON	Participant Identity Code	999975620
Organisation Short Name	UCL	Beneficiary nr	4
Funding % for RTD activities (A)	75.0	If flat rate for indirect costs, specify %	60

1. Declaration of eligible costs/lump sum/flat-rate/scale of unit (in €)

	Type of Activity				Total (A+B+C+D)
	RTD (A)	Demonstration (B)	Management (C)	Other (D)	
Personnel costs	203,361	0	0	17,506	220,867
Subcontracting	0	0	0	0	0
Other direct costs	18,380	0	0	0	18,380
Indirect costs	133,044	0	0	10,503	143,547
Total costs	354,785	0	0	28,009	382,794
Maximum EU contribution	266,088	0	0	28,009	294,097
Requested EU contribution					294,097

2. Declaration of receipts

Did you receive any financial transfers or contributions in kind, free of charge from third parties or did the project generate any income which could be considered a receipt according to Art.II. 17 of the grant agreement ?

If yes, please mention the amount (in €)

No

4. Certificate on the methodology

Do you declare average personnel costs according to Art.II.14.1 ?

Is there a certificate on the methodology provided by an independent auditor and accepted by the Commission according to Art.II.4.4 ?

No

No

Name of the auditor		Cost of the certificate (in €), if charged under this project	
---------------------	--	---	--

. Certificate on the financial statements

Is there a certificate on the financial statements provided by an independent auditor attached to this financial statement according to Art.II.4.4 ?

Yes

Name of the auditor	Contractauditline Ltd.	Cost of the certificate (in €)	2,333
---------------------	------------------------	--------------------------------	-------

6. Beneficiary's declaration on its honour

We declare on our honour that:

- the costs declared above are directly related to the resources used to attain the objectives of the project and fall within the definition of eligible costs specified in Articles II.14 and II.15 of the grant agreement, and, if relevant, Annex III and Article 7 (special clauses) of the grant agreement;
- the receipts declared above are the only financial transfers or contributions in kind, free of charge, from third parties and the only income generated by the project which could be considered as receipts according to Art.II.17 of the grant agreement;
- the interest declared above is the only interest yielded by the pre-financing which falls within the definition of Art.II.19 of the grant agreement;
- there is full supporting documentation to justify the information hereby declared. It will be made available at the request of the Commission and in the event of an audit by the Commission and/or by the Court of Auditors and/or their authorised representatives.

Beneficiary's Stamp	Name of the Person(s) Authorised to sign this Financial Statement
	Donna Grant
	Date & signature

FP7 - Grant Agreement - Annex VI - Collaborative project

Form C - Financial Statement (to be filled in by each beneficiary)

Project Number	270089	Funding scheme	Collaborative project
Project Acronym	p-medicine		
Period from	01/02/2012	Is this an adjustment to a previous statement ?	Yes
To	31/01/2013	Adjustment relates to Period :	1
Legal Name	UNIVERSITY COLLEGE LONDON	Participant Identity Code	999975620
Organisation Short Name	UCL	Beneficiary nr	4
Funding % for RTD activities (A)	75.0	If flat rate for indirect costs, specify %	60

1. Declaration of eligible costs/lump sum/flat-rate/scale of unit (in €)

	Type of Activity				Total (A+B+C+D)
	RTD (A)	Demonstration (B)	Management (C)	Other (D)	
Personnel costs	-10,908	0	0	0	-10,908
Subcontracting	0	0	0	0	0
Other direct costs	-170	0	0	0	-170
Indirect costs	-6,646	0	0	0	-6,646
Total costs	-17,724	0	0	0	-17,724
Maximum EU contribution	-13,293	0	0	0	-13,293
Requested EU contribution					-13,293

2. Declaration of receipts

Did you receive any financial transfers or contributions in kind, free of charge from third parties or did the project generate any income which could be considered a receipt according to Art.II. 17 of the grant agreement ?
If yes, please mention the amount (in €)

No

4. Certificate on the methodology

Do you declare average personnel costs according to Art.II.14.1 ?

No

Is there a certificate on the methodology provided by an independent auditor and accepted by the Commission according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €), if charged under this project	
---------------------	--	---	--

. Certificate on the financial statements

Is there a certificate on the financial statements provided by an independent auditor attached to this financial statement according to Art.II.4.4 ?

Yes

Name of the auditor	Contractauditline Ltd.	Cost of the certificate (in €)	2,333
---------------------	------------------------	--------------------------------	-------

6. Beneficiary's declaration on its honour

We declare on our honour that:

- the costs declared above are directly related to the resources used to attain the objectives of the project and fall within the definition of eligible costs specified in Articles II.14 and II.15 of the grant agreement, and, if relevant, Annex III and Article 7 (special clauses) of the grant agreement;
- the receipts declared above are the only financial transfers or contributions in kind, free of charge, from third parties and the only income generated by the project which could be considered as receipts according to Art.II.17 of the grant agreement;
- the interest declared above is the only interest yielded by the pre-financing which falls within the definition of Art.II.19 of the grant agreement;
- there is full supporting documentation to justify the information hereby declared. It will be made available at the request of the Commission and in the event of an audit by the Commission and/or by the Court of Auditors and/or their authorised representatives.

Beneficiary's Stamp	Name of the Person(s) Authorised to sign this Financial Statement
	Donna Grant
	Date & signature

FP7 - Grant Agreement - Annex VI - Collaborative project

Form C - Financial Statement (to be filled in by each beneficiary)

Project Number	270089	Funding scheme	Collaborative project
Project Acronym	p-medicine		
Period from	01/02/2012	Is this an adjustment to a previous statement ?	No
To	31/01/2013		
Legal Name	FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V	Participant Identity Code	999984059
Organisation Short Name	FhG	Beneficiary nr	5
Funding % for RTD activities (A)	75.0	If flat rate for indirect costs, specify %	N/A

1. Declaration of eligible costs/lump sum/flat-rate/scale of unit (in €)

	Type of Activity				Total (A+B+C+D)
	RTD (A)	Demonstration (B)	Management (C)	Other (D)	
Personnel costs	304,986	0	0	4,199	309,185
Subcontracting	0	0	0	0	0
Other direct costs	15,527	0	0	0	15,527
Indirect costs	252,132	0	0	3,608	255,740
Total costs	572,645	0	0	7,807	580,452
Maximum EU contribution	429,483	0	0	7,807	437,290
Requested EU contribution					437,290

2. Declaration of receipts

Did you receive any financial transfers or contributions in kind, free of charge from third parties or did the project generate any income which could be considered a receipt according to Art.II. 17 of the grant agreement ?

If yes, please mention the amount (in €)

No

4. Certificate on the methodology

Do you declare average personnel costs according to Art.II.14.1 ?

Is there a certificate on the methodology provided by an independent auditor and accepted by the Commission according to Art.II.4.4 ?

Yes

Yes

Name of the auditor	Deloitte & Touche GmbH	Cost of the certificate (in €), if charged under this project	0
---------------------	------------------------	---	---

. Certificate on the financial statements

Is there a certificate on the financial statements provided by an independent auditor attached to this financial statement according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €)	
---------------------	--	--------------------------------	--

6. Beneficiary's declaration on its honour

We declare on our honour that:

- the costs declared above are directly related to the resources used to attain the objectives of the project and fall within the definition of eligible costs specified in Articles II.14 and II.15 of the grant agreement, and, if relevant, Annex III and Article 7 (special clauses) of the grant agreement;
- the receipts declared above are the only financial transfers or contributions in kind, free of charge, from third parties and the only income generated by the project which could be considered as receipts according to Art.II.17 of the grant agreement;
- the interest declared above is the only interest yielded by the pre-financing which falls within the definition of Art.II.19 of the grant agreement;
- there is full supporting documentation to justify the information hereby declared. It will be made available at the request of the Commission and in the event of an audit by the Commission and/or by the Court of Auditors and/or their authorised representatives.

Beneficiary's Stamp	Name of the Person(s) Authorised to sign this Financial Statement
	Simon Hanselmann
	Date & signature

FP7 - Grant Agreement - Annex VI - Collaborative project

Form C - Financial Statement (to be filled in by each beneficiary)

Project Number	270089	Funding scheme	Collaborative project
Project Acronym	p-medicine		
Period from	01/02/2012	Is this an adjustment to a previous statement ?	Yes
To	31/01/2013	Adjustment relates to Period :	1
Legal Name	FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V	Participant Identity Code	999984059
Organisation Short Name	FhG	Beneficiary nr	5
Funding % for RTD activities (A)	75.0	If flat rate for indirect costs, specify %	N/A

1. Declaration of eligible costs/lump sum/flat-rate/scale of unit (in €)

	Type of Activity				Total (A+B+C+D)
	RTD (A)	Demonstration (B)	Management (C)	Other (D)	
Personnel costs	509	0	0	21	530
Subcontracting	0	0	0	0	0
Other direct costs	0	0	0	0	0
Indirect costs	884	0	0	16	900
Total costs	1,393	0	0	37	1,430
Maximum EU contribution	1,044	0	0	37	1,081
Requested EU contribution					1,081

2. Declaration of receipts

Did you receive any financial transfers or contributions in kind, free of charge from third parties or did the project generate any income which could be considered a receipt according to Art.II. 17 of the grant agreement ?
If yes, please mention the amount (in €)

No

4. Certificate on the methodology

Do you declare average personnel costs according to Art.II.14.1 ?

Yes

Is there a certificate on the methodology provided by an independent auditor and accepted by the Commission according to Art.II.4.4 ?

Yes

Name of the auditor	Deloitte & Touche GmbH	Cost of the certificate (in €), if charged under this project	0
---------------------	------------------------	---	---

. Certificate on the financial statements

Is there a certificate on the financial statements provided by an independent auditor attached to this financial statement according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €)	
---------------------	--	--------------------------------	--

6. Beneficiary's declaration on its honour

We declare on our honour that:

- the costs declared above are directly related to the resources used to attain the objectives of the project and fall within the definition of eligible costs specified in Articles II.14 and II.15 of the grant agreement, and, if relevant, Annex III and Article 7 (special clauses) of the grant agreement;
- the receipts declared above are the only financial transfers or contributions in kind, free of charge, from third parties and the only income generated by the project which could be considered as receipts according to Art.II.17 of the grant agreement;
- the interest declared above is the only interest yielded by the pre-financing which falls within the definition of Art.II.19 of the grant agreement;
- there is full supporting documentation to justify the information hereby declared. It will be made available at the request of the Commission and in the event of an audit by the Commission and/or by the Court of Auditors and/or their authorised representatives.

Beneficiary's Stamp	Name of the Person(s) Authorised to sign this Financial Statement
	Simon Hanselmann
	Date & signature

FP7 - Grant Agreement - Annex VI - Collaborative project

Form C - Financial Statement (to be filled in by each beneficiary)

Project Number	270089	Funding scheme	Collaborative project
Project Acronym	p-medicine		
Period from	01/02/2012	Is this an adjustment to a previous statement ?	No
To	31/01/2013		
Legal Name	GOTTFRIED WILHELM LEIBNIZ UNIVERSITAET HANNOVER	Participant Identity Code	999981828
Organisation Short Name	LUH	Beneficiary nr	6
Funding % for RTD activities (A)	75.0	If flat rate for indirect costs, specify %	60

1. Declaration of eligible costs/lump sum/flat-rate/scale of unit (in €)

	Type of Activity				Total (A+B+C+D)
	RTD (A)	Demonstration (B)	Management (C)	Other (D)	
Personnel costs	71,627	0	0	0	71,627
Subcontracting	0	0	0	0	0
Other direct costs	6,005	0	0	0	6,005
Indirect costs	46,579	0	0	0	46,579
Total costs	124,211	0	0	0	124,211
Maximum EU contribution	93,158	0	0	0	93,158
Requested EU contribution					93,158

2. Declaration of receipts

Did you receive any financial transfers or contributions in kind, free of charge from third parties or did the project generate any income which could be considered a receipt according to Art.II. 17 of the grant agreement ?

If yes, please mention the amount (in €)

No

4. Certificate on the methodology

Do you declare average personnel costs according to Art.II.14.1 ?

Is there a certificate on the methodology provided by an independent auditor and accepted by the Commission according to Art.II.4.4 ?

No

No

Name of the auditor		Cost of the certificate (in €), if charged under this project	
---------------------	--	---	--

. Certificate on the financial statements

Is there a certificate on the financial statements provided by an independent auditor attached to this financial statement according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €)	
---------------------	--	--------------------------------	--

6. Beneficiary's declaration on its honour

We declare on our honour that:

- the costs declared above are directly related to the resources used to attain the objectives of the project and fall within the definition of eligible costs specified in Articles II.14 and II.15 of the grant agreement, and, if relevant, Annex III and Article 7 (special clauses) of the grant agreement;
- the receipts declared above are the only financial transfers or contributions in kind, free of charge, from third parties and the only income generated by the project which could be considered as receipts according to Art.II.17 of the grant agreement;
- the interest declared above is the only interest yielded by the pre-financing which falls within the definition of Art.II.19 of the grant agreement;
- there is full supporting documentation to justify the information hereby declared. It will be made available at the request of the Commission and in the event of an audit by the Commission and/or by the Court of Auditors and/or their authorised representatives.

Beneficiary's Stamp	Name of the Person(s) Authorised to sign this Financial Statement
	Mr Henning Howind
	Date & signature

FP7 - Grant Agreement - Annex VI - Collaborative project

Form C - Financial Statement (to be filled in by each beneficiary)

Project Number	270089	Funding scheme	Collaborative project
Project Acronym	p-medicine		
Period from	01/02/2012	Is this an adjustment to a previous statement ?	No
To	31/01/2013		
Legal Name	CUSTODIX NV	Participant Identity Code	999697812
Organisation Short Name	CUSTODIX	Beneficiary nr	7
Funding % for RTD activities (A)	75.0	If flat rate for indirect costs, specify %	N/A

1. Declaration of eligible costs/lump sum/flat-rate/scale of unit (in €)

	Type of Activity				Total (A+B+C+D)
	RTD (A)	Demonstration (B)	Management (C)	Other (D)	
Personnel costs	89,479	0	0	1,714	91,193
Subcontracting	0	0	0	0	0
Other direct costs	3,422	0	0	0	3,422
Indirect costs	49,115	0	0	941	50,056
Total costs	142,016	0	0	2,655	144,671
Maximum EU contribution	106,512	0	0	2,655	109,167
Requested EU contribution					109,167

2. Declaration of receipts

Did you receive any financial transfers or contributions in kind, free of charge from third parties or did the project generate any income which could be considered a receipt according to Art.II. 17 of the grant agreement ?
If yes, please mention the amount (in €)

No

4. Certificate on the methodology

Do you declare average personnel costs according to Art.II.14.1 ?

No

Is there a certificate on the methodology provided by an independent auditor and accepted by the Commission according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €), if charged under this project	
---------------------	--	---	--

. Certificate on the financial statements

Is there a certificate on the financial statements provided by an independent auditor attached to this financial statement according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €)	
---------------------	--	--------------------------------	--

6. Beneficiary's declaration on its honour

We declare on our honour that:

- the costs declared above are directly related to the resources used to attain the objectives of the project and fall within the definition of eligible costs specified in Articles II.14 and II.15 of the grant agreement, and, if relevant, Annex III and Article 7 (special clauses) of the grant agreement;
- the receipts declared above are the only financial transfers or contributions in kind, free of charge, from third parties and the only income generated by the project which could be considered as receipts according to Art.II.17 of the grant agreement;
- the interest declared above is the only interest yielded by the pre-financing which falls within the definition of Art.II.19 of the grant agreement;
- there is full supporting documentation to justify the information hereby declared. It will be made available at the request of the Commission and in the event of an audit by the Commission and/or by the Court of Auditors and/or their authorised representatives.

Beneficiary's Stamp	Name of the Person(s) Authorised to sign this Financial Statement
	Marita Borms
	Date & signature

FP7 - Grant Agreement - Annex VI - Collaborative project

Form C - Financial Statement (to be filled in by each beneficiary)

Project Number	270089	Funding scheme	Collaborative project
Project Acronym	p-medicine		
Period from	01/02/2012	Is this an adjustment to a previous statement ?	Yes
To	31/01/2013	Adjustment relates to Period :	1
Legal Name	CUSTODIX NV	Participant Identity Code	999697812
Organisation Short Name	CUSTODIX	Beneficiary nr	7
Funding % for RTD activities (A)	75.0	If flat rate for indirect costs, specify %	N/A

1. Declaration of eligible costs/lump sum/flat-rate/scale of unit (in €)

	Type of Activity				Total (A+B+C+D)
	RTD (A)	Demonstration (B)	Management (C)	Other (D)	
Personnel costs	953	0	0	0	953
Subcontracting	0	0	0	0	0
Other direct costs	0	0	0	0	0
Indirect costs	-1,226	0	0	0	-1,226
Total costs	-273	0	0	0	-273
Maximum EU contribution	-204	0	0	0	-204
Requested EU contribution					-204

2. Declaration of receipts

Did you receive any financial transfers or contributions in kind, free of charge from third parties or did the project generate any income which could be considered a receipt according to Art.II. 17 of the grant agreement ?

If yes, please mention the amount (in €)

No

4. Certificate on the methodology

Do you declare average personnel costs according to Art.II.14.1 ?

Is there a certificate on the methodology provided by an independent auditor and accepted by the Commission according to Art.II.4.4 ?

No

No

Name of the auditor		Cost of the certificate (in €), if charged under this project	
---------------------	--	---	--

. Certificate on the financial statements

Is there a certificate on the financial statements provided by an independent auditor attached to this financial statement according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €)	
---------------------	--	--------------------------------	--

6. Beneficiary's declaration on its honour

We declare on our honour that:

- the costs declared above are directly related to the resources used to attain the objectives of the project and fall within the definition of eligible costs specified in Articles II.14 and II.15 of the grant agreement, and, if relevant, Annex III and Article 7 (special clauses) of the grant agreement;
- the receipts declared above are the only financial transfers or contributions in kind, free of charge, from third parties and the only income generated by the project which could be considered as receipts according to Art.II.17 of the grant agreement;
- the interest declared above is the only interest yielded by the pre-financing which falls within the definition of Art.II.19 of the grant agreement;
- there is full supporting documentation to justify the information hereby declared. It will be made available at the request of the Commission and in the event of an audit by the Commission and/or by the Court of Auditors and/or their authorised representatives.

Beneficiary's Stamp	Name of the Person(s) Authorised to sign this Financial Statement
	Marita Borms
	Date & signature

FP7 - Grant Agreement - Annex VI - Collaborative project

Form C - Financial Statement (to be filled in by each beneficiary)

Project Number	270089	Funding scheme	Collaborative project
Project Acronym	p-medicine		
Period from	01/02/2012	Is this an adjustment to a previous statement ?	No
To	31/01/2013		
Legal Name	PHILIPS ELECTRONICS NEDERLAND B.V.	Participant Identity Code	999991625
Organisation Short Name	Philips	Beneficiary nr	8
Funding % for RTD activities (A)	50.0	If flat rate for indirect costs, specify %	N/A

1. Declaration of eligible costs/lump sum/flat-rate/scale of unit (in €)

	Type of Activity				Total (A+B+C+D)
	RTD (A)	Demonstration (B)	Management (C)	Other (D)	
Personnel costs	104,173	0	0	1,974	106,147
Subcontracting	0	0	0	0	0
Other direct costs	0	0	0	0	0
Indirect costs	205,439	0	0	1,216	206,655
Total costs	309,612	0	0	3,190	312,802
Maximum EU contribution	154,806	0	0	3,190	157,996
Requested EU contribution					157,996

2. Declaration of receipts

Did you receive any financial transfers or contributions in kind, free of charge from third parties or did the project generate any income which could be considered a receipt according to Art.II. 17 of the grant agreement ?
If yes, please mention the amount (in €)

No

4. Certificate on the methodology

Do you declare average personnel costs according to Art.II.14.1 ?

No

Is there a certificate on the methodology provided by an independent auditor and accepted by the Commission according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €), if charged under this project	
---------------------	--	---	--

. Certificate on the financial statements

Is there a certificate on the financial statements provided by an independent auditor attached to this financial statement according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €)	
---------------------	--	--------------------------------	--

6. Beneficiary's declaration on its honour

We declare on our honour that:

- the costs declared above are directly related to the resources used to attain the objectives of the project and fall within the definition of eligible costs specified in Articles II.14 and II.15 of the grant agreement, and, if relevant, Annex III and Article 7 (special clauses) of the grant agreement;
- the receipts declared above are the only financial transfers or contributions in kind, free of charge, from third parties and the only income generated by the project which could be considered as receipts according to Art.II.17 of the grant agreement;
- the interest declared above is the only interest yielded by the pre-financing which falls within the definition of Art.II.19 of the grant agreement;
- there is full supporting documentation to justify the information hereby declared. It will be made available at the request of the Commission and in the event of an audit by the Commission and/or by the Court of Auditors and/or their authorised representatives.

Beneficiary's Stamp	Name of the Person(s) Authorised to sign this Financial Statement
	Piet van Prooijen
	Date & signature

FP7 - Grant Agreement - Annex VI - Collaborative project

Form C - Financial Statement (to be filled in by each beneficiary)

Project Number	270089	Funding scheme	Collaborative project
Project Acronym	p-medicine		
Period from	01/02/2012	Is this an adjustment to a previous statement ?	Yes
To	31/01/2013	Adjustment relates to Period :	1
Legal Name	PHILIPS ELECTRONICS NEDERLAND B.V.	Participant Identity Code	999991625
Organisation Short Name	Philips	Beneficiary nr	8
Funding % for RTD activities (A)	50.0	If flat rate for indirect costs, specify %	N/A

1. Declaration of eligible costs/lump sum/flat-rate/scale of unit (in €)

	Type of Activity				Total (A+B+C+D)
	RTD (A)	Demonstration (B)	Management (C)	Other (D)	
Personnel costs	1,102	0	0	0	1,102
Subcontracting	0	0	0	0	0
Other direct costs	0	0	0	0	0
Indirect costs	1,478	0	0	0	1,478
Total costs	2,580	0	0	0	2,580
Maximum EU contribution	1,290	0	0	0	1,290
Requested EU contribution					1,290

2. Declaration of receipts

Did you receive any financial transfers or contributions in kind, free of charge from third parties or did the project generate any income which could be considered a receipt according to Art.II. 17 of the grant agreement ?

If yes, please mention the amount (in €)

No

4. Certificate on the methodology

Do you declare average personnel costs according to Art.II.14.1 ?

Is there a certificate on the methodology provided by an independent auditor and accepted by the Commission according to Art.II.4.4 ?

No

No

Name of the auditor		Cost of the certificate (in €), if charged under this project	
---------------------	--	---	--

. Certificate on the financial statements

Is there a certificate on the financial statements provided by an independent auditor attached to this financial statement according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €)	
---------------------	--	--------------------------------	--

6. Beneficiary's declaration on its honour

We declare on our honour that:

- the costs declared above are directly related to the resources used to attain the objectives of the project and fall within the definition of eligible costs specified in Articles II.14 and II.15 of the grant agreement, and, if relevant, Annex III and Article 7 (special clauses) of the grant agreement;
- the receipts declared above are the only financial transfers or contributions in kind, free of charge, from third parties and the only income generated by the project which could be considered as receipts according to Art.II.17 of the grant agreement;
- the interest declared above is the only interest yielded by the pre-financing which falls within the definition of Art.II.19 of the grant agreement;
- there is full supporting documentation to justify the information hereby declared. It will be made available at the request of the Commission and in the event of an audit by the Commission and/or by the Court of Auditors and/or their authorised representatives.

Beneficiary's Stamp	Name of the Person(s) Authorised to sign this Financial Statement
	Piet van Prooijen
	Date & signature

FP7 - Grant Agreement - Annex VI - Collaborative project

Form C - Financial Statement (to be filled in by each beneficiary)

Project Number	270089	Funding scheme	Collaborative project
Project Acronym	p-medicine		
Period from	01/02/2012	Is this an adjustment to a previous statement ?	No
To	31/01/2013		
Legal Name	HEINRICH-HEINE-UNIVERSITAET DUESSELDORF	Participant Identity Code	999856116
Organisation Short Name	UDUS	Beneficiary nr	9
Funding % for RTD activities (A)	75.0	If flat rate for indirect costs, specify %	60

1. Declaration of eligible costs/lump sum/flat-rate/scale of unit (in €)

	Type of Activity				Total (A+B+C+D)
	RTD (A)	Demonstration (B)	Management (C)	Other (D)	
Personnel costs	100,437	0	0	165	100,602
Subcontracting	0	0	0	0	0
Other direct costs	1,698	0	0	4,213	5,911
Indirect costs	61,038	0	0	2,626	63,664
Total costs	163,173	0	0	7,004	170,177
Maximum EU contribution	122,379	0	0	7,004	129,383
Requested EU contribution					129,383

2. Declaration of receipts

Did you receive any financial transfers or contributions in kind, free of charge from third parties or did the project generate any income which could be considered a receipt according to Art.II. 17 of the grant agreement ?

If yes, please mention the amount (in €)

No

4. Certificate on the methodology

Do you declare average personnel costs according to Art.II.14.1 ?

Is there a certificate on the methodology provided by an independent auditor and accepted by the Commission according to Art.II.4.4 ?

No

No

Name of the auditor		Cost of the certificate (in €), if charged under this project	
---------------------	--	---	--

. Certificate on the financial statements

Is there a certificate on the financial statements provided by an independent auditor attached to this financial statement according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €)	
---------------------	--	--------------------------------	--

6. Beneficiary's declaration on its honour

We declare on our honour that:

- the costs declared above are directly related to the resources used to attain the objectives of the project and fall within the definition of eligible costs specified in Articles II.14 and II.15 of the grant agreement, and, if relevant, Annex III and Article 7 (special clauses) of the grant agreement;
- the receipts declared above are the only financial transfers or contributions in kind, free of charge, from third parties and the only income generated by the project which could be considered as receipts according to Art.II.17 of the grant agreement;
- the interest declared above is the only interest yielded by the pre-financing which falls within the definition of Art.II.19 of the grant agreement;
- there is full supporting documentation to justify the information hereby declared. It will be made available at the request of the Commission and in the event of an audit by the Commission and/or by the Court of Auditors and/or their authorised representatives.

Beneficiary's Stamp	Name of the Person(s) Authorised to sign this Financial Statement
	Doris Neubert or Hans-Peter Bons
	Date & signature

FP7 - Grant Agreement - Annex VI - Collaborative project

Form C - Financial Statement (to be filled in by each beneficiary)

Project Number	270089	Funding scheme	Collaborative project
Project Acronym	p-medicine		
Period from	01/02/2012	Is this an adjustment to a previous statement ?	Yes
To	31/01/2013	Adjustment relates to Period :	1
Legal Name	HEINRICH-HEINE-UNIVERSITAET DUESSELDORF	Participant Identity Code	999856116
Organisation Short Name	UDUS	Beneficiary nr	9
Funding % for RTD activities (A)	75.0	If flat rate for indirect costs, specify %	60

1. Declaration of eligible costs/lump sum/flat-rate/scale of unit (in €)

	Type of Activity				Total (A+B+C+D)
	RTD (A)	Demonstration (B)	Management (C)	Other (D)	
Personnel costs	0	0	0	0	0
Subcontracting	0	0	0	0	0
Other direct costs	942	0	0	0	942
Indirect costs	0	0	0	0	0
Total costs	942	0	0	0	942
Maximum EU contribution	706	0	0	0	706
Requested EU contribution					706

2. Declaration of receipts

Did you receive any financial transfers or contributions in kind, free of charge from third parties or did the project generate any income which could be considered a receipt according to Art.II. 17 of the grant agreement ?
If yes, please mention the amount (in €)

No

4. Certificate on the methodology

Do you declare average personnel costs according to Art.II.14.1 ?

No

Is there a certificate on the methodology provided by an independent auditor and accepted by the Commission according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €), if charged under this project	
---------------------	--	---	--

. Certificate on the financial statements

Is there a certificate on the financial statements provided by an independent auditor attached to this financial statement according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €)	
---------------------	--	--------------------------------	--

6. Beneficiary's declaration on its honour

We declare on our honour that:

- the costs declared above are directly related to the resources used to attain the objectives of the project and fall within the definition of eligible costs specified in Articles II.14 and II.15 of the grant agreement, and, if relevant, Annex III and Article 7 (special clauses) of the grant agreement;
- the receipts declared above are the only financial transfers or contributions in kind, free of charge, from third parties and the only income generated by the project which could be considered as receipts according to Art.II.17 of the grant agreement;
- the interest declared above is the only interest yielded by the pre-financing which falls within the definition of Art.II.19 of the grant agreement;
- there is full supporting documentation to justify the information hereby declared. It will be made available at the request of the Commission and in the event of an audit by the Commission and/or by the Court of Auditors and/or their authorised representatives.

Beneficiary's Stamp	Name of the Person(s) Authorised to sign this Financial Statement
	Doris Neubert or Peter Bons
	Date & signature

FP7 - Grant Agreement - Annex VI - Collaborative project

Form C - Financial Statement (to be filled in by each beneficiary)

Project Number	270089	Funding scheme	Collaborative project
Project Acronym	p-medicine		
Period from	01/02/2012	Is this an adjustment to a previous statement ?	No
To	31/01/2013		
Legal Name	INSTITUTE OF COMMUNICATION AND COMPUTER SYSTEMS	Participant Identity Code	999654356
Organisation Short Name	ICCS	Beneficiary nr	10
Funding % for RTD activities (A)	75.0	If flat rate for indirect costs, specify %	60

1. Declaration of eligible costs/lump sum/flat-rate/scale of unit (in €)

	Type of Activity				Total (A+B+C+D)
	RTD (A)	Demonstration (B)	Management (C)	Other (D)	
Personnel costs	159,576	0	0	19,715	179,291
Subcontracting	0	0	0	0	0
Other direct costs	4,897	0	0	1,233	6,130
Indirect costs	98,683	0	0	12,568	111,251
Total costs	263,156	0	0	33,516	296,672
Maximum EU contribution	197,367	0	0	33,516	230,883
Requested EU contribution					230,883

2. Declaration of receipts

Did you receive any financial transfers or contributions in kind, free of charge from third parties or did the project generate any income which could be considered a receipt according to Art.II. 17 of the grant agreement ?

If yes, please mention the amount (in €)

No

4. Certificate on the methodology

Do you declare average personnel costs according to Art.II.14.1 ?

Is there a certificate on the methodology provided by an independent auditor and accepted by the Commission according to Art.II.4.4 ?

No

No

Name of the auditor		Cost of the certificate (in €), if charged under this project	
---------------------	--	---	--

. Certificate on the financial statements

Is there a certificate on the financial statements provided by an independent auditor attached to this financial statement according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €)	
---------------------	--	--------------------------------	--

6. Beneficiary's declaration on its honour

We declare on our honour that:

- the costs declared above are directly related to the resources used to attain the objectives of the project and fall within the definition of eligible costs specified in Articles II.14 and II.15 of the grant agreement, and, if relevant, Annex III and Article 7 (special clauses) of the grant agreement;
- the receipts declared above are the only financial transfers or contributions in kind, free of charge, from third parties and the only income generated by the project which could be considered as receipts according to Art.II.17 of the grant agreement;
- the interest declared above is the only interest yielded by the pre-financing which falls within the definition of Art.II.19 of the grant agreement;
- there is full supporting documentation to justify the information hereby declared. It will be made available at the request of the Commission and in the event of an audit by the Commission and/or by the Court of Auditors and/or their authorised representatives.

Beneficiary's Stamp	Name of the Person(s) Authorised to sign this Financial Statement
	Yannis Vassiliou
	Date & signature

FP7 - Grant Agreement - Annex VI - Collaborative project

Form C - Financial Statement (to be filled in by each beneficiary)

Project Number	270089	Funding scheme	Collaborative project
Project Acronym	p-medicine		
Period from	01/02/2012	Is this an adjustment to a previous statement ?	No
To	31/01/2013		
Legal Name	UNIVERSIDAD POLITECNICA DE MADRID	Participant Identity Code	999974844
Organisation Short Name	UPM	Beneficiary nr	11
Funding % for RTD activities (A)	75.0	If flat rate for indirect costs, specify %	N/A

1. Declaration of eligible costs/lump sum/flat-rate/scale of unit (in €)

	Type of Activity				Total (A+B+C+D)
	RTD (A)	Demonstration (B)	Management (C)	Other (D)	
Personnel costs	83,280	0	0	5,569	88,849
Subcontracting	0	0	0	0	0
Other direct costs	3,795	0	0	0	3,795
Indirect costs	58,063	0	0	3,882	61,945
Total costs	145,138	0	0	9,451	154,589
Maximum EU contribution	108,853	0	0	9,451	118,304
Requested EU contribution					118,304

2. Declaration of receipts

Did you receive any financial transfers or contributions in kind, free of charge from third parties or did the project generate any income which could be considered a receipt according to Art.II. 17 of the grant agreement ?
If yes, please mention the amount (in €)

No

4. Certificate on the methodology

Do you declare average personnel costs according to Art.II.14.1 ?

No

Is there a certificate on the methodology provided by an independent auditor and accepted by the Commission according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €), if charged under this project	
---------------------	--	---	--

. Certificate on the financial statements

Is there a certificate on the financial statements provided by an independent auditor attached to this financial statement according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €)	
---------------------	--	--------------------------------	--

6. Beneficiary's declaration on its honour

We declare on our honour that:

- the costs declared above are directly related to the resources used to attain the objectives of the project and fall within the definition of eligible costs specified in Articles II.14 and II.15 of the grant agreement, and, if relevant, Annex III and Article 7 (special clauses) of the grant agreement;
- the receipts declared above are the only financial transfers or contributions in kind, free of charge, from third parties and the only income generated by the project which could be considered as receipts according to Art.II.17 of the grant agreement;
- the interest declared above is the only interest yielded by the pre-financing which falls within the definition of Art.II.19 of the grant agreement;
- there is full supporting documentation to justify the information hereby declared. It will be made available at the request of the Commission and in the event of an audit by the Commission and/or by the Court of Auditors and/or their authorised representatives.

Beneficiary's Stamp	Name of the Person(s) Authorised to sign this Financial Statement
	Roberto Prieto Lopez
	Date & signature

FP7 - Grant Agreement - Annex VI - Collaborative project

Form C - Financial Statement (to be filled in by each beneficiary)

Project Number	270089	Funding scheme	Collaborative project
Project Acronym	p-medicine		
Period from	01/02/2012	Is this an adjustment to a previous statement ?	No
To	31/01/2013		
Legal Name	CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL	Participant Identity Code	999839529
Organisation Short Name	CAU	Beneficiary nr	12
Funding % for RTD activities (A)	75.0	If flat rate for indirect costs, specify %	60

1. Declaration of eligible costs/lump sum/flat-rate/scale of unit (in €)

	Type of Activity				Total (A+B+C+D)
	RTD (A)	Demonstration (B)	Management (C)	Other (D)	
Personnel costs	63,057	0	0	2,125	65,182
Subcontracting	0	0	0	0	0
Other direct costs	0	0	0	0	0
Indirect costs	37,834	0	0	1,275	39,109
Total costs	100,891	0	0	3,400	104,291
Maximum EU contribution	75,668	0	0	3,400	79,068
Requested EU contribution					79,068

2. Declaration of receipts

Did you receive any financial transfers or contributions in kind, free of charge from third parties or did the project generate any income which could be considered a receipt according to Art.II. 17 of the grant agreement ?
If yes, please mention the amount (in €)

No

4. Certificate on the methodology

Do you declare average personnel costs according to Art.II.14.1 ?

No

Is there a certificate on the methodology provided by an independent auditor and accepted by the Commission according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €), if charged under this project	
---------------------	--	---	--

. Certificate on the financial statements

Is there a certificate on the financial statements provided by an independent auditor attached to this financial statement according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €)	
---------------------	--	--------------------------------	--

6. Beneficiary's declaration on its honour

We declare on our honour that:

- the costs declared above are directly related to the resources used to attain the objectives of the project and fall within the definition of eligible costs specified in Articles II.14 and II.15 of the grant agreement, and, if relevant, Annex III and Article 7 (special clauses) of the grant agreement;
- the receipts declared above are the only financial transfers or contributions in kind, free of charge, from third parties and the only income generated by the project which could be considered as receipts according to Art.II.17 of the grant agreement;
- the interest declared above is the only interest yielded by the pre-financing which falls within the definition of Art.II.19 of the grant agreement;
- there is full supporting documentation to justify the information hereby declared. It will be made available at the request of the Commission and in the event of an audit by the Commission and/or by the Court of Auditors and/or their authorised representatives.

Beneficiary's Stamp	Name of the Person(s) Authorised to sign this Financial Statement
	Dr. Katja Barth
	Date & signature

FP7 - Grant Agreement - Annex VI - Collaborative project

Form C - Financial Statement (to be filled in by Third Party) Only applicable if special clause nr 10 is used

Project Number	270089	Funding scheme	Collaborative project
Project Acronym	p-medicine		
Period from	01/02/2012	Is this an adjustment to a previous statement ?	No
To	31/01/2013		
3rd party legal Name	UNIVERSITATSKLINIKUM SCHLESWIG-HOLSTEIN		
3rd party Organisation Short Name	UKSH	Working for beneficiary nr	12
Funding % for RTD activities (A)	75.0	If flat rate for indirect costs, specify %	60

1. Declaration of eligible costs/lump sum/flat-rate/scale of unit (in €)

	Type of Activity				Total (A+B+C+D)
	RTD (A)	Demonstration (B)	Management (C)	Other (D)	
Personnel costs	0	0	0	0	0
Subcontracting	0	0	0	0	0
Other direct costs	5,302	0	0	147	5,449
Indirect costs	3,181	0	0	88	3,269
Total costs	8,483	0	0	235	8,718
Maximum EU contribution	6,362	0	0	235	6,597
Requested EU contribution					6,597

2. Declaration of receipts

Did you receive any financial transfers or contributions in kind, free of charge from third parties or did the project generate any income which could be considered a receipt according to Art.II. 17 of the grant agreement ?
If yes, please mention the amount (in €)

No

4. Certificate on the methodology

Do you declare average personnel costs according to Art.II.14.1 ?

No

Is there a certificate on the methodology provided by an independent auditor and accepted by the Commission according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €), if charged under this project	
---------------------	--	---	--

. Certificate on the financial statements

Is there a certificate on the financial statements provided by an independent auditor attached to this financial statement according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €)	
---------------------	--	--------------------------------	--

6. Beneficiary's declaration on its honour

We declare on our honour that:

- the costs declared above are directly related to the resources used to attain the objectives of the project and fall within the definition of eligible costs specified in Articles II.14 and II.15 of the grant agreement, and, if relevant, Annex III and Article 7 (special clauses) of the grant agreement;
- the receipts declared above are the only financial transfers or contributions in kind, free of charge, from third parties and the only income generated by the project which could be considered as receipts according to Art.II.17 of the grant agreement;
- the interest declared above is the only interest yielded by the pre-financing which falls within the definition of Art.II.19 of the grant agreement;
- there is full supporting documentation to justify the information hereby declared. It will be made available at the request of the Commission and in the event of an audit by the Commission and/or by the Court of Auditors and/or their authorised representatives.

Beneficiary's Stamp	Name of the Person(s) Authorised to sign this Financial Statement
	Martin Schrappe
	Date & signature

FP7 - Grant Agreement - Annex VI - Collaborative project

Form C - Financial Statement (to be filled in by each beneficiary)

Project Number	270089	Funding scheme	Collaborative project
Project Acronym	p-medicine		
Period from	01/02/2012	Is this an adjustment to a previous statement ?	No
To	31/01/2013		
Legal Name	ISTITUTO EUROPEO DI ONCOLOGIA SRL	Participant Identity Code	999969703
Organisation Short Name	IEO	Beneficiary nr	13
Funding % for RTD activities (A)	50.0	If flat rate for indirect costs, specify %	20

1. Declaration of eligible costs/lump sum/flat-rate/scale of unit (in €)

	Type of Activity				Total (A+B+C+D)
	RTD (A)	Demonstration (B)	Management (C)	Other (D)	
Personnel costs	147,198	0	0	5,126	152,324
Subcontracting	0	0	0	0	0
Other direct costs	1,734	0	0	0	1,734
Indirect costs	29,786	0	0	1,025	30,811
Total costs	178,718	0	0	6,151	184,869
Maximum EU contribution	89,359	0	0	6,151	95,510
Requested EU contribution					95,510

2. Declaration of receipts

Did you receive any financial transfers or contributions in kind, free of charge from third parties or did the project generate any income which could be considered a receipt according to Art.II. 17 of the grant agreement ?

If yes, please mention the amount (in €)

No

4. Certificate on the methodology

Do you declare average personnel costs according to Art.II.14.1 ?

Is there a certificate on the methodology provided by an independent auditor and accepted by the Commission according to Art.II.4.4 ?

No

No

Name of the auditor		Cost of the certificate (in €), if charged under this project	
---------------------	--	---	--

. Certificate on the financial statements

Is there a certificate on the financial statements provided by an independent auditor attached to this financial statement according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €)	
---------------------	--	--------------------------------	--

6. Beneficiary's declaration on its honour

We declare on our honour that:

- the costs declared above are directly related to the resources used to attain the objectives of the project and fall within the definition of eligible costs specified in Articles II.14 and II.15 of the grant agreement, and, if relevant, Annex III and Article 7 (special clauses) of the grant agreement;
- the receipts declared above are the only financial transfers or contributions in kind, free of charge, from third parties and the only income generated by the project which could be considered as receipts according to Art.II.17 of the grant agreement;
- the interest declared above is the only interest yielded by the pre-financing which falls within the definition of Art.II.19 of the grant agreement;
- there is full supporting documentation to justify the information hereby declared. It will be made available at the request of the Commission and in the event of an audit by the Commission and/or by the Court of Auditors and/or their authorised representatives.

Beneficiary's Stamp	Name of the Person(s) Authorised to sign this Financial Statement
	Mauro Melis
	Date & signature

FP7 - Grant Agreement - Annex VI - Collaborative project

Form C - Financial Statement (to be filled in by each beneficiary)

Project Number	270089	Funding scheme	Collaborative project
Project Acronym	p-medicine		
Period from	01/02/2012	Is this an adjustment to a previous statement ?	No
To	31/01/2013		
Legal Name	ecancermedicalscience AG	Participant Identity Code	997983046
Organisation Short Name	ecancer	Beneficiary nr	14
Funding % for RTD activities (A)	75.0	If flat rate for indirect costs, specify %	60

1. Declaration of eligible costs/lump sum/flat-rate/scale of unit (in €)

	Type of Activity				Total (A+B+C+D)
	RTD (A)	Demonstration (B)	Management (C)	Other (D)	
Personnel costs	67,126	0	0	36,153	103,279
Subcontracting	0	0	0	0	0
Other direct costs	11,864	0	0	9,780	21,644
Indirect costs	47,394	0	0	27,559	74,953
Total costs	126,384	0	0	73,492	199,876
Maximum EU contribution	94,788	0	0	73,492	168,280
Requested EU contribution					168,280

2. Declaration of receipts

Did you receive any financial transfers or contributions in kind, free of charge from third parties or did the project generate any income which could be considered a receipt according to Art.II. 17 of the grant agreement ?

If yes, please mention the amount (in €)

No

4. Certificate on the methodology

Do you declare average personnel costs according to Art.II.14.1 ?

Is there a certificate on the methodology provided by an independent auditor and accepted by the Commission according to Art.II.4.4 ?

No

No

Name of the auditor		Cost of the certificate (in €), if charged under this project	
---------------------	--	---	--

. Certificate on the financial statements

Is there a certificate on the financial statements provided by an independent auditor attached to this financial statement according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €)	
---------------------	--	--------------------------------	--

6. Beneficiary's declaration on its honour

We declare on our honour that:

- the costs declared above are directly related to the resources used to attain the objectives of the project and fall within the definition of eligible costs specified in Articles II.14 and II.15 of the grant agreement, and, if relevant, Annex III and Article 7 (special clauses) of the grant agreement;
- the receipts declared above are the only financial transfers or contributions in kind, free of charge, from third parties and the only income generated by the project which could be considered as receipts according to Art.II.17 of the grant agreement;
- the interest declared above is the only interest yielded by the pre-financing which falls within the definition of Art.II.19 of the grant agreement;
- there is full supporting documentation to justify the information hereby declared. It will be made available at the request of the Commission and in the event of an audit by the Commission and/or by the Court of Auditors and/or their authorised representatives.

Beneficiary's Stamp	Name of the Person(s) Authorised to sign this Financial Statement
	Danny Burke
	Date & signature

FP7 - Grant Agreement - Annex VI - Collaborative project

Form C - Financial Statement (to be filled in by each beneficiary)

Project Number	270089	Funding scheme	Collaborative project
Project Acronym	p-medicine		
Period from	01/02/2012	Is this an adjustment to a previous statement ?	No
To	31/01/2013		
Legal Name	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD	Participant Identity Code	999984350
Organisation Short Name	UOXF.BP	Beneficiary nr	15
Funding % for RTD activities (A)	75.0	If flat rate for indirect costs, specify %	60

1. Declaration of eligible costs/lump sum/flat-rate/scale of unit (in €)

	Type of Activity				Total (A+B+C+D)
	RTD (A)	Demonstration (B)	Management (C)	Other (D)	
Personnel costs	77,265	0	0	0	77,265
Subcontracting	0	0	0	0	0
Other direct costs	5,810	0	0	125	5,935
Indirect costs	49,845	0	0	75	49,920
Total costs	132,920	0	0	200	133,120
Maximum EU contribution	99,690	0	0	200	99,890
Requested EU contribution					99,890

2. Declaration of receipts

Did you receive any financial transfers or contributions in kind, free of charge from third parties or did the project generate any income which could be considered a receipt according to Art.II. 17 of the grant agreement ?

If yes, please mention the amount (in €)

No

4. Certificate on the methodology

Do you declare average personnel costs according to Art.II.14.1 ?

Is there a certificate on the methodology provided by an independent auditor and accepted by the Commission according to Art.II.4.4 ?

No

No

Name of the auditor		Cost of the certificate (in €), if charged under this project	
---------------------	--	---	--

. Certificate on the financial statements

Is there a certificate on the financial statements provided by an independent auditor attached to this financial statement according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €)	
---------------------	--	--------------------------------	--

6. Beneficiary's declaration on its honour

We declare on our honour that:

- the costs declared above are directly related to the resources used to attain the objectives of the project and fall within the definition of eligible costs specified in Articles II.14 and II.15 of the grant agreement, and, if relevant, Annex III and Article 7 (special clauses) of the grant agreement;
- the receipts declared above are the only financial transfers or contributions in kind, free of charge, from third parties and the only income generated by the project which could be considered as receipts according to Art.II.17 of the grant agreement;
- the interest declared above is the only interest yielded by the pre-financing which falls within the definition of Art.II.19 of the grant agreement;
- there is full supporting documentation to justify the information hereby declared. It will be made available at the request of the Commission and in the event of an audit by the Commission and/or by the Court of Auditors and/or their authorised representatives.

Beneficiary's Stamp	Name of the Person(s) Authorised to sign this Financial Statement
	Mr Samuel Hannis
	Date & signature

FP7 - Grant Agreement - Annex VI - Collaborative project

Form C - Financial Statement (to be filled in by each beneficiary)

Project Number	270089	Funding scheme	Collaborative project
Project Acronym	p-medicine		
Period from	01/02/2012	Is this an adjustment to a previous statement ?	No
To	31/01/2013		
Legal Name	A. PERSIDIS & SIA OE	Participant Identity Code	985410100
Organisation Short Name	BIOVISTA	Beneficiary nr	16
Funding % for RTD activities (A)	75.0	If flat rate for indirect costs, specify %	N/A

1. Declaration of eligible costs/lump sum/flat-rate/scale of unit (in €)

	Type of Activity				Total (A+B+C+D)
	RTD (A)	Demonstration (B)	Management (C)	Other (D)	
Personnel costs	98,317	0	0	27,837	126,154
Subcontracting	0	0	0	0	0
Other direct costs	14,004	0	0	7,848	21,852
Indirect costs	16,714	0	0	4,732	21,446
Total costs	129,035	0	0	40,417	169,452
Maximum EU contribution	96,776	0	0	40,417	137,193
Requested EU contribution					137,193

2. Declaration of receipts

Did you receive any financial transfers or contributions in kind, free of charge from third parties or did the project generate any income which could be considered a receipt according to Art.II. 17 of the grant agreement ?

If yes, please mention the amount (in €)

No

4. Certificate on the methodology

Do you declare average personnel costs according to Art.II.14.1 ?

Is there a certificate on the methodology provided by an independent auditor and accepted by the Commission according to Art.II.4.4 ?

No

No

Name of the auditor		Cost of the certificate (in €), if charged under this project	
---------------------	--	---	--

. Certificate on the financial statements

Is there a certificate on the financial statements provided by an independent auditor attached to this financial statement according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €)	
---------------------	--	--------------------------------	--

6. Beneficiary's declaration on its honour

We declare on our honour that:

- the costs declared above are directly related to the resources used to attain the objectives of the project and fall within the definition of eligible costs specified in Articles II.14 and II.15 of the grant agreement, and, if relevant, Annex III and Article 7 (special clauses) of the grant agreement;
- the receipts declared above are the only financial transfers or contributions in kind, free of charge, from third parties and the only income generated by the project which could be considered as receipts according to Art.II.17 of the grant agreement;
- the interest declared above is the only interest yielded by the pre-financing which falls within the definition of Art.II.19 of the grant agreement;
- there is full supporting documentation to justify the information hereby declared. It will be made available at the request of the Commission and in the event of an audit by the Commission and/or by the Court of Auditors and/or their authorised representatives.

Beneficiary's Stamp	Name of the Person(s) Authorised to sign this Financial Statement
	Andreas Persidis
	Date & signature

FP7 - Grant Agreement - Annex VI - Collaborative project

Form C - Financial Statement (to be filled in by each beneficiary)

Project Number	270089	Funding scheme	Collaborative project
Project Acronym	p-medicine		
Period from	01/02/2012	Is this an adjustment to a previous statement ?	Yes
To	31/01/2013	Adjustment relates to Period :	1
Legal Name	A. PERSIDIS & SIA OE	Participant Identity Code	985410100
Organisation Short Name	BIOVISTA	Beneficiary nr	16
Funding % for RTD activities (A)	75.0	If flat rate for indirect costs, specify %	N/A

1. Declaration of eligible costs/lump sum/flat-rate/scale of unit (in €)

	Type of Activity				Total (A+B+C+D)
	RTD (A)	Demonstration (B)	Management (C)	Other (D)	
Personnel costs	3,558	0	0	-15	3,543
Subcontracting	0	0	0	0	0
Other direct costs	0	0	0	0	0
Indirect costs	1,020	0	0	2,292	3,312
Total costs	4,578	0	0	2,277	6,855
Maximum EU contribution	3,433	0	0	2,277	5,710
Requested EU contribution					5,710

2. Declaration of receipts

Did you receive any financial transfers or contributions in kind, free of charge from third parties or did the project generate any income which could be considered a receipt according to Art.II. 17 of the grant agreement ?
If yes, please mention the amount (in €)

No

4. Certificate on the methodology

Do you declare average personnel costs according to Art.II.14.1 ?

No

Is there a certificate on the methodology provided by an independent auditor and accepted by the Commission according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €), if charged under this project	
---------------------	--	---	--

. Certificate on the financial statements

Is there a certificate on the financial statements provided by an independent auditor attached to this financial statement according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €)	
---------------------	--	--------------------------------	--

6. Beneficiary's declaration on its honour

We declare on our honour that:

- the costs declared above are directly related to the resources used to attain the objectives of the project and fall within the definition of eligible costs specified in Articles II.14 and II.15 of the grant agreement, and, if relevant, Annex III and Article 7 (special clauses) of the grant agreement;
- the receipts declared above are the only financial transfers or contributions in kind, free of charge, from third parties and the only income generated by the project which could be considered as receipts according to Art.II.17 of the grant agreement;
- the interest declared above is the only interest yielded by the pre-financing which falls within the definition of Art.II.19 of the grant agreement;
- there is full supporting documentation to justify the information hereby declared. It will be made available at the request of the Commission and in the event of an audit by the Commission and/or by the Court of Auditors and/or their authorised representatives.

Beneficiary's Stamp	Name of the Person(s) Authorised to sign this Financial Statement
	Andreas Persidis
	Date & signature

FP7 - Grant Agreement - Annex VI - Collaborative project

Form C - Financial Statement (to be filled in by each beneficiary)

Project Number	270089	Funding scheme	Collaborative project
Project Acronym	p-medicine		
Period from	01/02/2012	Is this an adjustment to a previous statement ?	No
To	31/01/2013		
Legal Name	SWISS INSTITUTE OF BIOINFORMATICS	Participant Identity Code	999629815
Organisation Short Name	SIB	Beneficiary nr	17
Funding % for RTD activities (A)	75.0	If flat rate for indirect costs, specify %	60

1. Declaration of eligible costs/lump sum/flat-rate/scale of unit (in €)

	Type of Activity				Total (A+B+C+D)
	RTD (A)	Demonstration (B)	Management (C)	Other (D)	
Personnel costs	75,012	0	0	3,261	78,273
Subcontracting	0	0	0	0	0
Other direct costs	1,726	0	0	328	2,054
Indirect costs	46,042	0	0	2,153	48,195
Total costs	122,780	0	0	5,742	128,522
Maximum EU contribution	92,085	0	0	5,742	97,827
Requested EU contribution					97,827

2. Declaration of receipts

Did you receive any financial transfers or contributions in kind, free of charge from third parties or did the project generate any income which could be considered a receipt according to Art.II. 17 of the grant agreement ?

If yes, please mention the amount (in €)

No

4. Certificate on the methodology

Do you declare average personnel costs according to Art.II.14.1 ?

Is there a certificate on the methodology provided by an independent auditor and accepted by the Commission according to Art.II.4.4 ?

No

No

Name of the auditor		Cost of the certificate (in €), if charged under this project	
---------------------	--	---	--

. Certificate on the financial statements

Is there a certificate on the financial statements provided by an independent auditor attached to this financial statement according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €)	
---------------------	--	--------------------------------	--

6. Beneficiary's declaration on its honour

We declare on our honour that:

- the costs declared above are directly related to the resources used to attain the objectives of the project and fall within the definition of eligible costs specified in Articles II.14 and II.15 of the grant agreement, and, if relevant, Annex III and Article 7 (special clauses) of the grant agreement;
- the receipts declared above are the only financial transfers or contributions in kind, free of charge, from third parties and the only income generated by the project which could be considered as receipts according to Art.II.17 of the grant agreement;
- the interest declared above is the only interest yielded by the pre-financing which falls within the definition of Art.II.19 of the grant agreement;
- there is full supporting documentation to justify the information hereby declared. It will be made available at the request of the Commission and in the event of an audit by the Commission and/or by the Court of Auditors and/or their authorised representatives.

Beneficiary's Stamp	Name of the Person(s) Authorised to sign this Financial Statement
	Jocelyne Bocquet
	Date & signature

FP7 - Grant Agreement - Annex VI - Collaborative project

Form C - Financial Statement (to be filled in by each beneficiary)

Project Number	270089	Funding scheme	Collaborative project
Project Acronym	p-medicine		
Period from	01/02/2012	Is this an adjustment to a previous statement ?	No
To	31/01/2013		
Legal Name	NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY	Participant Identity Code	991511982
Organisation Short Name	UHok	Beneficiary nr	18
Funding % for RTD activities (A)	75.0	If flat rate for indirect costs, specify %	20

1. Declaration of eligible costs/lump sum/flat-rate/scale of unit (in €)

	Type of Activity				Total (A+B+C+D)
	RTD (A)	Demonstration (B)	Management (C)	Other (D)	
Personnel costs	29,325	0	0	0	29,325
Subcontracting	0	0	0	0	0
Other direct costs	2,723	0	0	0	2,723
Indirect costs	6,409	0	0	0	6,409
Total costs	38,457	0	0	0	38,457
Maximum EU contribution	28,842	0	0	0	28,842
Requested EU contribution					

2. Declaration of receipts

Did you receive any financial transfers or contributions in kind, free of charge from third parties or did the project generate any income which could be considered a receipt according to Art.II. 17 of the grant agreement ?

If yes, please mention the amount (in €)

No

4. Certificate on the methodology

Do you declare average personnel costs according to Art.II.14.1 ?

Is there a certificate on the methodology provided by an independent auditor and accepted by the Commission according to Art.II.4.4 ?

No

No

Name of the auditor		Cost of the certificate (in €), if charged under this project	
---------------------	--	---	--

. Certificate on the financial statements

Is there a certificate on the financial statements provided by an independent auditor attached to this financial statement according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €)	
---------------------	--	--------------------------------	--

6. Beneficiary's declaration on its honour

We declare on our honour that:

- the costs declared above are directly related to the resources used to attain the objectives of the project and fall within the definition of eligible costs specified in Articles II.14 and II.15 of the grant agreement, and, if relevant, Annex III and Article 7 (special clauses) of the grant agreement;
- the receipts declared above are the only financial transfers or contributions in kind, free of charge, from third parties and the only income generated by the project which could be considered as receipts according to Art.II.17 of the grant agreement;
- the interest declared above is the only interest yielded by the pre-financing which falls within the definition of Art.II.19 of the grant agreement;
- there is full supporting documentation to justify the information hereby declared. It will be made available at the request of the Commission and in the event of an audit by the Commission and/or by the Court of Auditors and/or their authorised representatives.

Beneficiary's Stamp	Name of the Person(s) Authorised to sign this Financial Statement
	Yuzuru Tanaka, Director of Meme Media Laboratory, Hokkaido University
	Date & signature

FP7 - Grant Agreement - Annex VI - Collaborative project

Form C - Financial Statement (to be filled in by each beneficiary)

Project Number	270089	Funding scheme	Collaborative project
Project Acronym	p-medicine		
Period from	01/02/2012	Is this an adjustment to a previous statement ?	No
To	31/01/2013		
Legal Name	INSTYTUT CHEMII BIOORGANICZNEJ PAN	Participant Identity Code	999586359
Organisation Short Name	PSNC	Beneficiary nr	20
Funding % for RTD activities (A)	75.0	If flat rate for indirect costs, specify %	60

1. Declaration of eligible costs/lump sum/flat-rate/scale of unit (in €)

	Type of Activity				Total (A+B+C+D)
	RTD (A)	Demonstration (B)	Management (C)	Other (D)	
Personnel costs	113,078	0	0	0	113,078
Subcontracting	0	0	0	0	0
Other direct costs	6,804	0	0	0	6,804
Indirect costs	71,929	0	0	0	71,929
Total costs	191,811	0	0	0	191,811
Maximum EU contribution	143,858	0	0	0	143,858
Requested EU contribution					143,858

2. Declaration of receipts

Did you receive any financial transfers or contributions in kind, free of charge from third parties or did the project generate any income which could be considered a receipt according to Art.II. 17 of the grant agreement ?

If yes, please mention the amount (in €)

Yes

27,595

4. Certificate on the methodology

Do you declare average personnel costs according to Art.II.14.1 ?

Is there a certificate on the methodology provided by an independent auditor and accepted by the Commission according to Art.II.4.4 ?

No

No

Name of the auditor		Cost of the certificate (in €), if charged under this project	
---------------------	--	---	--

. Certificate on the financial statements

Is there a certificate on the financial statements provided by an independent auditor attached to this financial statement according to Art.II.4.4 ?

No

Name of the auditor		Cost of the certificate (in €)	
---------------------	--	--------------------------------	--

6. Beneficiary's declaration on its honour

We declare on our honour that:

- the costs declared above are directly related to the resources used to attain the objectives of the project and fall within the definition of eligible costs specified in Articles II.14 and II.15 of the grant agreement, and, if relevant, Annex III and Article 7 (special clauses) of the grant agreement;
- the receipts declared above are the only financial transfers or contributions in kind, free of charge, from third parties and the only income generated by the project which could be considered as receipts according to Art.II.17 of the grant agreement;
- the interest declared above is the only interest yielded by the pre-financing which falls within the definition of Art.II.19 of the grant agreement;
- there is full supporting documentation to justify the information hereby declared. It will be made available at the request of the Commission and in the event of an audit by the Commission and/or by the Court of Auditors and/or their authorised representatives.

Beneficiary's Stamp	Name of the Person(s) Authorised to sign this Financial Statement
	Krzysztof Kurowski/Maria Szubinska
	Date & signature

Use of Resources

Period 2 (13 - 24)
(01-02-2012 - 31-01-2013)

Project Number	270089	Project Acronym	p-medicine
----------------	--------	-----------------	------------

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 1 for the period.				
UNIVERSITAET DES SAARLANDES				
Work Package	Item description	Amount in €	Explanation	Free Text
WP 8 WP 15	Other direct cost	163 €	Holger Stenzhorn wp-meeting 03-04.04.2012 Düsseldorf	travel costs
WP 8	Other direct cost	105 €	software	consumables
WP 2 WP 3 WP 4 WP 5 WP 6 WP 7 WP 8 WP 9 WP 10 WP 11 WP 12 WP 13 WP 14 WP 15	Other direct cost	1,959 €	storage space, Since the item is entered in the inventory of the clinic it is considered „consumables“ in the university's accounting system	consumables
WP 5 WP 8 WP 15	Other direct cost	66 €	mains adapter	consumables
WP 8 WP 15	Other direct cost	202 €	Holger Stenzhorn ObTiMA meeting 04.05.2012 Ghent	travel costs
WP 4 WP 8	Other direct cost	736 €	Holger Stenzhorn Konferenz 20-28.07.2012 Graz	travel costs
WP 5 WP 8 WP 15	Other direct cost	315 €	Holger Stenzhorn ObTiMA meeting 29-31.08.2012 Bonn	travel costs
WP 8	Other direct cost	617 €	Holger Stenzhorn VHP-Konferenz 18-20.09.2012 London	travel costs
WP 9	Other direct cost	499 €	David Ruslan Workshop IARWISOCI 22-23.10.2012 Athen	travel costs
WP 8 WP 9 WP 15	Other direct cost	64 €	Holger Stenzhorn ObTiMA meeting 18.06.2012 Bonn	travel costs
WP 5	Other direct cost	40 €	Holger Stenzhorn TMF-Workshop 10.05.2012 Mainz	travel costs
WP 10	Personnel costs	13,661 €	Luc Schneider 2,5 pm	researcher
WP 4	Personnel costs	5,192 €	Nikolina Koleva 1,1 pm	assistant
WP 4	Personnel costs	20,948 €	Emilio Sanfilippo 4,5 pm	researcher

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 1 for the period.				
UNIVERSITAET DES SAARLANDES				
Work Package	Item description	Amount in €	Explanation	Free Text
WP 3	Personnel costs	3,991 €	Ulf Schwarz 0,83 pm	senior researcher
WP 4	Personnel costs	41,313 €	Ulf Schwarz 8,14 pm	senior researcher
WP 9	Personnel costs	3,987 €	Ulf Schwarz 0,83 pm	senior researcher
WP 14	Personnel costs	4,462 €	Ulf Schwarz 0,93 pm	senior researcher
WP 4	Other direct cost	558 €	Ulf Schwarz, Emilio Sanfilippo, Progressmeeting 18.-22.03.2012, Poznan	travel costs
WP 4	Other direct cost	751 €	Ulf Schwarz, Emilio Sanfilippo, Progressmeeting 28.-31.08.2012, Bonn	travel costs
WP 2	Personnel costs	38,657 €	David Ruslan 7,58 pm	researcher
WP 9	Personnel costs	21,197 €	David Ruslan 4,41 pm	researcher
WP 2	Personnel costs	501 €	Holger Stenzhorn 0,04 pm	researcher
WP 4	Personnel costs	4,775 €	Holger Stenzhorn 0,36 pm	researcher
WP 5	Personnel costs	1,740 €	Holger Stenzhorn 0,13 pm	researcher
WP 8	Personnel costs	48,065 €	Holger Stenzhorn 3,58 pm	researcher
WP 9	Personnel costs	2,919 €	Holger Stenzhorn 0,22 pm	researcher
WP 10	Personnel costs	617 €	Holger Stenzhorn 0,05 pm	researcher
WP 15	Personnel costs	2,157 €	Holger Stenzhorn 0,16 pm	researcher
WP 3	Personnel costs	35 €	Norbert Graf 0,01 pm	senior researcher
WP 4	Personnel costs	67 €	Norbert Graf 0,01 pm	senior researcher
WP 5	Personnel costs	161 €	Norbert Graf 0,03 pm	senior researcher
WP 9	Personnel costs	1,244 €	Norbert Graf 0,21 pm	senior researcher
WP 10	Personnel costs	451 €	Norbert Graf 0,08 pm	senior researcher
WP 13	Personnel costs	53 €	Norbert Graf 0,01 pm	senior researcher
WP 13	Personnel costs	284 €	Holger Stenzhorn 0,02 pm	researcher

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 1 for the period.				
UNIVERSITAET DES SAARLANDES				
Work Package	Item description	Amount in €	Explanation	Free Text
WP 14	Personnel costs	71 €	Norbert Graf 0,01 pm	senior researcher
WP 1	Personnel costs	1,792 €	Holger Stenzhorn 0,13 pm	researcher
WP 1	Personnel costs	9,377 €	Norbert Graf 1,59 pm	senior researcher
WP 1	Other direct cost	420 €	Norbert Graf wp-meeting 27.02.2012 London	travel costs
WP 1	Other direct cost	3,244 €	Holger Stenzhorn, Norbert Graf, EAB (Akay Metin, Jan-Eric Litton, David Ingram) 18.-22.03-2012 Poznan	travel costs
WP 1	Other direct cost	394 €	2 Think Pads, depreciation	durable equipment
WP 1	Other direct cost	484 €	Norbert Graf, Holger Stenzhorn Rewiewmeeting 02-03.05.2012 Brüssel	travel costs
WP 1	Other direct cost	390 €	Norbert Graf Projectmeeting VPH-Share 29-31.08.2012 Bonn	travel costs
WP 1	Other direct cost	865 €	Norbert Graf VPH-Konferenz, 18-20.09.2012 London	travel costs
WP 1	Other direct cost	52 €	Service Project meeting 26.04.2012 in Homburg	other
WP 1	Other direct cost	1,350 €	bank charges Advance payment	
WP 17	Personnel costs	4,294 €	Holger Stenzhorn 0,32 pm	researcher
WP 17	Personnel costs	13,761 €	Norbert Graf 2,32 pm	senior researcher
WP 17	Other direct cost	339 €	Norbert Graf VPH-meeting 07-11.05.2012 Barcelona	travel costs
WP 17	Other direct cost	154 €	Holger Stenzhorn PerMediCon 19-20.06.2012 Köln	travel costs
WP 17	Other direct cost	271 €		travel costs

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 1 for the period.				
UNIVERSITAET DES SAARLANDES				
Work Package	Item description	Amount in €	Explanation	Free Text
			Holger Stenzhorn ObTiMA meeting 11-12.09.2012 Gent	
WP 17	Other direct cost	198 €	Holger Stenzhorn p-med Kooperationen mit neuen EU-Projekten 13-14.09.2012 Brüssel	travel costs
WP 17	Other direct cost	449 €	Norbert Graf Workshop mit UC 18-19.10.2012 London	travel costs
WP 17	Other direct cost	1,633 €	Norbert Graf exploitation Meeting 29.11-03.12.2012 Yokohama	travel costs
WP 17	Other direct cost	2,368 €	Norbert Graf BIBE2012 11-13.11.2012 Larnaka	travel costs
WP 17	Other direct cost	209 €	Holger Stenzhorn Projekt Collaboration 07-08.11.2012 Basel	travel costs
WP 17	Personnel costs	2,278 €	Emilio Sanfilippo 0,5 pm	researcher
WP 17	Personnel costs	342 €	Ulf Schwarz 0,07 pm	senior researcher
WP 17	Other direct cost	456 €	Emilio Sanfilippo 5th Int. Advances Research Workshop on In Silico Oncology and Cancer Investigation 22.-23.10.2012 Athen	travel costs
WP 17	Other direct cost	9,000 €	VPH-Institut, membership fee - VPH Institute represents the follow-up initiative of the VPH NoE; Prof. Graf is a member of the Board of Directors, who pay to guarantee for the sustainability of the Institute. The VPH Institute is considered to be an excellent platform for the dissemination of p-medicine results and interfacing with	other

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 1 for the period.				
UNIVERSITAET DES SAARLANDES				
Work Package	Item description	Amount in €	Explanation	Free Text
			similar projects and initiatives.	
WP 17	Other direct cost	10 €	Poster for Project performance	other
WP 17	Other direct cost	74 €	Service IEC-meeting 13.12.2012 in Homburg	other
	Indirect costs	166,094 €		
TOTAL COSTS		442,921 €		

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 2 for the period.				
EUROPEAN RESEARCH AND PROJECT OFFICE GMBH				
Work Package	Item description	Amount in €	Explanation	Free Text
WP 1	Personnel costs	12,417 €	Corinna Hahn,programme manager/1,3PM	
WP 1	Personnel costs	4,306 €	Janine Hintz,project officer/1,0PM	
WP 1	Personnel costs	6,087 €	Katharina Sabellek,programme manager/1,4PM	
WP 1	Personnel costs	6,294 €	Hannah Weber,project officer/1,5PM	
WP 1	Personnel costs	4,916 €	Nina Lind,project officer/0,9PM	
WP 1	Personnel costs	4,405 €	Jörg Scherer,programme manager/0,3PM	
WP 1	Personnel costs	13,916 €	Julia Petry,project officer/3,5PM	
WP 1	Other direct cost	905 €	Janine Hintz,Progress meeting, 18.03.2012-22.03.2012,Poznan	Travel costs
WP 1	Other direct cost	806 €	Corinna Hahn,Progress meeting, 18.03.2012-22.03.2012,Poznan	Travel costs
WP 1	Other direct cost	124 €	Corinna Hahn,Review meeting,02.05.2012-03.05.2012,Brüssel	Travel costs
WP 1	Other direct cost	284 €	Julia Petry,Progress meeting,28.08.2012-31.08.2012,Bonn	Travel costs
WP 1	Other direct cost	287 €		Travel costs

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 2 for the period.				
EUROPEAN RESEARCH AND PROJECT OFFICE GMBH				
Work Package	Item description	Amount in €	Explanation	Free Text
			Corinna Hahn, Progress meeting, 28.08.2012-31.08.2012, Bonn	
WP 1	Other direct cost	1,418 €	1st review meeting, organisation costs	Brussels meeting rooms 1,00x360,00=360,00/ Biscuit, coffe break, 50,00x4,50=225,00/ Meal trays, 25,00x13,50=337,50/ Drinks, 25,00x1,50=37,50/ Tempo internet connection, 24,00x10,00=240,00/ Rent of switsh and connection, 2,00x20,00=40,00/ Video projector, Beamer, 1,00x60,00=60,00/ meeting material, 16,00x0,75=12,00/ meeting material, 586,00x0,13=76,18/ Secretarial assistance, 30,00x0,58=17,40/ Small office supplies, 5,00x2,50=12,50
WP 17	Personnel costs	3,471 €	Corinna Hahn, programme manager/0,4PM	
WP 17	Personnel costs	3,072 €	Janine Hintz, project officer/0,7PM	
WP 17	Personnel costs	3,464 €	Hannah Weber, project officer/0,8PM	
WP 17	Personnel costs	6,032 €	Holger Jung, communication officer/1,5PM	
WP 17	Personnel costs	7,035 €	Regina Schwald, communication officer/1,3PM	
WP 17	Personnel costs	237 €	Julia Petry, project officer/0,1PM	
WP 17	Personnel costs	3,492 €	Irma Mantilla, project officer/0,8PM	
WP 17	Other direct cost	485 €	Dissemination material	USB cards
WP 17	Other direct cost	122 €	Dissemination material	
WP 17	Other direct cost	124 €	Hotel, keynote speaker Prof. Mons,	Travel costs

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 2 for the period.				
EUROPEAN RESEARCH AND PROJECT OFFICE GMBH				
Work Package	Item description	Amount in €	Explanation	Free Text
			progress meeting St. Augustin	
WP 17	Other direct cost	198 €	Hotel, EAB member Metin Akay, progress meeting Poznan	Travel costs
WP 17	Other direct cost	1,652 €	Hannah Weber, 19.08.2012-26.08.2012, Namibia, Dissemination Meeting with Medical School, University of Namibia/Ministry of Health to discuss potential collaboration and synergies with medical research initiatives and clinical studies performed in Namibia. Added value of P-Medicine to relevant clinical trials supported by EDCTP programs	Travel costs
WP 17	Other direct cost	1,799 €	Jörg Scherer, 19.08.2012-26.08.2012, Namibia, Dissemination Meeting with Medical School, University of Namibia/Ministry of Health to discuss potential collaboration and synergies with medical research initiatives and clinical studies performed in Namibia. Added value of P-Medicine to relevant clinical trials supported by EDCTP programs	Travel costs
	Indirect costs	67,154 €		
TOTAL COSTS		154,502 €		

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 3 for the period.				
FOUNDATION FOR RESEARCH AND TECHNOLOGY HELLAS				
Work Package	Item description	Amount in €	Explanation	Free Text
WP 2 WP 3 WP 4 WP 7 WP 8 WP 10 WP 12 WP 13 WP 16	Personnel costs	88,034 €	RTD Activity Personnel P2. Total P-Months 37,77 as per following	RTD Personnel

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 3 for the period.				
FOUNDATION FOR RESEARCH AND TECHNOLOGY HELLAS				
Work Package	Item description	Amount in €	Explanation	Free Text
			Team: (1) Principal Researchers: Marias/Tsiknakis / Potamias (7,76 P-Months) , (2) Researcher: Sakalis Evangelos (P-Months 2,44) , (3) Technical Staff-8 fellows: Sfakianakis/ Koumakis/Roniotis/ Kritsotakis/ Zacharioudakis/ Kazantzaki/Iatraki/ Pediaditakis (23,47 P-Months), (4) Phd Technical Staff : Kondylakis / Giannakakis (3,43 P-Mopnths) , (5) Associated Professor: Tollis Ioannis (0,66 P-Months)	
	Other direct cost	4,091 €	PC & ELECTRONICS [low value- All items under "in year depreciation" -Equipment Purchases as following : (1) Four pieces of : PC DELL OPT990MT [i7-2600,4GB, 500G] & Screen / Depreciation within year of purchase (Purchase date: 1/3/2012) & (2) HDD EXT 2TB PASSPORT USB 3.0 BLACK (Purchase Date: 1/10/2012)	RTD Other : Equipments
WP 8	Other direct cost	1,368 €	(1) Marias to Poznan Poland 18.03-22.03.12 / 3rd Progress Meeting P-Medicine	RTD Other /Travel
WP 3	Other direct cost	1,196 €	(2) Zacharioudakis to Poznan Poland 17.03-26.03.12 / 3rd Progress Meeting P-Medicine	RTD Other /Travel
WP 3	Other direct cost	1,235 €	(3) Sfakianakis to Poznan Poland	RTD Other /Travel

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 3 for the period.				
FOUNDATION FOR RESEARCH AND TECHNOLOGY HELLAS				
Work Package	Item description	Amount in €	Explanation	Free Text
			Document: 185 205/18.03-22.03.12	
WP 3	Other direct cost	656 €	(4) Genitsaridis to Milan 10.04-12.04.12 / Participation to Empowerment Meeting for P-Medicine	RTD Other /Travel
WP 3	Other direct cost	651 €	(6) Zacharioudakis to Bonn Germany 28.08-02.09.12 / 4th Progress Meeting P-Medicine	RTD Other /Travel
WP 3	Other direct cost	1,168 €	(7) Sfakianakis Bonn Germany 28.08-01.09.12 / 4th Progress Meeting P-Medicine	RTD Other /Travel
WP 3	Other direct cost	1,137 €	(7) Sfakianakis Bonn Germany 28.08-01.09.12 / 4th Progress Meeting P-Medicine	RTD Other /Travel
WP 8	Other direct cost	1,325 €	(8) Marias to Bohh Germany 28.08-01.09.12 / 4th Progress Meeting P-Medicine	RTD Other /Travel
	Other direct cost	88 €	Various Consumables for PCs	RTD Other /Consumables
WP 1	Other direct cost	805 €	(1) Sfakianakis to Brussels 02.05-03.05.12 / Review Meeting [preparation 2/5/12 & Review Meeting 3/5/2012]	Management Activity: Travel
WP 1	Other direct cost	1,143 €	(2) Tsiknakis to Brussels 02.05-03.05.12 Review Meeting [preparation 2/5/12 & Review Meeting 3/5/2012]	Management Activity: Travel
WP 17	Other direct cost	1,233 €	(1) Marias to Cyprus 11.11-14.11.12 12th International Conference on Bioinformatics & Bioengineering [BIBE 2012]	OTHER Activity -Travel

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 3 for the period.				
FOUNDATION FOR RESEARCH AND TECHNOLOGY HELLAS				
Work Package	Item description	Amount in €	Explanation	Free Text
	Other direct cost	45 €	(2) Maniadi to Heraklion Participation at the Conference HSCBB12, 4-6/10/2012	OTHER Activity -Travel
WP 17	Other direct cost	284 €	(3) Marias to Barcelona Spain 07.05-12.05.12 / Participation at the Cancer Challenge of SG3 VPH Group	OTHER Activity -Travel
WP 17	Other direct cost	1,835 €	(4) Spanakis Paris France 20.11-24.11.12 / Workshop at 3rd International Conference on Wireless Mobile Communication and Healthware	OTHER Activity -Travel
WP 17	Other direct cost	3,141 €	(5) Pediaditis USA 11.08-10.09.12 / 34th Annual International Conference of the IEEE Engineering in Medicine and Biology Society	OTHER Activity -Travel
WP 17	Personnel costs	2,412 €	Other Acitivity -Personnel Costs Principal Researcher : C. Marias / P-Months 0.69	OTHER Activity: Personnel
	Indirect costs	78,688 €		
TOTAL COSTS		190,535 €		

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 4 for the period.				
UNIVERSITY COLLEGE LONDON				
Work Package	Item description	Amount in €	Explanation	Free Text
WP 7 WP 9	Other direct cost	905 €	CONSUMABLES	Small Laboratory Chemical & Consumable Items: Pastette, Microtube, PCR microplate, Sodium chloride, Film Adhesive Thermo Scientific, RNase-Free DNase Set, Optical Adhesive Film, Reagent Reservoir,

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 4 for the period.				
UNIVERSITY COLLEGE LONDON				
Work Package	Item description	Amount in €	Explanation	Free Text
				Isoamyl Alcohol, Equilibrated Microbiology Reagent, Chloroform, Diethyl Pyrocarbonate, Hematoxylin Solution
WP 9	Other direct cost	163 €	OTHER	Laser microdissection training
WP 9	Other direct cost	174 €	CONSUMABLES	Adhesive Cap 500 opaque
WP 3	Personnel costs	5,670 €	Benjamin Jefferys, 1.23 PMs	
WP 7	Personnel costs	39,236 €	Benjamin Jefferys, 8.54 PMs	
WP 8	Personnel costs	5,216 €	Benjamin Jefferys, 1.14 PMs	
WP 7	Personnel costs	20,525 €	David Chang, 5.41 PMs	
WP 12	Personnel costs	68,083 €	Shunzou Wan, 12.00 PMs	
WP 7	Personnel costs	10,457 €	Lev Shamardin, 2.58 PMs	
WP 8	Personnel costs	5,762 €	Lev Shamardin, 1.42 PMs	
WP 12	Personnel costs	8,902 €	Benjamin Hall, 1.91 PMs	
WP 7	Personnel costs	6,838 €	Richard Williams, 1.21 PMs	
WP 7	Personnel costs	17,329 €	Mariana Maschietto, 4.88 PMs	
WP 9	Personnel costs	15,343 €	Mariana Maschietto, 4.32 PMs	
WP 9	Other direct cost	179 €	TRAVEL	Kathy Pritchard-Jones, p-medicine Meeting, London, UK, 23/06/2011 to 23/06/2011 (cost entered UCL accounts in February 2012)
WP 9	Other direct cost	101 €	TRAVEL	Kathy Pritchard-Jones, p-medicine Research Ethics Committee Review, Derby,

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 4 for the period.				
UNIVERSITY COLLEGE LONDON				
Work Package	Item description	Amount in €	Explanation	Free Text
				UK, 05/01/2012 to 05/01/2012 (cost entered UCL accounts in February 2012)
WP 7	Other direct cost	77 €	TRAVEL	Benjamin Jefferys, VIZBI 2012, Heidelberg, Germany, 06/03/2012 to 08/03/2012
WP 7 WP 12	Other direct cost	1,324 €	TRAVEL	David Chang (€362.00, WP7) Shunzou Wan (€276.00, WP12)), Benjamin Jefferys (€686.00, WP7), 3rd p-medicine Progress Meeting, Poznan, Poland, 18/03/2012 to 22/03/2012
WP 9	Other direct cost	223 €	TRAVEL	Mariana Maschietto, ENCCA Workshop, Rome, Italy, 09/06/2012 to 10/06/2012
WP 7	Other direct cost	341 €	TRAVEL	Benjamin Jefferys, p-medicine Review Meeting, Brussels, Belgium, 02/05/2012 to 03/05/2012
WP 9	Other direct cost	364 €	TRAVEL	Shunzou Wan, Conference registration fee, VPH 2012 conference, London, UK, 18/09/2012 to 20/09/2012
WP 7	Other direct cost	875 €	TRAVEL	Benjamin Jefferys, p-medicine 18 Month Consortium Meeting, Bonn, Germany, 29/08/2012 to 31/08/2012
WP 7	Other direct cost	754 €	TRAVEL	Benjamin Jefferys, EUDAT conference, Barcelona, Spain, 16/10/2012 to 18/10/2012
WP 9	Other direct cost	177 €	TRAVEL	Kathy Pritchard-Jones, meetings with EU collaborators, London, UK,

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 4 for the period.				
UNIVERSITY COLLEGE LONDON				
Work Package	Item description	Amount in €	Explanation	Free Text
				17/09/2012 and 18/10/2012
WP 7 WP 12	Other direct cost	121 €	CONSUMABLES	Media Services
WP 9	Other direct cost	195 €	CONSUMABLES	Adobe Creative Suite Design Standard software
WP 7	Other direct cost	6,985 €	NON-DURABLE EQUIPMENT	HX425T2i 2U Quad Motherboard Compute Node
WP 7	Other direct cost	835 €	NON-DURABLE EQUIPMENT	Dell OptiPlex 990 MT & Accessories
WP 7	Other direct cost	130 €	NON-DURABLE EQUIPMENT	Computer accessories
WP 7	Other direct cost	481 €	TRAVEL	Benjamin Jefferys, Custodix/UCL integration meeting, Sint-Martens-Latem, Belgium, 08/10/2012 to 10/10/2012
WP 9	Other direct cost	320 €	TRAVEL	Mariana Maschietto, AACR Annual Meeting 2013, Washington DC, USA, 06/04/2013 to 10/04/2013
WP 7	Other direct cost	1,757 €	NON-DURABLE EQUIPMENT	HX445Ca 1U Compute Node
WP 9	Other direct cost	684 €	CONSUMABLES	Genescan-500 ROX x 2
WP 9	Other direct cost	292 €	CONSUMABLES	LCM frozen section staining kit
WP 9	Other direct cost	418 €	CONSUMABLES	membrane slide 1.0 PET
WP 9	Other direct cost	263 €	CONSUMABLES	Picopure RNA Isolation Kit
WP 9	Other direct cost	242 €	CONSUMABLES	Taq DNA Polymerase, Recombinant
WP 17	Personnel costs	4,990 €	Benjamin Jefferys, 1.09 PMs	
WP 17	Personnel costs	2,348 €	Lev Shamardin, 0.58 PMs	
WP 17	Personnel costs	9,109 €	Benjamin Hall, 1.96 PMs	
WP 16	Personnel costs	1,059 €	Mariana Maschietto, 0.30 PMs	
	Indirect costs	143,547 €		

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 4 for the period.				
UNIVERSITY COLLEGE LONDON				
Work Package	Item description	Amount in €	Explanation	Free Text
TOTAL COSTS		382,794 €		

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 5 for the period.				
FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V				
Work Package	Item description	Amount in €	Explanation	Free Text
WP 2 WP 3 WP 5 WP 7 WP 8 WP 10 WP 11 WP 14 WP 15	Personnel costs	304,986 €	Salaries of 11 scientists (44.8 PM), 3 graduates (2.4 PM) and 1 student (1.9 PM) for 22.7 PM.	
WP 3 WP 5 WP 8 WP 10 WP 11 WP 13 WP 14	Other direct cost	10,620 €	Traveling to Hannover (Feb./ Mar. 2012, project meeting, 1 person), Poznan (Mar. 2012, progress meeting, 4 persons), Vancouver (May 2012, ISBER 2012, 1 person), Hannover (Apr. 2012, project meeting, 2 persons), Bad Neuenahr (Apr. 2012, workshop, 1 person), Brussels (May 2012, review meeting, 2 persons), Munich (Apr. 2012, meeting Prof. Domdey, 1 person), Köln (June 2012, PerMediCon 2012, 1 person), St. Augustin (Aug. 2012, consortium meeting, 2 persons), Granada (Nov. 2012, ESBB congress, 1 person), Homburg (June 2012, software test, 1 person), Kiel (July 2012, project meeting, 2 persons), Eindhoven (Nov. 2012, project meeting, 3 persons).	
WP 3 WP 8 WP 10 WP 11	Other direct cost	1,187 €	Depreciation on DELL Server (930.00 EUR) and Notebook Latitude (256.67 EUR).	
	Other direct cost	3,720 €	Catering costs for meetings held	

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 5 for the period.				
FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V				
Work Package	Item description	Amount in €	Explanation	Free Text
WP 3 WP 5 WP 8 WP 10 WP 11 WP 13 WP 14			between August 29 and 31, 2012 in St. Augustin/ Bonn (33 to 41 participants, 2.776,32 EUR); room rent for meeting on August 28/29, 2013 in Schloss Birlinghoven (172,00 EUR); DIN AO poster (313,60 EUR); computing costs - nonfiction books concerning big-data-applications, building of algorithms (Hadoop), data mining and profiling (187,65 EUR); transportation of external visitors from Airport Köln to Bonn, Hennef (141,36 EUR); business trips to clinical centers in Homburg (100.00 EUR allowance for car ride); catering for a meeting with Custodix on February 14, 2012 in St. Annual (29,41 EUR).	
WP 17	Personnel costs	4,199 €	Salaries of 5 scientists for 0.6 PM.	
	Indirect costs	255,740 €		
TOTAL COSTS		580,452 €		

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 6 for the period.				
GOTTFRIED WILHELM LEIBNIZ UNIVERSITAET HANNOVER				
Work Package	Item description	Amount in €	Explanation	Free Text
WP 5	Personnel costs	9,230 €	Hartwig Gerhartinger, Research Associate, Total: 1.24PM	All PM in WP5
WP 5	Personnel costs	19,664 €	Samuel Nwankwo, Research Associate, Total: 5.23 PM	All PM in WP5
WP 5	Personnel costs	11,952 €		All PM in WP5

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 6 for the period.				
GOTTFRIED WILHELM LEIBNIZ UNIVERSITAET HANNOVER				
Work Package	Item description	Amount in €	Explanation	Free Text
			Tina Krügel, Research Associate, Total: 1.74 PM	
WP 5	Personnel costs	27,415 €	Stefanie Hänold, Research Associate, Total: 8.56 PM	All PM in WP5
WP 5	Personnel costs	3,238 €	Sarah Jensen, Student Assistant, Total: 2.18 PM	All PM in WP5
WP 5	Personnel costs	128 €	Costs for the accidant's insuranace of Lower Saxony	The costs for the accident's insurance are part of the labour expenses but they are not claimed for each staff member seperately. Rather they are claimed in one sum for all staff members working in the project.
WP 5	Other direct cost	784 €	Travel	3rd Progress Meeting, 19.03.2012- 21.03.2012 in Poznan, Nikolaus Forgó, Magdalena Góralczyk
WP 5	Other direct cost	140 €	Travel	Ethical Committee Meeting, 13.12.2013 in Homburg, Nikolaus Forgó, Stefanie Hänold
WP 5	Other direct cost	143 €	Travel	Consortium Meeting, 15.11.2011- 18.11.2011 in Eindhoven, Nikolaus Forgó, Tina Krügel, Hartwig Gerhartinger [This travel costs were booked in 2012 so that we are reporting them for Period 2]
WP 5	Other direct cost	216 €	Travel	Meeting with CUSTODIX, 09.01.2013- 10.01.2013 in Brussels, Stefanie Hänold, Bennet Lodzig
WP 5	Other direct cost	962 €	Travel	BIBE Conference, 11.11.2012- 13.11.2012 in

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 6 for the period.				
GOTTFRIED WILHELM LEIBNIZ UNIVERSITAET HANNOVER				
Work Package	Item description	Amount in €	Explanation	Free Text
				Larnaca, Stefanie Hänold
WP 5	Other direct cost	516 €	Travel	1st Review Meeting, 03.05.2012 in Brussels, Nikolaus Forgó
WP 5	Other direct cost	527 €	Travel	Dissemination activity during a preparation meeting for an FP7-project being thematically and with regards to contents comparable to p-medicine, 30.01.2012-01.02.2012 in Athens, Hartwig Gerhartinger
WP 5	Other direct cost	557 €	Travel	EMA Workshop, 22.11.2012-23.11.2012 in London, Samuel Nwankwo
WP 5	Other direct cost	1,147 €	Travel	4th Progress Meeting, 29.08.2012-31.08.2012, Nikolaus Forgó, Stefanie Hänold, Samuel Nwankwo
WP 5	Other direct cost	1,013 €	Equipment	Lenovo Think Pad T420, Stefanie Hänold [will be depreciated in Y4: http://www.uni-hannover.de/imperia/md/content/dezernat5/dokumente/grundlagen/afa_tabelle_kpmg_okt_2001-lang-vollstaendig.pdf]
	Indirect costs	46,579 €		
TOTAL COSTS		124,211 €		

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 7 for the period.				
CUSTODIX NV				
Work Package	Item description	Amount in €	Explanation	Free Text
WP 3 WP 5 WP 8	Other direct cost	322 €	travel	Elias Neri, Portal authentication (SSO), authorisation,

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 7 for the period.				
CUSTODIX NV				
Work Package	Item description	Amount in €	Explanation	Free Text
				user management and Optima meeting, St-Ingbert & Homburg, DE, 13-16/2/2012
WP 5 WP 3 WP 8	Other direct cost	513 €	travel	Elias Neri, Anonymisation of Oxford data meeting & Data warehouse security meeting, Oxford-London, UK, 12-13/3/2012
WP 3 WP 5 WP 8 WP 2 WP 6 WP 7 WP 14	Other direct cost	969 €	travel	Elias Neri, Third Progress Meeting, Poznan, PL, 19-21/3/2012
WP 3 WP 5 WP 8 WP 2 WP 6 WP 7 WP 14	Other direct cost	197 €	travel	Elias Neri & Brecht Claerhout, Pre-review meeting, Brussels, BE, 2/5/2012
WP 3 WP 5 WP 8 WP 6 WP 7 WP 2 WP 14	Other direct cost	59 €	travel	Elias Neri & Brecht Claerhout, Review meeting, Brussels, BE, 3/5/2012
WP 3 WP 5 WP 8	Other direct cost	28 €	meeting organisation	Optima meeting, Custodix, BE, 4/5/2012
WP 2 WP 3 WP 5 WP 6 WP 7 WP 8 WP 14	Other direct cost	1,114 €	travel	Elias Neri & Wouter Dhaeze, Fourth Progress Meeting & P-Medicine / VPH-Share shared meeting, Bonn, DE, 29-31/8/2012
WP 3 WP 5 WP 8	Other direct cost	4 €	travel	Hackathon data warehouse security integration, Custodix, BE, 11-12/9/2012
WP 8 WP 3 WP 5	Other direct cost	216 €	meeting organisation	Hackathon data warehouse security integration, Custodix, BE, 11-12/9/2012
WP 2	Personnel costs	4,556 €	Brecht Claerhout (director/senior researcher)	total: 0.52 PM
WP 2 WP 3 WP 5 WP 6 WP 7 WP 8 WP 14	Personnel costs	37,361 €	Elias Neri (proj.mgr/senior researcher)	total: 7.7 PM
WP 2 WP 3 WP 7	Personnel costs	7,088 €		total: 1.96 PM

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 7 for the period.				
CUSTODIX NV				
Work Package	Item description	Amount in €	Explanation	Free Text
			Jelle Vandendriessche (researcher)	
WP 3 WP 5 WP 8 WP 14	Personnel costs	17,627 €	Wouter Dhaeze (senior researcher)	total: 3.53 PM
WP 8	Personnel costs	22,847 €	Ken Audenaert (senior researcher)	total: 3.06 PM
WP 17	Personnel costs	1,714 €	Brecht Claerhout (director/senior researcher)	total: 0.14 PM
	Indirect costs	50,056 €		
TOTAL COSTS		144,671 €		

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 8 for the period.				
PHILIPS ELECTRONICS NEDERLAND B.V.				
Work Package	Item description	Amount in €	Explanation	Free Text
WP 2 WP 3 WP 4 WP 11 WP 13 WP 14	Personnel costs	104,173 €	salaries of 4 researchers for 22.1 MM	
WP 17	Personnel costs	1,974 €	salary of 1 researcher for 0.2 MM	
	Indirect costs	206,655 €		
TOTAL COSTS		312,802 €		

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 9 for the period.				
HEINRICH-HEINE-UNIVERSITAET DUESSELDORF				
Work Package	Item description	Amount in €	Explanation	Free Text
WP 5	Other direct cost	405 €	travel cost	Kuchinke Brussels 28.-30.01.13
WP 2	Other direct cost	260 €	travel cost	Kuchinke Frankfurt 09.08.12
WP 5	Other direct cost	121 €	travel cost	Kuchinke, Ohmann St. Augustin 30+31.8.12
WP 6	Other direct cost	616 €	travel cost	Karakoyun Posen 18.-21.03.12
WP 6	Other direct cost	296 €	travel cost	Krauth, Braasch St. Augustin 30.+31.8.12
WP 2 WP 5 WP 6 WP 9	Personnel costs	35,453 €	Kuchinke, Res.-Assistant	WP 2 = 0,05 PM, WP 5 = 3,22 PM, WP 6 = 2,30 PM, WP 9 = 0,18 PM

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 9 for the period.				
HEINRICH-HEINE-UNIVERSITAET DUESSELDORF				
Work Package	Item description	Amount in €	Explanation	Free Text
WP 2 WP 6	Personnel costs	29,344 €	Calles, Res.-Assistant	WP 2 = 1,08 PM, WP 6 = 4,36 PM
WP 6	Personnel costs	28,036 €	Karakoyun, Res.-Assistant	WP 6 = 5,67 PM
WP 2 WP 6	Personnel costs	7,166 €	Krauth, Res.-Assistant	WP 2 = 0,23 PM, WP 6 = 1,34 PM
WP 2 WP 9	Personnel costs	438 €	Ohmann, Res.-Group leader	WP 6 = 0,02 PM, WP 9 = 0,04 PM
WP 17	Other direct cost	762 €	travel cost	Kuchinke Budapest 09.-10.02.12
WP 17	Other direct cost	622 €	travel cost	Kuchinke Braunschweig 17.-18.09.12
WP 17	Other direct cost	2,829 €	travel cost	Karakoyun,Kuchinke, eChallenges Conference, Lissabon 16.-19.10.12, registration fee 2 x 500 €, Hotel 2 x 196 €, Flight 1.284 €, other cost 174 €
WP 17	Personnel costs	165 €	0,02 PM Scientist	Ohmann
	Indirect costs	63,664 €		
TOTAL COSTS		170,177 €		

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 10 for the period.				
INSTITUTE OF COMMUNICATION AND COMPUTER SYSTEMS				
Work Package	Item description	Amount in €	Explanation	Free Text
WP 8 WP 9 WP 12 WP 13	Personnel costs	43,494 €	Personnel Costs	Georgios Stamatakos (Senior Researcher, 4.37PMs)
WP 8 WP 9 WP 12 WP 13	Personnel costs	54,900 €	Personnel Costs	Dimitra Dionysiou (Senior Researcher, 7.24PMs)
WP 9 WP 12	Personnel costs	16,864 €	Personnel Costs	Eleni Kolokotroni (Assistant Researcher, 3.66PMs)
WP 9 WP 12 WP 13	Personnel costs	6,767 €	Personnel Costs	Eleni Georgiadi (Assistant Researcher, 1.41PMs)
WP 9 WP 12	Personnel costs	15,969 €	Personnel Costs	Eleftherios Ouzounoglou (Junior Researcher, 4.31PMs)

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 10 for the period.				
INSTITUTE OF COMMUNICATION AND COMPUTER SYSTEMS				
Work Package	Item description	Amount in €	Explanation	Free Text
WP 9 WP 12	Personnel costs	14,784 €	Personnel Costs	Katerina Argyri (Junior Researcher, 4.03PMs)
WP 12	Personnel costs	3,486 €	Personnel Costs	Stavroula Giatili (Junior Researcher, 0.93PMs)
WP 13 WP 8	Personnel costs	3,312 €	Personnel Costs	Fotini Misichroni (Junior Researcher, 0.94PMs)
	Other direct cost	4,897 €	Travel Costs	Georgios Stamatakos (3rd progress meeting, 1st Review Meeting, 4th Progress Meeting)
WP 16 WP 17	Personnel costs	19,715 €	Personnel Costs	Georgios Stamatakos (Senior Researcher, 2PMs)
	Other direct cost	1,233 €	Travel costs	Georgios Stamatakos (VPH2012 conference), Stavroula Giatili (VPH 2012 Conference)
	Indirect costs	111,251 €		
TOTAL COSTS		296,672 €		

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 11 for the period.				
UNIVERSIDAD POLITECNICA DE MADRID				
Work Package	Item description	Amount in €	Explanation	Free Text
WP 2 WP 3 WP 4 WP 15 WP 7	Personnel costs	83,280 €	TOTAL Staff effort: 20,43 man-month. Prof. Victor Maojo (1 PM): Principal Investigator. Coordinator of UPM's activities within the project. Review of deliverables. Collaboration in tasks 3.2 and 4.2. Dr. Jose Crespo (1,5 PM): Senior investigator. Collaboration in task 4.2. Review of deliverables. Dr. Jose María Barrreiro (5,88 PM): Senior investigator.	

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 11 for the period.				
UNIVERSIDAD POLITECNICA DE MADRID				
Work Package	Item description	Amount in €	Explanation	Free Text
			<p>Collaboration in tasks 4.2 and 15.4. Review of deliverables. Dr. Andrés Silva (0,74 PM): Senior investigator.</p> <p>Collaboration in task 4.5. Dr. Miguel garcía Remesal (4,96 PM): Senior Researcher.</p> <p>Participation in several tasks: 3.2, 3.3, 4.2, 4.5 and 15.4. Attendance to project meetings. Dr. Alberto Anguita (3,86 PM): Researcher and developer.</p> <p>Participation in task 3.2, 4.2 and 4.5. Attendance to project meeting. MSc. Diana de la Iglesia (2,49 PM): Junior Researcher (postgraduate student).</p> <p>Collaboration in task 4.2. Review of deliverables.</p>	
WP 2 WP 3 WP 4 WP 7 WP 15	Other direct cost	1,671 €	Travel costs: Travel, subsistence and accomodation expenses, Consortium Meeting, Poznan (Poland), 18-21 March 2012: Alberto Anguita and Miguel Garcia Remesal	
WP 4 WP 7 WP 15 WP 2 WP 3	Other direct cost	1,659 €	Travel costs: Travel, subsistence and accomodation expenses, Consortium Meeting, St. Augustin (Germany), 28 August - 2 September 2012: Alberto Anguita, Miguel Garcia Remesal.	
WP 7 WP 15 WP 4 WP 3 WP 2	Other direct cost	183 €	Durable equipment: Two laptops HP Pavilion g6	

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 11 for the period.				
UNIVERSIDAD POLITECNICA DE MADRID				
Work Package	Item description	Amount in €	Explanation	Free Text
			Notebook PC (91,67€ x 2 = 183,34 €), depreciated (total cost: 550€ each one, useful life: 60 months, amount of time used in this period: 10 months)	
WP 2 WP 3 WP 4 WP 7 WP 15	Other direct cost	57 €	Durable equipment: External Hard Drive (57,02 €), depreciated (total cost: 311,02€, useful life: 60 months, amount of time used in this period: 11 months)	
WP 2 WP 3 WP 4 WP 7 WP 15	Other direct cost	112 €	Durable equipment: Server (111,71 €), depreciated (total cost: 609,32€, useful life: 60 months, amount of time used in this period: 11 months)	
WP 15 WP 7 WP 4 WP 3 WP 2	Other direct cost	113 €	Durable equipment: Server (112,85 €), depreciated (total cost: 677,12€, useful life: 60 months, amount of time used in this period: 10 months)	
WP 17 WP 16	Personnel costs	5,569 €	TOTAL Staff effort: 1,95 PM. Prof. Victor Maojo (0,2 PM): Principal Investigator. Coordinator of UPM's activities within the project. Coordinator of UPM's publications within the project framework. Collaboration in tasks 17.5 and 17.6. Dr. Jose María Barreiro (0,5 PM): Senior investigator. Collaboration in task 16.1. Dr. Miguel garcía Remesal (0,2 PM): Senior Researcher. Participation in tasks 17.4 and	

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 11 for the period.				
UNIVERSIDAD POLITECNICA DE MADRID				
Work Package	Item description	Amount in €	Explanation	Free Text
			17.5. Dr. Alberto Anguita (1,05 PM): Researcher and developer. Participation in task 16.1, 17.4, 17.5 and 17.6.	
	Indirect costs	61,945 €		
TOTAL COSTS		154,589 €		

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 12 for the period.				
CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL				
Work Package	Item description	Amount in €	Explanation	Free Text
WP 2 WP 6 WP 9 WP 12	Personnel costs	59,985 €	Antje Torge, Research Assistant 12 PM	WP2= 1 PM; WP6=1.05 PM; WP9=9.34 PM; WP12=0.61PM
WP 2 WP 6 WP 9 WP 12	Personnel costs	3,072 €	Susanne Kilian, Research Assistant, 0.76 PM	WP2=0.12 PM; WP6=0.2 PM; WP9=0.34 PM; WP12= 0.1 PM
WP 17	Personnel costs	2,125 €	Susanne Kilian, Research Assistant, 0.17 PM	WP 17=0.17 PM
	Indirect costs	39,109 €		
TOTAL COSTS		104,291 €		

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary -999 for the period.				
UNIVERSITATSKLINIKUM SCHLESWIG-HOLSTEIN				
Work Package	Item description	Amount in €	Explanation	Free Text
	Other direct cost	140 €	Travel	WP 2, 6, 9,12; 2 persons at progress meeting Eindhoven 16.11-18.11.2011
	Other direct cost	338 €	Travel	WP9; 2 people at working meeting, Hannover, 29.02.2012-01.03.2012
	Other direct cost	646 €	Travel	2 people at progress meeting, Poznan, 19.03.2012-21.03.2012
	Other direct cost	344 €	Travel	WP 2, 6, 9, 12; 1 person at Review Meeting, Brussels, 01.05.2012-05.05.2012

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary -999 for the period.				
UNIVERSITÄTSKLINIKUM SCHLESWIG-HOLSTEIN				
Work Package	Item description	Amount in €	Explanation	Free Text
	Other direct cost	423 €	Travel	1 person at progress meeting, St. Augustin, 29.08.2012-31.08.2012
	Other direct cost	98 €	Consumables	WP9; Catering Kiel, working meeting, 05.07.2012
	Other direct cost	230 €	Consumables	WP9; MATLAB-software license for 12 months
	Other direct cost	3,083 €	Equipment	Special computer equipment for mathematical modeling (depreciation: 3 yrs)
	Other direct cost	147 €	Travel	1 person at dissemination meeting, Wilsede, 06.03.2012-09.03.2012
	Indirect costs	3,269 €		
TOTAL COSTS		8,718 €		

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 13 for the period.				
ISTITUTO EUROPEO DI ONCOLOGIA SRL				
Work Package	Item description	Amount in €	Explanation	Free Text
WP 6 WP 9 WP 13 WP 14	Personnel costs	2,822 €	Laura Adamoli, Data Manager, Total PM: 0,79	WP6: 0,28 PM; WP9: 0,28 PM; WP13: 0,15 PM; WP14: 0,08 PM
WP 6 WP 9 WP 13 WP 14	Personnel costs	6,338 €	Giuseppe Curigliano, Division Director, Total PM: 0,66	WP6: 0,16 PM; WP9: 0,13 PM; WP13: 0,14 PM; WP14: 0,23 PM
WP 9 WP 13 WP 14	Personnel costs	12,362 €	Elisabetta Munzone, Division Deputy Director, Total PM: 1,63	WP9: 0,54 PM; WP13: 0,91 PM; WP14: 0,18 PM
WP 10	Personnel costs	2,199 €	Giuseppina Bonizzi, Staff Scientist, Total PM: 0,38	WP10: 0,38 PM
WP 12	Personnel costs	28,689 €	Alberto D'Onofrio, Group Leader, Total PM: 5,24	WP12: 5,24 PM
WP 9 WP 13 WP 14	Personnel costs	17,105 €	Alessandra Milani, Research Nurse, Total PM: 3,19	WP9: 1,56 PM; WP13: 0,92 PM; WP14: 0,70

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 13 for the period.				
ISTITUTO EUROPEO DI ONCOLOGIA SRL				
Work Package	Item description	Amount in €	Explanation	Free Text
WP 9 WP 13 WP 14	Personnel costs	2,445 €	Giulia Peruzzotti, Head Data Manager, Total PM: 0,48	WP9: 0,17 PM; WP13: 0,18 PM; WP14: 0,13
WP 9	Personnel costs	2,000 €	Alessandro Ermolli, Data Manager, Total PM: 2	WP9: 2,00 PM
WP 9	Personnel costs	10,500 €	Madia Boasi, Research Nurse, Total PM: 7 PM	WP9: 7,00 PM
WP 12	Personnel costs	27,000 €	Sebastiano De Franciscis, Post Doc, Total PM: 12	WP12: 12,00 PM
WP 9	Personnel costs	35,000 €	Angela Sciandivasci, Medical Oncologist, Total PM: 12	WP9: 12,00 PM
WP 9	Personnel costs	738 €	Stefania Pedroli, Data Manager, Total PM: 0,67	WP9: 0,67 PM
WP 6 WP 9 WP 10 WP 12 WP 13 WP 14	Other direct cost	659 €	Travel	Elisabetta Munzone, P-Medicine Project Meeting, St. Augustin, August 29-30, 2012
WP 12	Other direct cost	1,075 €	Travel	Albert D'Onofrio and Sebastiano De Franciscis, Mathways into cancer 2012, Almagro June 4-6, 2012
WP 16	Personnel costs	627 €	Laura Adamoli, Data Manager, Total PM: 0,18	WP 16: 0,18 PM
WP 16	Personnel costs	864 €	Giuseppe Curigliano, Division Director, Total PM: 0,09	WP 16: 0,09 PM
WP 17	Personnel costs	572 €	Elisabetta Munzone, Division Deputy Director, Total PM: 0,08	WP 17: 0,08 PM
WP 16	Personnel costs	1,743 €	Alessandra Milani, Research Nurse, Total PM: 0,32	WP 16: 0,32 PM
WP 16	Personnel costs	1,320 €	Giulia Peruzzotti, Head Data Manager, Total PM: 0,26	WP16: 0,26 PM
	Indirect costs	30,811 €		
TOTAL COSTS		184,869 €		

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 14 for the period. ecancermedicalsience AG				
Work Package	Item description	Amount in €	Explanation	Free Text
	Other direct cost	500 €	Other direct costs	ALGA translation costs
	Other direct cost	847 €	Travel	Paris - ALGA set up meeting 16th Dec - 1 person
	Other direct cost	116 €	Travel	Paris - ALGA set up meeting 16th Dec - 1 person
	Other direct cost	4 €	Travel	Paris - ALGA set up meeting 16th Dec - 1 person
	Other direct cost	19 €	Travel	Paris - ALGA set up meeting 16th Dec - 1 person
	Other direct cost	194 €	Other direct costs	Milan meeting expenses
WP 14	Other direct cost	751 €	Travel	Barcelona - VPH Study Group 7th May - 1 person
WP 14	Other direct cost	1,854 €	Travel	Brussels - European Association of Personalised Medicine meeting 12th June - 1 person
WP 14	Other direct cost	1,310 €	Travel	Sicily - Chronic cancer patients conf 8th June - 1 person
WP 14	Other direct cost	373 €	Other direct costs	Online survey creation
WP 14	Other direct cost	500 €	Direct costs	ALGA translation
WP 14	Other direct cost	295 €	Travel	Brussels (from Paris) - ALGA set up meeting 6th Feb - 2 people
WP 14	Personnel costs	17,248 €	2.96 PMs	Prof Gabriella Pravetoni - Psychology Professor
WP 14	Personnel costs	18,400 €	9.2 PMs	Ketti Mazzocco - Research Assistant
WP 14	Personnel costs	13,926 €	1.8 PMs	Prof Gordon McVie - Chairman
WP 2	Personnel costs	4,667 €	1 PM	Gabriella Pravetoni - Psychology Professor
WP 13	Personnel costs	9,285 €	2.7 PMs	

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 14 for the period.				
ecancermedicalsience AG				
Work Package	Item description	Amount in €	Explanation	Free Text
				Gabriella Pravetoni - Psychology Professor
WP 13	Personnel costs	3,600 €	1.8 PMs	Ketti Mazzocco - Research Assistant
WP 15	Other direct cost	58 €	Consumables	Analytical software - licence fee
WP 15	Other direct cost	58 €	Consumables	Analytical software - licence fee
WP 14	Other direct cost	455 €	Travel	Milan - FORTH meeting 10th Apr - 1 person
WP 14	Other direct cost	79 €	Travel	Brussels - Project review meeting 2nd May - 1 person
WP 14	Other direct cost	15 €	Travel	Brussels - Project review meeting 2nd May - 1 person
WP 14	Other direct cost	5 €	Travel	Brussels - Project review meeting 2nd May - 1 person
WP 14	Other direct cost	4 €	Travel	Brussels - Project review meeting 2nd May - 1 person
WP 14	Other direct cost	5 €	Travel	Brussels - Project review meeting 2nd May - 1 person
WP 14	Other direct cost	34 €	Travel	Brussels - Project review meeting 2nd May - 1 person
WP 14	Other direct cost	5 €	Travel	Brussels - Project review meeting 2nd May - 1 person
WP 14	Other direct cost	23 €	Travel	Brussels - Project review meeting 2nd May - 1 person
WP 14	Other direct cost	438 €	Travel	Sicily - Chronic cancer patients conf 8th June - 2 people
WP 13	Other direct cost	482 €	Other direct costs	Online survey creation
WP 14	Other direct cost	916 €	Travel	Bari - OECI ALGA meeting 25th Apr and Barcelona - VPH Study Group 7th May- 1 person
WP 14	Other direct cost	752 €	Travel	Geneva - Personalised

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 14 for the period. ecancermedicalsience AG				
Work Package	Item description	Amount in €	Explanation	Free Text
				medicine conference 1st May - 1 person
WP 14	Other direct cost	358 €	Travel	Copenhagen - Personalised medicine symposium 4th June - 2 people
WP 14	Other direct cost	108 €	Travel	Copenhagen - Personalised medicine symposium 4th June - 2 people
	Other direct cost	516 €	Travel	Madrid - ALGA set up meeting, 5th Feb - 2 people
	Other direct cost	378 €	Travel	Brussels - ALGA set up meeting, 6th Feb - 2 people
	Other direct cost	412 €	Travel	Paris ALGA set up meeting, 6th Feb - 2 people
WP 17	Other direct cost	502 €	Travel	London - SIOPE meeting 27th Feb
WP 17	Other direct cost	248 €	Travel	Poznan - Consortium meeting 19th Mar
WP 17	Other direct cost	52 €	Travel	Poznan - Consortium meeting 19th Mar
WP 17	Other direct cost	62 €	Travel	London - SIOPE meeting 27th Feb
WP 17	Other direct cost	188 €	Travel	London - SIOPE meeting 27th Feb
WP 17	Other direct cost	14 €	Travel	Cardiff - Learning dissemination meeting 29th Feb
WP 17	Other direct cost	6 €	Travel	Cardiff - Learning dissemination meeting 29th Feb
WP 16	Other direct cost	304 €	Travel	Brussels European Association of Personalised Medicine meeting 12 June
WP 17	Other direct cost	5 €	Travel	Poznan - Consortium meeting 19th Mar
WP 17	Other direct cost	14 €	Travel	Poznan - Consortium meeting 19th Mar
WP 17	Other direct cost	14 €	Travel	

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 14 for the period.				
ecancermedicalsience AG				
Work Package	Item description	Amount in €	Explanation	Free Text
				Poznan - Consortium meeting 19th Mar
WP 17	Other direct cost	48 €	Travel	Poznan - Consortium meeting 19th Mar
WP 17	Other direct cost	10 €	Travel	Poznan - Consortium meeting 19th Mar
WP 16	Other direct cost	73 €	Travel	Milan - FORTH meeting 10th Apr
WP 16	Other direct cost	35 €	Travel	Milan - FORTH meeting 10th Apr
WP 16	Other direct cost	9 €	Travel	Milan - FORTH meeting 10th Apr
WP 16	Other direct cost	181 €	Travel	Bari - OECl meeting 25th Apr
WP 16	Other direct cost	311 €	Travel	Barcelona - VPH Study Group 7th May
WP 16	Other direct cost	149 €	Travel	Geneva - Personalised medicine conf 1st May
WP 16	Other direct cost	752 €	Travel	Brussels - Project review meeting 2nd May
WP 16	Other direct cost	49 €	Travel	Poznan - Consortium meeting 19th Mar
WP 16	Other direct cost	270 €	Travel	Barcelona - VPH Study Group 7th May
WP 16	Other direct cost	423 €	Direct costs	Education filming backdrop
WP 16	Other direct cost	114 €	Direct costs	Learning platform development
WP 16	Other direct cost	147 €	Direct costs	Learning platform lisenca
WP 16	Other direct cost	1,130 €	Travel	Barcelona - VPH Study Group 7th May
WP 16	Other direct cost	666 €	Travel	Barcelona - VPH Study Group 7th May
WP 16	Other direct cost	318 €	Travel	Barcelona - VPH Study Group 7th May

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 14 for the period. ecancermedicalsience AG				
Work Package	Item description	Amount in €	Explanation	Free Text
WP 17	Other direct cost	457 €	Travel	
WP 16	Other direct cost	1,088 €	Direct costs	Learning platform license
WP 16	Other direct cost	109 €	Travel	London - European Medicines Association meeting 21st Sep
WP 16	Other direct cost	1,093 €	Direct costs	Learning platform license
WP 16	Other direct cost	26 €	Travel	Berlin - Online education conf 29th Nov
WP 16	Other direct cost	18 €	Travel	Berlin - Online education conf 29th Nov
WP 16	Other direct cost	17 €	Travel	Berlin - Online education conf 29th Nov
WP 16	Other direct cost	19 €	Travel	Berlin - Online education conf 29th Nov
WP 16	Other direct cost	15 €	Travel	Berlin - Online education conf 29th Nov
WP 16	Other direct cost	8 €	Travel	Berlin - Online education conf 29th Nov
WP 16	Other direct cost	435 €	Travel	Berlin - Online education conf 29th Nov
WP 16	Other direct cost	155 €	Travel	Berlin - Online education conf 29th Nov
WP 16	Other direct cost	246 €	Direct costs	Online film storage license
WP 16	Personnel costs	15,265 €	3.4 PMs	Danny Burke - Education Manager
WP 16	Personnel costs	17,020 €	2.2 PMs	Prof Gordon McVie - Chairman
WP 17	Personnel costs	3,868 €	0.5 PMs	Prof Gordon McVie - Chairman
	Indirect costs	74,953 €		
TOTAL COSTS		199,876 €		

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 15 for the period.				
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD				
Work Package	Item description	Amount in €	Explanation	Free Text
	Personnel costs	28,553 €	Personnel costs	researcher working on the project - Marian Taylor, 2.17 PM on WP2 and 2.48PM on WP9
	Personnel costs	47,811 €	Personnel costs	Researcher working on the project - Laura M Winchester, 5.99 PM on WP11, 6.56 PM on WP12
	Personnel costs	755 €	Personnel costs	Temporary researcher working on the project - Benjamin Harris, 0.41 PM on WP9
	Personnel costs	146 €	Personnel costs	30 days job posting on LinkedIn Ireland Ltd. WP9
	Other direct cost	4,048 €	Consumables	ONCOMINE RESEARCH PREMIUM EDITION (2 Pack) (inv: 219) WP9 Poster and tube for Laura Winchester, Med Onc. 49.33 ex VAT "Integrated Analysis of Copy Number Aberrations for Primary Breast Cancer Tumours (inv: 17068780) WP11 Bioinformatics Methods in Clinical ResearchSeries: Methods in Molecular Biology, Vol. 593 Matthiesen, Rune (Ed.) WP9 PowerToolsBatteries WP11 Knowledge-Based Bioinformatics: From analysis to interpretation Gil Alterovitz (Editor), Marco Ramoni (Editor) Publication Date: September 7, 2010 ISBN-10: 0470748311 ISBN-13: 978-0470748312 Edition: 1 WP11
	Other direct cost	409 €	Travel	Laura M Winchester - CRI sequencing

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 15 for the period.				
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD				
Work Package	Item description	Amount in €	Explanation	Free Text
				conference, Cambridge, UK 02/11/12 - 03/11/12 WP9
	Other direct cost	278 €	Travel	Francesca Buffa - CRI sequencing conference, Cambridge, UK 02/11/12 - 04/11/12 WP9
	Other direct cost	600 €	Travel	Laura M Winchester - VHP conference, London, UK 18/09/2012 - 20/09/2012 WP11&12
	Other direct cost	69 €	Travel	Laura M Winchester - JANET conference, London, UK 21/06/2012 WP11
	Other direct cost	27 €	Travel	Francesca Buffa - Joint Biomarker and Imaging CSG/ECMC Workshop to 'Proliferation Biomarkers in Cancer', London, UK, 24/05/2011 WP9
	Other direct cost	63 €	Travel	Marian Taylor - ECMC group chairs meeting, London, UK, 18/01/2012 WP9
	Other direct cost	316 €	Travel	Marian Taylor - P-Medicine Progress Meeting, Poland, 19/03/12 -22/03/12 WP9
	Other direct cost	125 €	Travel	Marian Taylor - P-Medicine Progress Meeting, Poland, 19/03/12 -22/03/12 WP9
	Indirect costs	49,920 €		
TOTAL COSTS		133,120 €		

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 16 for the period.				
A. PERSIDIS & SIA OE				
Work Package	Item description	Amount in €	Explanation	Free Text
WP 9 WP 11 WP 13	Personnel costs	15,200 €		

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 16 for the period.				
A. PERSIDIS & SIA OE				
Work Package	Item description	Amount in €	Explanation	Free Text
			salary of Andronis, C (Senior investigator)	WP9= 0.79 P/M, WP11= 3 P/M, WP13= 1.8 P/M. Total= 5.60 P/M
WP 8 WP 9 WP 11 WP 13	Other direct cost	1,727 €	travel costs	Sharma A, Koutsokeras M, Pmedicine Technical Meeting (18-22/03/12, Poznan, Poland)
WP 9	Personnel costs	2,124 €	salary of Deftereos, S (Senior Investigator)	WP9= 1.02 P/M. Total= 1.02 P/M
WP 8 WP 9 WP 13	Personnel costs	4,883 €	salary of Dodou, E (Senior Investigator)	WP8= 0.63 P/M, WP9= 0.98 P/M, WP13= 0.51 P/M. Total= 2.12 P/M
WP 8 WP 11 WP 13	Personnel costs	22,554 €	salary of Koutsokeras, M (IT programmer/ researcher)	WP8= 5.82 P/M, WP11= 2.97 P/M, WP13= 1 P/M. Total= 9.82 P/M
WP 8 WP 9 WP 11 WP 13	Personnel costs	9,110 €	salary of Lekka, Eftychia (Senior Investigator)	WP8= 0.53 P/M, WP9= 1.01 P/M, WP11= 1.38 P/M, WP13= 1.03 P/M. Total= 3.95 P/M
WP 11 WP 13	Personnel costs	4,400 €	salary of Lekka, Konstantina (Investigator)	WP11= 2.39 P/M, WP13= 0.85 P/M. Total= 3.24 P/M
WP 8 WP 11 WP 13	Personnel costs	20,315 €	salary of Sharma, A (IT programmer/ researcher)	WP8= 1.27 P/M, WP11=5.35 P/M, WP13= 2.97 P/M. Total= 9.6 P/M
WP 8 WP 11 WP 13	Personnel costs	19,731 €	salary of Virvilis, V (Senior investigator)	WP8= 1.56 P/M, WP11= 4.54 P/M, WP13= 1.29 P/M. Total= 7.4 P/M
WP 8 WP 9 WP 11 WP 13	Other direct cost	639 €	travel costs	Persidis, A, Pmedicine 1st Review Meeting (02-03/05/12, Brussels, Belgium)
WP 8 WP 9 WP 11 WP 13	Other direct cost	1,059 €	travel costs	Koutsokeras M, Pmedicine Technical Meeting (28-30/08/12, St Augustin, Germany)
WP 8 WP 9 WP 11 WP 13	Other direct cost	10,579 €	server hosting costs	The server is dedicated 100% to the p-medicine project. The costs cover only the

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 16 for the period.				
A. PERSIDIS & SIA OE				
Work Package	Item description	Amount in €	Explanation	Free Text
				hosting service at the co-location center of OTENET. This centre provides hosting, guaranteed uptime and basic management services to ensure the uninterrupted availability of the Biovista literature mining services to the p-medicine infrastructure. Note that the cost of the server itself is not claimed from the project.
WP 17	Other direct cost	7,848 €	travel costs	travel costs related to Biovista's dissemination activities (50% allocated to pmedicine project); meetings with Patient Advocacy Groups (PAG), such as CFIDS, pharmaceutical companies, participation to Drug Repositioning Congress
WP 17	Personnel costs	2,510 €	salary of Deftereos, S (Senior Investigator)	WP17= 1.21 P/M
WP 17	Personnel costs	198 €	salary of Dodou, E (Senior Investigator)	WP17= 0.09 P/M
WP 17	Personnel costs	214 €	salary of Lekka, E (Senior Investigator)	WP17= 0.09 P/M
WP 17	Personnel costs	24,915 €	salary of Persidis A (SME owner/manager flat hourly rate= 46.57). This was calculated according to the "SME owners and natural persons without a salary: hourly rate calculation tool" in CORDIS. Research category= more than 10yrs of experience, year of publication of the call=2009.	WP17= 3.55 P/M

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 16 for the period.				
A. PERSIDIS & SIA OE				
Work Package	Item description	Amount in €	Explanation	Free Text
	Indirect costs	21,446 €		
TOTAL COSTS		169,452 €		

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 17 for the period.				
SWISS INSTITUTE OF BIOINFORMATICS				
Work Package	Item description	Amount in €	Explanation	Free Text
WP 13	Personnel costs	6,523 €	1 pm (S.Rossi) / Started discussion with Biovista about available public data to use and planned to share a public dataset manually curated by SIB and never used internally.	
WP 15	Personnel costs	68,489 €	10.5 pm (S.Rossi) / started analysis of user needs and requirements; begun study of patient empowerment criteria; begun study of Good Clinical Practice (GCP) criteria; started discussion about specific objectives and tools to be tested, wiki page (http://atlas.ics.forth.gr/pMedicine/wiki/index.php/WP15) has been filled to promote exchange of ideas ; conducted first questionnaire to discover software requirements and internal quality assurance criteria used; d. We defined also the content of the general ;f. Defined an example of validation criteriaevaluation procedure; c. Accordingly with other participants we planned a table of contests for the internal verification and validation	

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 17 for the period.				
SWISS INSTITUTE OF BIOINFORMATICS				
Work Package	Item description	Amount in €	Explanation	Free Text
			periodic report. Deliverable D15.1 Evaluation criteria and verification procedures has been submitted.	
WP 15	Other direct cost	687 €	Travel	S.Rossi / flight + accommodation + transportation to London 3rd P-medicine progress Meeting (21 March 2013)
	Other direct cost	294 €	Travel	WP 15 S.Rossi / accommodation/ transportation 1st P-medicine progress Meeting (8 May 2012)
	Other direct cost	218 €	Travel	WP 15 S.Rossi / Flight to Brussels/ accommodation/ transportation Coltheres meeting(8 May 2012)
	Other direct cost	527 €	Travel	WP 15 S.Rossi / Train/accommodation/ hotel/transportation Bonn 3rd progress meeting P-Medicine (31 August 2012)
WP 17	Personnel costs	3,261 €	0.50 pm (S.Rossi) / Participation to the 3rd WIN Symposium, Presentation of a Poster at the 3rd WIN Symposium, o Submitted and accepted paper to ecan	ancermedicalscience
WP 17	Other direct cost	328 €	Travel	S.Rossi Flight to Brussels 1st review P-Medicine (30 March 2012)
	Indirect costs	48,195 €		
TOTAL COSTS		128,522 €		

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 18 for the period.				
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY				
Work Package	Item description	Amount in €	Explanation	Free Text
WP 3 WP 7 WP 8 WP 12 WP 17	Personnel costs	14,755 €		

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 18 for the period.				
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY				
Work Package	Item description	Amount in €	Explanation	Free Text
			Yuzuru Tanaka, Senior scientist, 2.8PM	WP3 = 0.8PM, WP7 = 0.3PM, WP8= 1.2 PM, WP17=0.5PM
WP 8	Personnel costs	7,392 €	Micke Kuwahara, Technician, 3.8PM	WP8= 3.8 PM
WP 11	Personnel costs	5,594 €	Tetsuya Yoshida, Scientist, 1.6PM	WP11=1.6PM
WP 12	Personnel costs	1,584 €	Jonas Sjobergh, Technician, 0.6PM	WP12=0.6PM
WP 3 WP 7 WP 8	Other direct cost	1,753 €	Yuzuru Tanaka, Micke Kuwahara, Jonas Sjobergh, p-medicine consortium meeting, Poznan, 17/3/2012-23/3/2012	
WP 17	Other direct cost	970 €	Yuzuru Tanaka, Joint Meeting with Yokohama City Government for the dissemination of p-medicine project, Yokohama, Japan, 24/12/2012-27/12/ 2012	
	Indirect costs	6,409 €		
TOTAL COSTS		38,457 €		

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 19 for the period.				
IBM ISRAEL - SCIENCE AND TECHNOLOGY LTD				
Work Package	Item description	Amount in €	Explanation	Free Text
	Indirect costs	0 €		
TOTAL COSTS		0 €		

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 20 for the period.				
INSTYTUT CHEMII BIOORGANICZNEJ PAN				
Work Package	Item description	Amount in €	Explanation	Free Text
WP 3	Personnel costs	8,706 €	J. Pukacki - Scientist (1,08PM), K. Kurowski - Senior Scientist (0,28PM)	
WP 7	Personnel costs	49,737 €	J. Pukacki - Scientist (0,55PM), D. Szejnfeld - Scientist (4,69PM), D. Tarnawczyk - Scientist (10,52PM)	

Table 3.1 Personnel, subcontracting and other Major cost items for beneficiary 20 for the period.				
INSTYTUT CHEMII BIOORGANICZNEJ PAN				
Work Package	Item description	Amount in €	Explanation	Free Text
WP 8	Personnel costs	36,641 €	J. Pukacki - Scientist (4,41PM), D. Szejnfeld - Scientist (2,90PM)	
WP 12	Personnel costs	17,994 €	M. Blazewicz - Scientist (4,70PM)	
WP 7	Other direct cost	677 €	Travel	J. Pukacki, Review Meeting, Belgium, Brussels (01-04.05.2012)
WP 7	Other direct cost	1,756 €	Travel	J. Pukacki, D. Szejnfeld, Consortium Meeting, St. Augustin, Germany (28.08-01.09.2012)
WP 7	Other direct cost	4,371 €	Catering costs for 3-day progress meeting for 47 people	Poznan, Poland, 19-21.03.2012
	Indirect costs	71,929 €		
TOTAL COSTS		191,811 €		